LITERATURA

1. Abdi EA, Nguyen G, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy or advanced renal cell carcinoma. Cancer. 1987;59:896–900.
2. Abe S, Yamaguchi E, Makimura S, Okasaki N, Kukikane H, Kawakami Y. Association of HLA--DR with sarcoidosis. Correlation with clinical course. Chest. 1987;92:488–90.
3. Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Brauner MW. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol. 2000;174:1751–7.
4. Abernathy RS. Childhood sarcoidosis in Arkansas. Southern Med J. 1985;78:435.
5. Abraham A, Hajar R, Virdi R, Singh J, Mustacchia P. Esophageal sarcoidosis: a review of cases and an update. ISRN Gastroenterol. 2013;2013:836203.
6. Abrey LE, Rosenblum MK, DeAngelis LM. Sarcoidosis of the cauda equina mimicking leptomeningeal malignancy. J Neurooncol. 1998;39:261–5.
7. Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med. 1985;161:755–65.
8. Adams JS, Sharma OP, Gacad MA, Singer FRl. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolat macrophages in sarcoidosis. J Clin Invest. 1983;72:1856–60.
9. Adams JS, Singer FR, Gacad MA, et al. Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab. 1985;60:960–6.
10. Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci. 2003;325:1–6.
11. Adorini L, Sinigaglia F. Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today. 1997;18:209–11.
12. Adrianto I, Lin CP, Hale JJ, Levin AM, Datta I, Parker R, et al. Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS One. 2012;7:e43907.
13. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic Considerations in Patients With Refractory Neurosarcoidosis. Arch Neurol. 1995;52:875–9.
14. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65.
15. Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging. 2015;16:949–58.
16. Agostini C, Cabrelle A, Calabrese F, et al. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med. 2005;172:1290–8.
17. Agostini C, Cassatella M, Zambello R, et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol. 1998;161:6413–20.
18. Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol. 1996;157:910–8.
19. Agostini C, Trentin L, Perin A, et al. Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. Am J Physiol. 1999;277:L240–50.
20. Agostini C, Trentin L, Zambello R, et al. CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. Am J Med. 1993;95:466–72.
21. Agrawal V, Crisi GM, D'Agati VD, Benjamin J, Freda DO. Renal sarcoidosis presenting as acute kidney injury with granulomatous interstitial nephritis and vasculitis. Am J Kidney Dis. 2009;59:303–8.

22. Ahluwalia A, Jones MK, Szabo S, Tarnawski AS. Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. Biochem Biophys Res Commun. 2013;437:515–20.
23. Ahmad R, Sylvester J, Zafarullah M. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell Signal. 2007;19:2549–57.
24. Ahmadzai H, Cameron B, Chui J, Lloyd A, Wakefield D, Thomas PS. Measurement of neopterin, TGF-β1 and ACE in the exhaled breath condensate of patients with sarcoidosis. J Breath Res. 2013;7:046003.
25. Acharya NR, Browne EN, Rao N, Mochizuki M. Distinguishing Features of Ocular Sarcoidosis in an International Cohort of Uveitis Patients. Ophthalmology. 2018;125:119–26.
26. Ainslie GM, Benatar SROV. Serum Angiotensin Converting Enzyme in Sarcoidosis: Sensitivity and Specificity in Diagnosis: Correlations with Disease Activity, Duration, Extra-thoracic Involvement, Radiographic Type and Therapy. Q J Med. 1985;55:253–70.
27. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–82.
28. Akinyemi E, Rohewall U, Tandorra M, Abdullah M. Gastric sarcoidosis. J Natl Med Assoc. 2006;98:948–9.
29. Al Maini M, Carrete S. Diagnosis of Wegener's granulomatosis in the ANCA era. J Rheumatol. 2006;33:2060–3.
30. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;34:293–321.
31. Alía P, Maná J, Capdevila O, Álvarez A, Navarro MÁ. Association between ACE gene I/D polymorphism and clinical presentation and prognosis of sarcoidosis. Scand J Clin Lab Invest. 2005;25:691–8.
32. Allen RKA, Fong KM. Severe sarcoid peripheral neurophathy in an elderly woman treated successfully with pulse methylprednisolone. Sarcoidosis. 1992;9:479–80.
33. Altiparmak M, Oygar D, Bilir M, Kilicarslan I, Serdengecti K. A rare cause of focal segmental glomerulosclerosis: Sarcoidosis. Nephron. 2002;90:211–2.
34. American Thoracic Society. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211–77.
35. American Thoracic Society/European Respiratory Society. ATS/ERS Statement on Respiratory Muscle Testing. Am J Respir Crit Care Med. 2002;166:518–624.
36. Amin EN, Closser DR, Crouser ED. Current best practice in the management of pulmonary and systemic sarcoidosis. Ther Adv Respir Dis. 2014; 8:111–32.
37. Ancuta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol. 2000;30:1872–83.
38. Anders T, Linville KC, Johnson JE, Blanton HM. Evaluation of the float sign for determining adequancy of specimens obtained with transbronchial biopsy. Am Rev Respir Dis. 1991;144:1406–7.
39. Andersen HA, Fontana R, Harrison E jr. Transbronchoscopic lung biopsy in diffuse pulmonary disease. Dis Chest. 1965;48:187–92.
40. Andersen HA. Transbronchoscopic lung biopsy for diffuse pulmonary diseases: results in 939 patients. Chest. 1978;78:734–6.
41. Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23:40–54.
42. Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res. 2006;26:400–5.
43. Aouizerate J, Matignon M, Kamar N, et al. Renal transplantation in patients with sarcoidosis: a French multicenter study. Clin J Am Soc Nephrol. 2010;5:2101–8.
44. Aragon SB, Coke JM, Greer RO jr. Sarcoidosis with involvement of the maxilla. J Oral Med. 1982;37:52–7.

45. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantaion. Chest. 2001;120:873–80.
46. Argyropoulon PK, Patakas DA, Louridas GE. Airway function in stage I and stage II pulmonary sarcoidosis. Resp. 1984;46:17–25.
47. Arinobu Y, Iwasaki H, Gurish MF, et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci USA. 2005;102, 18105–10.
48. Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018;9(11):227–40.
49. Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48:1690–9.
50. Arndt H, Tabori G, Behrend H. Strungen der Lungenfunktion bei Sarkoidose. Internist. 1969;10:313–6.
51. Arnoux A, Danel C, Chrétien J. Is broncho-alveolar lavage a mirror of granulomas in the lung? Sarcoidosis.1989;6(suppl 1):10–1.
52. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci USA. 2011;107:10984–9.
53. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased Risk for Cancer Following Sarcoidosis. Am J Resp Crit Care Med.1999;160:1668–72.
54. Asranna A, Mohimen A, Rajan R, Nair M. Neurosarcoidosis as a Cause of Longitudinally Extensive Myelitis: Neuroimaging Clues for Diagnosis. Ann Indian Acad Neurol. 2019;22:100–1.
55. Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Practice & Research Clinical Rheumatology. 2003;17:971–87.
56. B. T. T. A. Research Committee Investigation. Familial association in sarcoidosis. Tubercle. 1972;(Suppl 3):41–5.
57. Baccam M, Bishop GA. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol. 1999;29:3855–66.
58. Badrinas F, Morera J, Maná J, et al. Sarcoidosis in Barcelona: Spring cluster of Loögren syndrome. In: Grassi C, Rizzato G, Pozzi E, editors. Sarcoidosis and other granulomatous disorders. New York: Excerpta Medica; 1988. p. 317–38.
59. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines – CXC and CC chemokines. Advances in Immunol. 1994;55:97–179.
60. Bachmann M, Horn K, Poleganov MA, et al. Interleukin-18 secretion and Th1-like cytokine responses in human peripheral blood mononuclear cells under the influence of the toll-like receptor-5 ligand flagellin. Cell Microbiol. 2005;8:289–300.
61. Bachwich PR, Lynch JP, Larrick J, Spengler M, Kunkel ST. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol. 1986;125:421–5.
62. Baltzer G, Behrend H, Behrend T, Dombrowski H. Zur Haufigkeit zystischen Knoch veranderungen (Ostitis cystoides Jüngling) bei der Sarkoidose. D M Wsch. 1970;95:1926–9.
63. Bareš M. Evokované potenciály v diagnostice roztroušené sklerózy mozkomíšní. Neurol pro praxi. 2002;5:244–8.
64. Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P. Analysis of serum amyloid A in sarcoidosis patients. Respir Med. 2011;105:775–80.
65. Bargagli E, Mazzi A, Mezzasalma F, et al. The analysis of tryptase in serum of sarcoidosis patients. Inflammation. 2009;32:310–4.
66. Barna BP, Huizar I, Malur A, et al. Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation. Int J Mol Sci. 2013;14:23858–71.
67. Barna BP, McPeek M, Malur A, et al. Elevated MicroRNA-33 in sarcoidosis and a carbon nanotubemodel of chronic granulomatous disease. Am J Respir Cell Mol Biol. 2016;54:865–71.
68. Barnard J, Newman LS. Sarcoidosis: imunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol. 2001;13:84–91.
69. Barner WE. In vivo qantitation of activity by planar imaging. In: Henkin RE, editor. Nuclear Medicine. London: Mosby; 1996. p. 216–21.
70. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138:16–27.

71. Barré PE, Gascon-Barré M, Meakins JL, Goltzman D. Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med. 1987;82:1259–62.
72. Barth J, Kreipe H, Radzum HJ, Petermann W. Interleukin-1-Sekretion aus Alveolarmakrophagen bei pulmonaler Sarkoidose. Pneumologie. 1990;44:215–6.
73. Bartz RR, Stern EJ. Airways obstruction in patients with sarcoidosis: expiratory CT scan findings. J Thorac Imaging. 2000;15:285–9.
74. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009;39:124–45.
75. Bauer HJ, Löfgren S. International study of pulmonary sarcoidosis in mass chest radiography. Acta Med Scand Suppl. 1964;425:103–5.
76. Bauer KM, Costabel U. Bronchoalveolare Lavage: Was sagt bei Sarkoidose aus. Diagnostik. 1985;18:8–9.
77. Bauer W, Gorny MK, Morell A, Baumann HR. Bronchoalveolare Immunoglobuline bei Sarkoidose. Schweiz Med Schr. 1985;115:103–5.
78. Bauer W, Simona R, Morell A, Baumann HR. Aktivitätsbestimmung und Verlaufskontrolle der Sarkoidose mittels bronchoalveolarer Lavage. Schweiz Med Schr. 1984;114:920–4.
79. Baughman R, Teirstein A, Judson M, et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9.
80. Baughman R, Winget D, Lower E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcs Vasc Diff Lung Dis. 2000;17:60–6.
81. Baughman RB, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Resp Med. 2015;3:813–22.
82. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–81.
83. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.
84. Baughman RP, Eisentrout C. Predictive value of gallium scanning, bronchoalveolar lavage and angiotensin converting enzyme in two year follow-up of pulmonary sarcoidosis. Sarcoidosis. 1986;3:158.
85. Baughman RP, Fernandez M, Bosken CH, Mantil J, Hurtubise P. Comparison of gallium-67 scanning, bronchoalveolar lavage and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Am Rev Resp Dis. 1984;129:676–86.
86. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarc Vasculitis Diff Lung Dis. 2002;19:198–204.
87. Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:113–20.
88. Baughman RP, Judson MA, Costabel U, et al. Randomised, double blind, placebo controlled trial of infliximab in patients with chronic pulmonary sarcoidosis. Chest. 2005;128:202.
89. Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis. Arch Dermatol. 2012;148:262–4.
90. Baughman RP, Judson MA, Wells A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoid Vasc Dif Lung Dis. 2017;34:280–2.
91. Baughman RP, Judson MA,Teirstein AS, Moller DR, Lower EE. Thalidomide for Chronic Sarcoidosis. Chest. 2002;122:227–32.
92. Baughman RP, Keeton D, Lower EE. Relationship between Interleukin-8 and neutrophils in the BAL fluid of sarcoidosis. Sarcoidosis. 1994;11(Suppl 1):219–20.
93. Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med. 2012;41:289–302.
94. Baughman RP, Lower EE, Kaufman AH. Ocular Sarcoidosis. Semin Respir Crit Care Med. 2010;31:452–62.
95. Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013;107:2009–13.
96. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–8.

97. Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Current opinion in pulmonary medicine. 2007;13:439–44.
98. Baughman RP, Lower EE. Who Dies from Sarcoidosis and Why? Am J Respir Crit Care Med. 2011;183:1446–7.
99. Baughman RP, Nunes H, Sweiss N. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J. 2013;41:1424–38.
100. Baughman RP, Shipley R, Desai S. Changes in chest rentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2006;136:526–35.
101. Baughman RP, Shipley RT, London RG, Louwer EE. Comparison of crackles in interstitial lung disease. Sarcoidosis and Fibrosing alveolitis. Chest. 1991;100:96–101.
102. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132:207–13.
103. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 1990;115:36–42.
104. Baughman RP, Winget DB Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:154–8.
105. Baughman RP, Culver DA, Judson MA. A Concise Review of Pulmonary Sarcoidosis. AJRCCM. 2011;183:573–81.
106. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99:307–15.
107. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thor Soc. 2016;13:1244–52.
108. Bäumer I, Zissel G, Schlaak M, Müller-Quernheim J. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1997;16:171–7.
109. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001;120:102–8.
110. Bažil V. Physiological enzymatic cleavage of leukocyte membrane molecules. Immunol Today. 1995;16:135–40.
111. Beaumont D, Herry JY, Sapene M, Bourguet P, Lerzul JJ, DeLabarthe B. Gallium-67 in the evaluation of sasrcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax. 1982;37:11–18.
112. Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep. 2005;7:427–33.
113. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002;168:3536–42.
114. Belhassen B, Pines A, Laniado S. Failure of corticosteroid therapy to prevent induction of ventricular tachycardia in sarcoidosis. Chest. 1989;95:918–20.
115. Bell NH, et al. Evidence that increased circulating 1,25 -dihydroxyvitamin D is the probable couse for abnormal calcium metabolism in sarcoidosis. J Clin Invest. 1979;64:218–55.
116. Bell NH. Endocrine Complications of Sarcoidosis. Endocrin Metab Clin North Am. 1991;20:645–65.
117. Benatar SR. A comparative study of sarcoidosis in white, black and coloured South Africans. Cardiff: Alpha Omega Publishing Ltd.; 1980.
118. Benatar SR. A comparative study of sarcoidosis in white, black and coloured South Africans. In: Proc. 8th Internat. Conf. Sarcoidosis. Cardiff: Alpha and Omega Press; 1980. p. 508–13.
119. Benfield TL, van Steenwijk R, Nielsen TL, et al. IL8 and eicosanoid production in the lung during moderate to severe PNEUMOCYSTIS CARINII pneumonia in AIDS: a role of IL8 in the pathogenesis of P. CARINII pneumonia. Respir Med. 1995;89:285–90.
120. Benn BS, Lombard CM, Krishna G. Nivolumab-Induced Granulomatous Inflammation of the Pleura. J Thor Oncol. 2018;12:e100–1.
121. Benn BS, Lombard CM, Krishna G. Nivolumab-Induced Granulomatous Inflammation of the Pleura. J Thorac Oncol. 2017;12(7):e100–e101.

122. Bennet RM, Davis J. Lactoferin binding to human peripheral blood cells: An interaction with a B-enriched population of lymphocytes and a subpopulation of adherent mononuclear cells. J Immunol. 1981;127:1211–5.
123. Bergin CJ, Bell DO, Coblentz CL, et al. Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function test. Radiology. 1989;171:619–24.
124. Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:126–32.
125. Bermudez LEN, Wu M, Young HS. Naturally occurring antibodies against mycobacterium avium complex. Ann Clin Lab Sci. 1989;19:435–43.
126. Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2015;169:3–13.
127. Besnier E. Lupus pernio de la face: synovites fongueuses (scrofulo-tuberculeuses) symmétriques des extrémités. Ann derm syph. 1889;10:333.
128. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.
129. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.
130. Beste C, Kneiphof J, Woitalla D. Effects of fatigue on cognitive control in neurosarcoidosis. Eur Neuropsychopharmacol. 2015;25:522–30.
131. Betensky BP, Tschabrunn CM, Zado ES, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012;9:884–91.
132. Bhamra K, Stevens R. Pulmonary sarcoidosis following etanercept treatment. Case Rep Rheumatol. 2012;2012:724013.
133. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1304–23.
134. Bitterman PB, Rennard SI, Hunninghake GW, Crystal RG. Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest. 1982;70:806–22.
135. Bitterman PB, Wewers MD, Rennard SI, Adelberg S, Crystal RG. Modulation of alveolar macrophages-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest. 1986;77:700–8.
136. Bjermer L, Back O, Roos G, Thumnell M. Mast cells and lysozyme positive macrophages in bronchoalveolar lavage from patients with sarcoidosis. Acta Med Scan. 1986;220:161–6.
137. Bjermer L, Rosenhall L, Angstrom T, Hallgren R. Predicitive value of bronchoalveolar lavage cell analysis in sarcoidosis. Thorax. 1988;43:284–8.
138. Bjermer L, Thurell M, Hallgren R. Procollagen III peptide in bronchoalveolar lavage fluid. Lab Invets. 1986;55:654–9.
139. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36.
140. Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9:e000867.
141. Blaschke E, Eklund A. Antiotensin-converting enzyme (ACE) in human alveolar macrophages (AM) and bronchoalveolar lavage (BAL) fluid in sarcoidosis. Sarcoidosis. 1985;2:70.
142. Blasi A, et al. On the incidence of sarcoidosis in Italy. In: Iway K, Hosoda Y, editors. Proceedings of the 6th International Conference on Sarcoidosis. Tokyo: Univ. of Tokyo Press; 1974.
143. Bloedner CD. Die Behandlung der pulmonalen Sarkoidose. Dtsch Med Wschr. 1976;101:86–7.
144. Bloom CI, Graham CM, Berry MPR, et al. Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. PlosOne. 2013;8(8):e70630.
145. Boeck C. Multiple bening sarcoid of the skin. J Cutan Gen Uris Dis. 1907;17:543.
146. Boeck C. Nochmals zur klinik und zur stellung des "benignen miliarlupoids". Arch Dermat Syph (Wien). 1916;121:707–41.

147. Bohut V, Homolka J, et al. Naše zkušenosti s bronchoalveolární laváží. Technika, chyby, výhody, indikace, komplikace, kontraindikace. Stud Pneumol Phtiseol Cechoslov. 1985;45:579–83.
148. Bolland MJ, Wilsher ML, Grey A, et al. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open. 2013;3:e003562.
149. Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med. 2016; 22:484–91.
150. Bonham CA. Biomarkers in Sarcoidosis: Can microRNAs Fill the Gap? Am J Resp Cell Mol Biol. 2018;58:1–2.
151. Borgmann S, Haubitz M. Genetic impact of pathogenesis and prognosis of ANCA- associated vasculitides. Clin Exp Rheumatol. 2004;22(Suppl 36):79–86.
152. Borregaard N, Srensen OE, Theilgaard-Wnchl K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007;28:340–5.
153. Borucki SJ, Nguyen BV, Ladoulis CT, McKendall RR. Cerebrospinal fluid immunologlobulin abnormalities in neurosarcoidosis. Arch Neurol. 1989;46:270–3.
154. Borucki SJ, Nguyen BV, McKendall RR. Cerebrospinal Fluid Immunoglobulin Abnormalities in Neurosarcoidosis. Arch Neurol. 1989;46:270–3.
155. Bost TW, Riches DWH, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-d and interleukin-6 but not interleukin-1? Am J Respir Cell Mol Biol. 1994;10:506–13.
156. Böttger D. Indication and duration of the prednisolone therapy of chronic pulmonary sarcoidosis. A prognostic therapeutic screening as a result of a controlled trial. Z Erkr Atm Org. 1977;149:148–53.
157. Böttger D. Sarkoidose. Theorie und Praxis. Leipzig: J.A.Barth; 1982.
158. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164:4991–5.
159. Bourguet P, Delaval P, Herry JY. Direct quantitation of thoracic gallium-67 uptake in sarcoidosis. J Nucl Med. 1986;27:1550–6.
160. Bours S, de Vries F, van den Bergh JPW, et al. Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort. Osteoporos Int. 2016;27:1603–10.
161. Bradley DA, Baughmann RP, Raymond L Kaufman AH. Ocular manifestaion of Sarcoidosis. Semin Respir Crit Care Med 2002;23:543–8.
162. Brain JD. Lung macrophages: how many kinds are there? What do they do? Am Rev Respir Dis. 1988;137:507–9.
163. Brauner MW, Grenier P, Mompoint D, Lenoir S, de Crémoux H. Pulmonary sarcoidosis: evaluation with high-resolution CT. Radiology. 1989;172:467–71.
164. Brauner MW, Lenoir S, Grenier P, Cluzel P, Battesti JP, Valeyre D. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology. 1992;182:349–54.
165. Bredenoord AJ, Jafar Jafari, Saleheen Kadri, David E Simcock, Daniel Sifrim, Sean L Pres. Case report: Achalasia-like dysmotility secondary to oesophageal involvement of sarcoidosis. Gut. 2011;60:153–5.
166. Brennan NJ, Crean P, Long P, et al. High prevelane of familial sarcoidosis in an Irish population. Thorax. 1984;39:14–8.
167. Bresnitz EA, Stolley PD, Israel HL, Soper K. Possible risk factors for sarcoidosis. A case-control study. Ann N Y Acad Sci. 1986;465:632–42.
168. Brewerton DA, et al. HLA antigens in sarcoidosis. Clin Exp Immunol. 1977;27:227–9.
169. Brien TG. Dalrymple IJ. A longitudinal study of the free cortisol index in pregnancy. Br J Obstet Gynaecol. 1976;83:361–7.
170. Brill AK, Ott SR, Geiser T. Effect and Safety of Mycophenolate Mofetil in Chronic Pulmonary Sarcoidosis: A Retrospective Study. Respiration. 2013;86:376–83.
171. Brincker H. Coexistence of sarcoidosis and malignant disease: causality or coincidence? Sarcoidosis. 1980;6:31–43.
172. Brincker H. Sarcoid reactions in malignant tumours. Cancer Treat Rev. 1986;13:147–56.

173. Brincker H. Solid tumors preceding or following sarcoidosis. Med Pediatr Oncol. 1987;15:82–8.
174. Brincker H. The incidence of malignant tumors in patients with respiratory sarcoidosis. Br J Cancer. 1979;29:247–51.
175. Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer. 1986;54:467–73.
176. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–5.
177. Brodin P, Lakshmikanth T, Kärre K, Höglund P. Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets. J Immunol. 2012;188:2218–26.
178. Broos CE, van Nimwegen M, in ,t Veen JCCM, et al. Decreased Cytotoxic T-Lymphocyte Antigen 4 Expression on Regulatory T Cells and Th17 Cells in Sarcoidosis: Double Trouble? Am J Respir Crit Care Med. 2015;192:763–5.
179. Broos CE, Koth LL, van Nimwegen M, et al. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J. 2018;51:1701124.
180. Brun J, Kofman J, Faivre JM. Le traitement corticonigue de le sarcoidose médiastinopulmonaire: nécessité ï un traitement précoce et place de I A.C.T.H. thérapie (ï aprés un bilan de 75 observations). Poumon Coeur. 1972;28:321–4.
181. Buck AA, Sartwell PE. Epidemiologic investigations of sarcoidosis. II. Skin sensitivity and environmental factors. Am J Hyg. 1961;74:152–73.
182. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol. 2013;13:59–66.
183. Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate and Th2 immunity. Immunol Cell Biol. 2010;88:257–68.
184. Bulger K, O'Riordan M, Purdy S, O'Brien M, Lennon J. Gastrointestinal sarcoidosis Resembling Crohn's disease. Gastroent. 1988;83:1415–7.
185. Burns Am, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cut Pathol. 2011;289–93.
186. Burns DM, Shure D, Francoz R, et al. The physiologic consequences of saline lobar lavage in healthy human adults. Am Rev Resp Dis. 1983;127:695–701.
187. Burns TM. Neurosarcoidosis. Arch Neurol. 2003;60:1166–8.
188. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 1988;4:487–525. Review.
189. Busuttil A, Weigt SS, Keane MP, et al. CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. Eur Respir J. 2009;34:676–86.
190. Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. A registry based on incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:46–52.
191. Cahalin LP. Pulmonary evaluation. In: DeTurk W, Cahalin L, editors. Cardiovascular and pulmonary physical therapy. New York: McGraw-Hill; 2004. p. 221–72.
192. Caillaud DM, Vergnon JM, Madroszyk A, Melloni BM, Murris M, Dalphin JC; French Group of Environmental Immunoallergic Bronchopulmonary Diseases. Bronchoalveolar lavage in hypersensitivity pneumonitis: a series of 139 patients. Inflamm Allergy Drug Targets. 2012;11:15–9.
193. Cain H, Kraus B. Immunofluorescence microscopic demonstration of vimentin filaments in asteroid bodies of sarcoidosis. A comparison with electron microscopic findings. Virchows Arch B Cell Pathol Incl Mol Pathol. 1983;42(2):213–26.
194. Cameron LA, Taha RA, Tsicopoulos A, et al. Airway epithelium expresses interleukin-18. Eur Respir J. 1999;14:553–9.
195. Cannella KAS, Aquayo SM, Komaki AP. Psychosocial stress and quality life in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:11.
196. Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med. 2010;181:1217–22.
197. Carlens E, Hanngren A, Ivemark B. The concominance of feverish onset of sarcoidosis and necrosis formation in the lymph-nodes. In: Iwai K, Hosoda Z, editors. Proc. 6th International Conference on Sarcoidosis, Tokyo. Tokyo: University of Tokyo Press; 1974. p. 409–12.

198. Carlens E. Mediastinoscopy: A method for inspection and tissue biopsy in the superior mediastinum. Dis Chest. 1959;4:343.
199. Carrington CB, Gaensler EA, Mikus JP, et al. Structure and Function in Sarcoidosis. Ann New York Acad Sci. 1976;278:265–83.
200. Carter JD, Valeriano J, Frank B. Vasey, Bognar B. Refractory neurosarcoidosis: A dramatic response to infliximab. Am J Med. 2004;117:277–9.
201. Cartner BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA, de Groot PM. Immunotherapy in Non–Small Cell Lung Cancer Treatment. J Thorac Imaging, 2017;32:300–12.
202. Castell JV, Gómez-Lechón MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Letters.1988;232:347–50.
203. Castrignano L, Fasolini G, Nozza M, Schieppati A. Retroperitoneal Involvement in Sarcoidosis. In: Grassi C, Pozzi E, Rizzato G. Abstracts of XI WCS. Milano: Congress Studio Publisher; 1987. p. 25.
204. Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–5.
205. Cengiz C, Rodriguez-Davalos M, DeBoccardo G, et al. Recurrent hepatic sarcoidosis post--liver transplantation manifesting with severe hypercalcemia: a case report and review of the literature. Liver Transpl. 2005;11:1611–4.
206. Cerutti A, Trentin L, Zambello R, et al. Selection of V2.3 cells in the lung of patients with sarcoidosis. Sarcoidosis. 1993;10:165–6.
207. Ceuppens JL, Lacquet LM, Marien G, Demedts M, Van den Eechout A, Stevens E. Alveolar T-cell subsets in pulmonary sarcoidosis: correlation with disease activity and effect of steroid treatment. Am Rev Resp Dis. 1984;129:563–8.
208. Coates R, Neville E. The development of airways obstruction in sarcoidosis among smokers and non-smokers. Sarcoidosis. 1993;10:115–7.
209. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol 2007;25:326–33.
210. Cohen RD, Bunting PS, Meindok HO. Does serum angiotensin converting enzyme reflect intensity of alveolitis in sarcoidosis? Thorax. 1985;40:497–500.
211. Cohen ZA, Fedorko ME, Hirsch JG, Morse SI, Siltzbach LE. The distribution of Kveim activity in subcellullar fractions from sarcoid lymph nodes. In: Turiaf J, Chabot J, editors. Proceedings of the 4th International Conference on Sarcoidosis. Paris: Masson and Co; 1967. p. 141–9.
212. Cole DA, Mercer-Smith JA, Norman JK, et al. Copper-67 labeced porphyrin localization in inflamed tissue. Proceedings of the American Society Symposium on Copper Biovailability and Metabolism. New York: Plenum Press; 1989, p. 259–72.
213. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10:411–20.
214. Colover J. Sarcoidosis with involvement of the nervous system. Brain. 1948;71:451–75.
215. Conant EF, Glickstein MF, Mahar P, Miller WT. Pulmonary sarcoidosis in the older patient: conventional radiographic features. Radiology. 1988;169:315–9.
216. Conron M, Beynon HL. Ketoconazole for the treatment of refractory hypercalcemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:277–80.
217. Conroy S. Sarcoidosis. Medical mystery uncovered. PC Publications. New Jersey: Piscataway; 1991.
218. Cooke G, Govender P, Watson CJ, et al. Sarcoidosis, alveolar beta-actin and pulmonary fibrosis. QJ Med. 2013;106:897–902.
219. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007;82:1365–74.
220. Cormier Y, Brown M, Worthy S, Racine G, Müller NL. High-resolution computed tomographic characteristics in acute farmer's lung and in its follow-up. Eur Respir J. 2000;16:56–60.
221. Corte TJ, Wells AU, Nicholson AG, Hansell DM, Wort SJ. Pulmonary hypertension in sarcoidosis: A review. Respirology. 2011;16:69–77.

222. Costabel U, Andreesen R, Bross KJ, Kroegel C, Teschler H, Walter M. Role of cells and mediators for granuloma formation in pulmonary sarcoidosis. In: Yoshida T, Torisu M. Basic Mechanisms of Granulomatous Inflammation. Amsterdam: Elsevier; 1989. p. 319–43.
223. Costabel U, Bross KJ, Guzman J, Nilles A, Ruhle KH, Matthys H. Predictive value of bronchoalveolar T-cell subsets for the course of pulmonary sarcoidosis. Ann NY Acad Sci. 1986;465:418–23.
224. Costabel U, Bross KJ, Matthys H. Lymphozyten-Subpopulationen in der bronchoalveolaren Lavage bei Sarkoidose. Verh Dtsch Ges Inn Med. 1982;88:422–6.
225. Costabel U, Bross KJ, Reuter C, Ruhle KH, Matthys H. Alteration in immuno regulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest. 1986;90:39–44.
226. Costabel U, Bross KJ, Ruhle KH, Lohr GW, Matthys H. Ia-like antigens on T-cells and their subpopulations in pulmonary sarcoidosis and hypersensitivity pneumonitis. Amer Rev Resp Dis. 1985;131:337–42.
227. Costabel U, Guzman J, Freudenburg N, Matthys H. Treffrequencien der transbronchialen Biopsie bei der Sarkoidose in Abhangigkeit von T-helferzell-Anteil in der bronchoalveolaren Lavage. Atemwegs-Lungenkrankh. 1984;10:303–5.
228. Costabel U, Zaiss A, Wagner DJ, Baur R, Ruhle KH, Matthys H. Value of bronchoalveolar lavage lymphocyte subpopulations for the diagnosis of sarcoidosis. In: Grasi C, Rizzato G, Pozzi E. Sarcoidosis and Other Granulomatous Disorders. Amsterdam: Elsevier; 1988. p. 429–32.
229. Costabel U. Consensus conference: activity of sarcoidosis. Eur Respir J. 1994;7:624–7.
230. Costabel U. Lung T-cells in granulomatous disease. In: Proceding of WASOG and BSACI Joint Meeting. London; 1995. p. 1.
231. Costabel U. Sarcoidosis. Clinical update. Eur Respir J. 2001;18:56–68.
232. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997–1004.
233. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The sarcoidosis health questionnaire: A new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168:323–9.
234. Cozier YC, et al. Obesity and weight gain in relation to incidence of sarcoidosis in US black women: data from the Black Women's Health Study. Chest. 2015;147:1086–93.
235. Craig DA, Colletti PM, Ratto D, Gordonson JS, Raval JK, Sharma OP. MRI findings in pulmonary sarcoidosis. Magn Reson Imaging. 1988;5:567–73.
236. Crawford T, Sarsam S, Mueller G, et al. The role of magnetic resonance imaging in identifying patients with cardiac sarcoidosis and preserved left ventricular function in predicting future ventricular arrhythmias. J Am Coll Cardiol. 2012;59:e575.
237. Crawshaw A, Kendrick YR, McMichael AJ, Ho LP. Abnormalities in iNKT cells are associated with impaired ability of monocytes to produce IL-10 and suppress T-cell proliferation in sarcoidosis. Eur J Immunol. 2014;44(7):2165–74.
238. Crawshaw AP, Wotton CJ, Yeates DG, Goldacre MJ, Ho LP. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax. 2011 May;66(5):447–8.
239. Criado E, Sánchez M, Ramírez J, et al. Pulmonary sarcoidosis: Typical and atypical manifestations at high-resolution CT with pathologic correlation. RadioGraphics. 2010;30:1567–86.
240. Crystal RG, Bitterman PB, Rennard SL, Kheogh BA. Interstitial lung disease of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. Engl J Med. 1984;310:154–6.
241. Crystal RG, Ferrans VJ, Gadek JE, Fulmer JD, Line BR, Hunninghake GW. Interstitial lung disease: current concepts of pathogenesis, stating and therapy. Am J Med. 1981;70:542–68.
242. Crystal RG, Roberts WC, Hunninghake GW, Gadek JE, Fulmer JD, Line BR. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. Ann Intern Med. 1981;94:73–94.
243. Crystal RG, Saltini C, Moller D, Spurzem J, Muller-Quernheim J, Wewers J. The T-lymphocyte and sarcoidosis-State of art. Sarcoidosis. 1986;3:112.

244. Cummings MM. An evaluation of the possible relationship of pine pollen to sarcoidosis. Acta Med Cand. 1964;176(suppl 425):48–50.
245. da Silva LCC, Hertz FT, Cruz DB, et al. Sarcoidose no sul do Brasil: estudo de 92 pacientes. J Bras Pneumol. 2005;31:398–406.
246. Dähnert W. Radiology review manual. 7th ed. Philadelphia: Lippincott Williams&Wilkins; 2011.
247. Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48:883–6.
248. Danila E, Norknien J, Jurgauskien L, Malickait R. Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis. Clin Respir J. 2009;3:214–21.
249. Darier J, Roussy G. Des sarcoides sous cutanées. Arch Méd Exp d'Ant Path. 1906;18:1.
250. Dauber JH, Rossman MD, Daniele RP. Bronchoalveolar cell population in acute sarcoidosis: Observations in smoking and nosmoking patients. J Clin Med. 1979;94:862–71.
251. Davies CW, Tasker AD, Padley SP, Davies RJ, Gleeson FV. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000;55:217–21.
252. De Kleijn WPE, De Vries J, Lower EE, Elfferich MDP, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Current Opin Pulm Med. 2009;15:499–506.
253. De Kleijn WPE, Drent M, Vermunt JK, Shigemitsu H, De Vrie J. Types of fatigue in sarcoidosis patients. J Psychosom Res. 2011;71:416–22.
254. de Kleijn WPE, Elfferich MD, De Vries J, et al. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Disease. 2009;26:92–7.
255. De Rose V, Trentin L, Crivellari MT. Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis. Thorax. 1997;52:76–83.
256. De Vries J, Michielsen H, van Heck G, Drent M. Measuring fatigue in sarcoidosis: The Fatigue Assessement Scale (FAS). Br J Health Psychol. 2004;9:279–91.
257. de Vries VC, Elgueta R, Lee DM, Noelle RJ. Mast cell protease 6 is required for allograft tolerance. Transplant Proceed. 2010;42:2759–62.
258. Delaval PM, Renetit NM, Merdrignac G, Coetmeur D. T-lymphocytosis in bronchoalveolar lavage fluid of hypersensitivity pneumonitis. Chest. 1985;87:133.
259. DeRemee RA, Donald TJ, Weiland LH. Wegener's granulomatosis: experience with over 100 cases. New approaches for treatment. Sarcoidosis. 1986;3:143–4.
260. DeRemee RA. A Decade of ANCA. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:208.
261. DeRemee RA. Clinical profiles of diffuse interstitial pulmonary disease. New York: Futura Publishing Co; 1990.
262. DeRemee RA. Sarcoidosis. Current perspectives on diagnosis and treatment. Postgrad Med. 1984;76:167–72.
263. DeRemee RA. The present status of treatment of pulmonary carcoidosis: house divided. Chest. 1977;71:588–92.
264. DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest. 1983;83:128–33.
265. Descombes E, Gardiol D, Leuenberger P. Transbronchial lung biopsy: an analysis of 530 cases with reference to the number of samples. Monaldi Arch Chest Dis. 1997;52:324–9.
266. deShazo RD, Banks DE, Diem JE, et al. Broncho-alveolar lavage celllymphocyte interactions in normal nonsmokers and smokers. Amer Rev Resp Dis. 1983;127:545–8.
267. deShazo RD, O'Brien MM, Justice WK, Pitcock J. Diagnostic criteria for sarcoidosis of the sinuses. J Allergy Clin Immunol. 1999;103:789–95.
268. Désogère P, Tapias LF, Hariri LP, et al. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017;9:eaaf4696.
269. Deubner DC, Goodman M, Iannuzzi J. Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey. Appl Occup Environ Hyg. 2001;16:521–6.
270. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol. 1993;17:1272–80.

271. Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol. 2011;31:1397–402.
272. Di Mauro M, Fazi P, Solfanelli S, et al. Efficasy of inhaled Budesonide on pulmonary activity in sarcoidosis. In: Proceedings of WASOG and BSACI Joint Meeting. London; 1995. p. 47.
273. DiCarlo FJ, DiCarlo JP, Robboy SJ, Lyons MM. sarcoidosis of uterus. Arch Pathol Lsb Med. 1999;113:941–3.
274. Diesing D, Axt-Fliedner R, Hornung D, Weiss JM, Diedrich K, Friedric M. Granulomatous mastitis. Arch Gyn Obst. 2004;269:233–6.
275. Dinarello CA, Marnoy SO, Rosenwasser LJ. Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol. 1983;130:890–5.
276. Djurić B. Sarcoidosis in Eastern Europe. Sarcoidosis. 1985;2(1):35–7.
277. Doerner AM, Zuraw BL. TGF-beta1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL-1beta but not abrogated by corticosteroids. Respir Res. 2009;10:100.
278. Donghi M, Giura R, Antonelli P. Increase of serum copper concentration in Löfgren syndrome. Sarcoidosis. 1995;12:147–9.
279. Donnelly RP, Crofford LJ, Freeman SL, et al. Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-kappa B activity in monocytes and fibroblasts. J Immunol. 1993;151:5603–12.
280. Doubková M, Moulis M, Skřičková J. Intersticiální plicní procesy a granulomatózy asociované s bižným variabiní deficitem. Vnitř Lék. 2015;61:119–24.
281. Doubková M, Pospíšil Z, Skřičková J, Doubek M. Prognostic markers of sarcoidosis: an analysis of patients from everyday pneumological practice. Clin Resp J. 2014;9:443–9.
282. Douglas AC. Epidemiology of sarcoidosis in Scotland. Acta Med Scand Suppl. 1964;425:118–21.
283. Douglas JG, Middleton WG, Gaddie J, Petrie GR, Choo-Kang YF, Prescott RJ, Crompton GK. Sarcoidosis: a disorder commoner in non-smokers? Thorax. 1986;41(10):787–91.
284. Drajna M, Hutyrová B, Lošáková V, Stejskal D, Kolek V. Význam sIL2R při hodnocení závažnosti sarkoidózy: vztah k jiným vyšetřovacím metodám. Stud Pneumol Phthiseol. 2007;6:239–43.
285. Drent M, Grutters JC, Mulder PG, van Velzen-Blad H, Wouters EF, van den Bosch JM. Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile? Sarcoidisis Vasculitis Diffuse Lung Dis. 1997;14:31–8.
286. Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem IH, Wouters EF. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J. 1999;13:1338–44.
287. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40:255–63.
288. Drent M, Mansour K, Linssen C. Bronchoalveolar Lavage in Sarcoidosis. Semin Respir Crit Care Med. 2007;28:486–95.
289. Drent M, Mulder PG, Wagenaar SS, Hoogsteden HC, van Velzen-Blad H, van den Bosch JM. Differences in BAL fluid variables in interstitial lung diseases evaluated by discriminant analysis. Eur Respir J. 1993;6:803–10.
290. Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of Sarcoidosis. Clin Chest Med. 2015;36:727–37.
291. du Bois RM, Holroyd KJ, Saltini C, Crystal RG. Granulomatous processes. In: Crystal RG, editor. The Lung: Scientific Foundations. New York: Raven Press; 1991.
292. du Bois RM, Kirby M, Balbi B, Saltini C, Crystal RG. T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor. Am Rev Respir Dis. 1992;145:1205–11.
293. du Bois RM. Advances in our understanding of the pathogenesis of fibrotic lung disease. Respir Med. 1990;84(3):185–7.
294. du Bois RM. The alveolar macrophage in sarcoidosis. Sarcoidosis. 1990;7(1):15–8. Review.

295. Dubaniewicz A. Microbial and human heat shock proteins as 'danger signals' in sarcoidosis. Hum Immunol. 2013;74(12):1550–8.
296. Dubaniewicz A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun Rev. 2010;9:419–24.
297. Dubaniewicz A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun Rev. 2010;9(6):419–24.
298. Dubrey S, Shah S, Hardman T, Sharma R. Sarcoidosis: the links between epidemiology and aetiology. Postgrad Med J. 2014;90:582–9.
299. Duchemann B, Macsamo A, de Naurois JC, et al. Prevalence and incidence of intersticital lung diseases in multi-ethnic county of Greater Paris. Eur Respir J. 2017;50:1602419.
300. Dulai PS, Rothstein RI. Disseminated sarcoidosis presenting as granulomatous gastritis: a clinical review of the gastrointestinal and hepatic manifestations of sarcoidosis. J Clin Gastroenterol. 2012;46:367–74.
301. Dumas O, Abramovitz L, Wiley AS, Cozier YC, Canargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort of U.S. women. Ann Am Thorac Soc. 2016;13:67–71.
302. Dumas O, Boggs KM, Cozier YC, Stampfer MJ, Camargo CA Jr. Prospective study of body mass index and risk of sarcoidosis in US women. Eur Respir J. 2017;50:1701397.
303. Duric O, Dostanic D. Roentgenographic atypical form of pulmonary sarcoidosis. Sarcoidosis. 1992;9(Suppl 1):369–70.
304. Dušek J, Kubašta M, Ošťádal O, Šimeček C. K metodice punkčních bioptických vyšetření jater u sarkoidózy nitrohrudních uzlin. Rozhl Tuberk. 1967;278:685–9.
305. Dutton RE, Renzi PM, Lopez-Majano V, Renzi GD. Airway function in sarcoidosis: Smoker versus non-smoker. Resp. 1982;43:164–73.
306. Dyskova T, Fillerova R, Novosad T, et al. Correlation Network Analysis Reveals Relationships between MicroRNAs, Transcription Factor T-bet, and Deregulated Cytokine/Chemokine-Receptor Network in Pulmonary Sarcoidosis. Mediators Inflamm. 2015;2015:121378.
307. Eckert H. Organmanifestation der Sarkoidose. Z Erkr Atmungsorg. 1988;170:257–261.
308. Eden E, Turino GM. Interleukin-1 secretion by human alveolar macrophages stimulated with endotoxin is augmented by recombinant immune (gamma) interferon. American Rev Respir Dis. 1986;133:455–60.
309. Eggelmeier F, Dijkmans BA. Sarcoidosis post-partum: a description of four cases (letter). Br J Rheumatol. 1989;28:270–1.
310. Eishi Y, Miyamae C, Ando N, et al. Seeking a causative agent of Sarcoidosis: a monclonal antibody prepared by the immunization with a crude tissue suspension of sarcoidosis lymph nodes. Sarcoidosis. 1994;11:265–8.
311. Eishi Y, Ishige I, Ishige Y et al. Etiology of Sarcoidosis: the Role of Propionibacterium acnes. Acta histochemica et cytochemica. Review. 2003;36:15–26.
312. Eishi Y. Etiologic link between sarcoidosis and Propionibacterium acnes. Respir Investig. 2013;51(2):56–68.
313. Ekenga CC, Friendman-Jiménez G. Epidemiology of Respiratory Health Outcomes Among World Trade Center Disaster Workers: Review of the Literature 10 Years After the September 11, 2001 Terrorist Attacks. Disaster Med Public Health Prep. 2011;5:S189–96.
314. Eklund A, Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung. 1986;164:325–32.
315. Eklund AG, Sigurdardottir O, Ohrn M. Vintronectin and its relationship to other extracellular matrix components in bronchoalveolar lavage fluid in sarcoidosis. Am Rev Respir Dis. 1992;145:646–50.
316. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday Cognitive Failure in Sarcoidosis: The Prevalence and the Effect of Anti-TNF-alfa Treatment. Respiration. 2010;80:212–9.
317. Elias JA, Reynolds MM, Kotloff RM, Kern JA. Fibroblast interleukin 1 beta: synergistic stimulation by recombinant interleukin 1 and tumor necrosis factor and posttranscriptional regulation. Proce Natl Acad Sci USA. 1989;86:6171–5.
318. Ellis K, Renthal G. Pulmonary sarcoidosis:Roentgenographic observations on course of disease. AJR Am J Roentgenol. 1962;88:1070–83.

319. El-Zammar OA, Katzenstein ALA. Pathological diagnosis of granulomatous lung disease: a review. Histopathology. 2007;50:289–310.
320. English JC, Purvisha JP, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol. 2001;44:724–43.
321. Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high prevalence of sarcoidosis in a representative U.S. Metropolitan population. Resp Med. 2012;106:893–9.
322. Erskine KJ, Taylor KJ, Agnew RAL. Serial estimation of serum angiotensin – converting enzyme activity during and after pregnancy in woman with sarcoidosis. Br Med J. 1985;290:269–70.
323. Esteves T, Aparicio G, Garcia-Patos V. Is there any association between sarcoidosis and infectious agents? : a systematic review and meta-analysis. BMC Pulm Med. 2016;16:13.
324. Esteves T, Aparicio G, Garcia-Patos V. Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis. BMC Pulm Med. 2016;16(1):165. Review.
325. Eule H, Weinecke A, Roth I, Wuthe H. The Possible Influence of Corticosteroid Therapy on the Natural Course of Pulmonary Sarcoidosis. Ann NY Acad Sci. 1986;465:695–701.
326. Ewert EG. Epidemiologie der Sarkoidose. Internist. 1982;23:298–303.
327. Facco M, Baesso I, Miorin M, Bortoli M, et al. Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. J Leukoc Biol. 2007;82:946–55.
328. Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66:144–50.
329. Facchinetti F, Gnetti L, Balestra V, Silva M, Silini EM, Ventura L, et al. Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib. Invest New Drugs. 2019;37(2):360–363.
330. Facchinetti F, Gnetti L, Balestra V, et al. Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib. Investigational New Drugs, 2019;37:360–3.
331. Faehling M, Hetzel M, Anders D, Trischler G, Bachem M. Antifibrotic role of HGF in sarcoidosis. Lung. 2012;190:303–12.
332. Faguet GB. Cellular immunity in sarcoidosis: evidence for an intrinsic defect of effector cell function. Am Rev Respir Dis. 1978;118(1):89–96.
333. Fallon MD, Perry HM, Teitelbaum SM. Skeletal sarcoidosis with osteopenia. Metab Bone Dis. 1981;3:171–5.
334. Fauci AS, Haynes BF, Costa J, Katz P, Wolff SM. Lymphomatoid Granulomatosis — Prospective Clinical and Therapeutic Experience over 10 Years. N Engl J Med. 1982;306:68–74.
335. Fazel SB, Howie SE, Krajewski AS, Lamb D. B lymphocyte accumulations in human pulmonary sarcoidosis. Thorax. 1992;47:964–7.
336. Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J. 2003;21:421–8.
337. Fidler HM, Rook GA, Johnson NM, McFadden J. Mycobacterium tuberculosis DNA in tissue affected by sarcoidosis. BMJ. 1993;306(6877):546–9.
338. Fillerova R, Kriegova E, Tomankova T, et al. Expression profiling of Th17 cell activators revealed elevation of STAT-3 in progressing sarcoidosis. Eur Respir J. 2011;38:p4762.
339. Finco O, Martinetti M, Dondi E, Luisetti M, Pasturenzi L, Cuccia M. Sarcoidosis and major histocompatibility complex genes with special emphasis on BFF subtypes. Complement Inflamm. 1991;8:80–5.
340. Finley TN, Swenson EW, Curran WS, et al. Broncho-pulmonary lavage in normal subjects and patients with obstructive lung disease. Ann intern Med. 1967;66:651–8.
341. Fischer A, Ellinghaus D, Nutsua M, et al. Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. Am J Respir Crit Care Med. 2015;192:727–36.
342. Fischer A, Ellinghaus D, Nutsua M, Hofmann S, Montgomery CG, Iannuzzi MC, et al. Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. Am J Respir Crit Care Med. 2015;192:727–36.
343. Fischer A, Schmid B, Ellinghaus D, Nothnagel M, Gaede KI, Schürmann M, et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. Am J Resp Crit Care Med. 2012;186(9):877–85.

344. Fischer C, André-Obadia N, Mauguire F. Diagnostic criteria of multiple sclerosis: electrophysiological criteria. Rev Neurol. 2001;157:974–80.
345. Fišer F, et al. Separované alveolární výplachy. Stud Pneumol Phtiseol Cechoslov. 1985;45:572–8.
346. Fišer F, Helbich P, Kolaříková R, et al. Komplexní vyšetřování bronchoalveolární tekutiny. Stud Pneumol Phtiseol Cechoslov. 1986;46:504–11.
347. Fleminb H, Bailey S. Cardiac sarcoidosis. In: James DG, editor, Dekker M. Sarcoidosis and other granulomatous disorders. New York: CRC Press; 1994. p. 323.
348. Fleming HA. Sarcoid Heart Disease. Br Med J. 1986;292:1095–6.
349. Florian S, Sonneck K, Czerny M, et al. Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy. 2006;61:1054–62.
350. Foldes C, Vauthieu J, Bentata M, Perie G. Sarcoidose conjugale. Ann Dermatol Venereol. 1991;118:834–6.
351. Foley KT, Hewell JD, Junck L. Progression of hydrocephalus during corticosteroid therapy for neurosarcoidosis. Postgrad Med J. 1989;65:481–4.
352. Foley MM, Coral AP, Tung K, Hudspith BN, Jamos DG, Johnson N. Bronchoalveolar lavage cell counts as a predictor of short term outcome in pulmonary sarcoidosis. Thorax. 1989;44:732–8.
353. Foley P, Lympany P, Puscinska E, et al. HLA-DRB1 and TAP1. Polymorphism in Sarcoidosis. Chest. 1997;111:73.
354. Forge NI, Mountford PJ, O'Doherty MJ. Quantification of technetium-99m lung radioactivity from planar images. Eur J Nucl Med. 1993;20:10–5.
355. Forman JD, Klein JT, Silver RF, Lui MC, Greenlee BM, Moller DR. Selective activation and accumulation of oligoclonal V-specific T-cells in active pulmonary sarcoidosis. J Clin Invest. 1994;94:1533–42.
356. Forsén KO, Milman N, Piettinalho A, Selroos O. Sarcoidosis in the Nordic countries 1950-1987. Sarcoidosis. 1992;9:140–1.
357. Foulon G, Wislez M, Naccache JM, et al. Sarcoidosis in HIV- infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38:418–25.
358. Fox HB, Israel HL. A cause of precordial pain. In: Abstracts of the IXth International Conference on Sarcoidosis. Paris: Masson and Co; 1981. p. 82.
359. Fraioli P, Montemurro L. Local sarcoid reaction. Sarcoidosis. 1994;11:405–7.
360. Franke A, Fischer A, Nothnagel M, Becker C, Grabe N, Till A, et al. Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. Gastroenterology. 2008;135(4):1207–15.
361. Frasca L, Nasso M, Spensieri F, et al. IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol. 2008;180:1471–81.
362. Fraser RS, Pare JAP, Fraser RG, Pare PD. Synopsis of diseases of the chest. 2nd ed. Philadelphia: Saunders; 1993.
363. Fraser SD, Sadofsky LR, Kaye PM, Hart SP. Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis. Sci Rep. 2016;6:38689.
364. Freeman AM, Curran-Everett D, Weinberger HD, et al. Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Cardiol. 2013;112:280–5.
365. Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1972;176:1655–71.
366. Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16:220.
367. Fuchs A, Gliwinski M, Grageda N, et al. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol. 2018;8:01844.
368. Fujisawa M, Okabe T, Yotsumoto H, Takaku F, Lanzillo JJ, Fanburg BL. Familial clustering of eleveted serum angiotensin-converting enzyme. Sarcoidosis. 1985;2:72.
369. Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer. 2011;129:424–32.

370. Furfaro S, Berman JS. The relation between cell migration and activation in inflammation: beyond adherence. Am J Respir Cell Mol Biol. 1996;7:248–50.
371. Gaeta M, Blandino A, Scribano E, et al. Chronic infiltrative lung diseases: value of gadolinium--enhanced MRI in the evaluation of disease activity – early report. Chest. 2000;117:1173–8.
372. Gansler TS, Wheeler JE. Mammary sarcoidosis. Two cases and literature review. Arch Pathol Lab Med. 1984;108:673–5.
373. Garay SM, Gardella JE, Fazzini EP, Goldring RM. Hermansky-Pudlak syndrome. Pulmonary manifestations of ceroid storage disorder. Amer J Med. 1979;66:737–47.
374. Garcia C, Kumar V, Sharma OP. Pancreatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:28–32.
375. Gardner J, Kennedy HG, Hamblin A, Jones E. HLA association in sarcoidosis: a study of two ethnic groups. Thorax. 1984;39:19–22.
376. Garrett J, O'Neill H, Blake S. Constrictive pericarditis associated with sarcoidosis. Am Heart J. 1984;107:394.
377. Garzoni C, Brugger SD, Qi W, et al. Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax. 2013;68:1150–6.
378. Gebreselassie NG, Moorhead AR, Fabre V, Gagliardo LF, Lee NA, Lee JJ, Appleton JA. Eosinophils preserve parasitic nematode larvae by regulating local immunity. J Immunol. 2012;188:417–25.
379. Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017;89:2092–100.
380. Geratz JD, Pryzwansky KB, Anderle SK, Tidwell RR. Control of glucan-induced systemic granulomatosis by Cyclosporine A. Inflammation. 1995;19:221–31.
381. Gerdes J, Richter E, Rusch-Gerdes S, et al. Mycobacterial nucleic acids in sarcoid lesions. Lancet. 1992;339:1536–7.
382. Ghalib HW, Whittle JA, Kubin M, et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol. 1995;154:4623–9.
383. Gibbons WJ, Levy RD, Nava S, et al. Subclinical Cardiac Dysfunction in Sarcoidosis. Chest. 1991;100:44–50.
384. Gibbs CJ, Peacock M. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Postgrad Med J. 1986;62:937–8.
385. Gibejova A, Mrazek F, Subrtova D, et al. Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2003;167:1695–703.
386. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.Thorax. 1996;51:238–47.
387. Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis--like reactions induced by checkpoint inhibitors. J Thorac Oncol. 2018;13:1076–82.
388. Gold RS, Sager E. Oral sarcoidosis: review of the literature. J Oral Surgery. 1976;34:237.
389. Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008;30:441–5.
390. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in Sarcoidosis. The Relationship of Relapse to Corticosteroid Therapy. Chest. 1997;111:623–31.
391. Gounari E, Chatzizisi O, Diza-Mataftsi E, et al. Potential prognostic value of intracellular cytokine detection by flow cytometry in pulmonary sarcoidosis. J Interferon Cytokine Res. 2013;33:261–9.
392. Govender P, Berman JS. The Diagnosis of Sarcoidosis. Clin Chest Med. 2015;36:585–602.
393. Grange JM, Gibson J, Nassau E. Enzyme-Linked Immunosorbent Assay (ELISA): a Study of antibodies to Mycobacterium tuberculosis in the IgG, IgA and IgM classes in tuberculosis, sarcoidosis and Crohn's disease. Tubercle. 1980;61:145–52.
394. Grassi C, Rizzato G, Pozzi E, editors. Sarcoidosis and Other Granulomatous Disorders. Proceedings of the Conference: 11. world congress on sarcoidosis and other granulomatous disorders, Milan, Italy, 6 Sep 1987.
395. Greco FG, Spagnolo P, Muri M, et al. The value of chest radiograph and computed tomography in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:108–16.

396. Greenacre M. Correspondence analysis in medical research. Stat Meth Med Res. 1992;1:97–117.
397. Greenacre MJ, Degos L. Correspondence analysis of HLA gene frequency data from 124 population samplex. Am J Hum Genet. 1977;29:60–75.
398. Greenhalgh PM, Southcott AM, Harris TA, et al. Randomised controlled trial of inhaled fluticasonepropionate in pulmonary sarcoidosis-a pilot study. In: Proceedings of WASOG and BSACI Joint Meeting. London; 1995, p. 69.
399. Gregor P. Echocardiography in sarcoid heart disease. In: Abstracta Vth Symposium on Echocardiology. Rotterdam; 1983, p. 77.
400. Greuel H. Thorakoskopische Lungenbiopsie. Dtsch Med Wschr. 1961;86:1680–2.
401. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.
402. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501.
403. Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.
404. Griff S, Schönfeld N, Ammenwerth W, et al. Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series. BMC Pulm Med. 2014;14:171–5.
405. Grifoni A, Montesano C, Palma P, Salerno A, Colizzi V, Amicosante M. Role of HLA-B α-3 domain amino acid position 194 in HIV disease progression. Mol Immunol. 2013;53(4):410–3.
406. Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med. 1981;94:553–600.
407. Grizzanti A, Knapp AB, Schecter AJ, Williams MH. Treatment of sarcoid meningitis with radiotherapy. Am J Med. 1982;73:605–8.
408. Groeneveld ABJ, Raijmakers PGHM, Hack CE, Thijs LG. IL8-related neutrophil elastase and severity of the adult respiratory distress syndrome. Cytokine. 1995;7:746–52.
409. Grossman LW, Fernandes-Ulloa M, Lukes SJ, Mantil J. Gallium-67 lung uptake: Conjugate--view technique. Radiology. 1985;157:789–93.
410. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med. 2009;50:538–45.
411. Gruber R, Pforte A, Beer B, Riethmuller G. Determination of gamma/delta and other T – lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood from patients with sarcoidosis and idiopathic fibrosis of the lung. APMIS. 1996;104:199–205.
412. Grunewald J, Eklund A, Olerup O. Human Leukocyte Antigen Class I Alleles and the Disease Course in Sarcoidosis Patients. Am J Respir Crit Care Med. 2004;169:696–702.
413. Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;45:1–22.
414. Grunewald J, Kaiser Y, Ostadkarampour M, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. 2016;47:898–909.
415. Grunewald J, Shigematsu M, Nagai S, et al. T-cell receptor V gene expression in HLA-typed Japanese patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 1995;151:151–6.
416. Grunewald J. Focusing on the Human T Cell Receptor for Antigen. Sarcoidosis. 1994;11:61–5.
417. Grunewald J, Olerup O, Persson U, Ohrn MB, Wigzell H, Eklund A. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci. 1994;91:4965–9.
418. Grutters JC, Fellrath JM, Mulder L, Janssen R, van de Bosch J, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: A clinical evaluation. Chest. 2003;124:186–95.
419. Grutters JC, van den Bosch JMM. Corticosteroid treatment in sarcoidosis. Eur Resp J. 2006;28:627–36.
420. Guber A, Jawad AQ, Salomon P, Mekori YA, Shitrit D. Oncostatin M in bronchoalveolar lavage correlates with the severity of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:194–200.

421. Gumustas S, Inan N, Akansel G, Basyigit I, Ciftci E. Differentiation of lymphoma versus sarcoidosis in the setting of mediastinal-hilar lymphadenopathy: Assessment with diffusion--weighted MR imaging. Sarcoidosis Vascul. Diffuse Lung Dis. 2013;30:52–9.
422. Gungor S, Ozseker F,Yalcinsoy M, et al. Conventional markers in determination of activity of sarcoidosis. Intl Immunopharmacol. 2015; 25:174–9.
423. Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders. Curr Opin Pulm Med. 2012;18:506–16.
424. Gupta RC, Kueppers F, DeRemee RA, Huston KR, McDuffie FC. Pulmonary and extrapulmonary sarcoidosis in relation to circulationg immune complexes. Am Rev Resp Dis. 1977;116:261–4.
425. Gupta SK, Gupta S. Sarcoidosis in India: a review of 125 biopsy-proven cases from Eastern India. Sarcoidosis. 1990;7:43–9.
426. Gupta SK. Steroid aerosol therapy in sarcoidosis: limitations, an experience over 20 years. In: Proceedings of WASOG and BSACI Joint Meeting. London; 1995, p. 18.
427. Guyatt GH, Bensen WG, Stolmon LP. HLA B-8 and erythema nodosum. Can Med Ass J. 1982;127:1005–6.
428. Hadid V, Valerie Patenaude V, Oddy L, Abenhaim HA. Sarcoidosis and pregnancy: obstetrical and neonatal outcomes in a population-based cohort of 7 million births. J Perinatal Med. 2014;43:201–7.
429. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol. 2004;150:146–9.
430. Hall AO, Beiting DP, Tato C, et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity. 2012;37:511–23.
431. Hall LR, Mehlotra RK, Higgins AW, Haxhiu MA, Pearlman E. An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. Infect Immun. 1998;66:4425–30.
432. Hamm H, Luhrs J, Guzman y Rotaeche J, Costabel U, Fabel H, Bartsch W. Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest. 1994;106:1766–70.
433. Hamper UM, Fishman EK, Khouri NF, Johns CJ, Wang KP, Siegelman SS. Typical and atypical CT manifestations of pulmonary sarcoidosis. J Comput Assist Tomogr. 1986;10:928–36.
434. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010;11:789–806.
435. Hamzeh N, Voelkera A, Forsse A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108:1663–6.
436. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States. A Dalphi Study. Chest. 2012;141:154–62.
437. Hance AJF, Basset G, Saumon G, et al. Smoking and interstitial lung disease. Ann NY Acad Sci. 1986;465:643–56.
438. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129:1246–52.
439. Hannuksela M, Jannson E. Isolation af a mycoplasma from sarcoid tissue. In: Iwai K, Hosoda Y, editors. Proc. 6th Internat. Conf. Sarcoidosis. Tokyo: Tokyo University Press; 1974. p. 4.
440. Hansell DM, Milne DG, Wilsher ML, Wells AU. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology. 1998;209:697–704.
441. Hanson RR, Zavala DC, Rhodes ML, et al. Transbronchial biopsy via flexible fiberoptic bronchoscope: results in 164 patients. Am Rev Resp Dis. 1976;114:67–72.
442. Harari S, Torre O, Moss J. Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev. 2011;20:34–44.
443. Harkleroad LE, Young RL, Savage PJ, Jenkins DW, Lordon RE. Pulmonary Sarcoidosis: Long--term Follow-up of the Effects of Steroid Therapy. Chest. 1982;82:84–7.

444. Harrell GT, Fisher S. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium and phosphatase values. J Clin Invest. 1939;18:687–93.
445. Harrington DW, Major M, Rybicki B, et al. Familial sarcoidosis: Analysis of 91 families. Sarcoidosis. 1994;11:240–3.
446. Harrison PV, et al. Sarcoidosis in husband and wife. NY State J Med. 1978;78:2130.
447. Haslam PL, Parker DJ, Townsend PJ. Increases in HLA-DQ, DP, DR, and transferrin receptors on alveolar macrophages in sarcoidosis and allergic alveolitis compared with fibrosing alveolitis. Chest. 1990;97(3):651–61.
448. Haubitz M, Schellong S, Göbel U, et al. Intravenous pulse administration of cyclophosphamide vs daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthr Rheum. 1998;41:1835–44.
449. Hayashi S, Ikeda T, Kamikawaji N, Shigematsu N. Relationship Between Susceptibility to Sarcoidosis and Peripheral T-cell Response to Streptococcal Cell Wall Antigen. Which is Regulated by HLA ClassII Antigens. Sarcoidosis. 1991;8:155.
450. Headings VE, et al. Familial sarcoidosis with multiple occurence in eleven families: A possible mechanism of inheritance. Ann NY Acad Sci. 1976;278:377–86.
451. Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Seminars in immunology. 2015;27:149–60.
452. Hebel R, Dubaniewicz-Wybieralska M, Dubaniewic A. Overview of neurosarcoidosis: recent advances. J Neurol. 2015;262:258–67.
453. Hedfors E, Moller E. HLA antigens in sarcoidosis. Tissue Antigens. 1976;3:95–9.
454. Hedfors E. Characterization of peripheral blood lymphocytes in sarcoidosis. Ann NY Acad Sci. 1976;278:101–4.
455. Hedl M, Abraham C. Negative regulation of human mononuclear phagocyte function. Mucosal Immunol. 2013;6:205–23.
456. Heerfordt CF. über eine „Febris uveo-parotidea subchronica", an der Glandula parotis und der Uvea des Auges lokalisiert und häufug mit Paresen cerebrospinaler Nerven kompliziert. Albrecht von Grafes Archiv für Opthalmologie. 1909;70:254–73.
457. Heijckmann AC, Huijberts MS, De Vries J, Menheere PP, Van Der Veer E, Kruseman AC, Wolffenbuttel BH, Geusens P, Drent M. Bone turnover and hip bone mineral density in patient with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24:51–8.
458. Heine F. Die Probeexcision aus Veranderungen im Thoraxraum und Lunge unter thorakoskopischer Sicht. Beitr Klin Tuberk. 1957;116:615–27.
459. Heissigerová J, Callanan D, de Smet MD, et al. Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): The Phase 2 SATURN Study. Ophthalmology. 2019;126:428–37.
460. Helming L, Böse J, Ehrchen J, et al. 1,25-dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood. 2005;106:4351–8.
461. Hendrick OY, Blackworrd RA, Black JM. Chest pain in the presentation of sarcoidosis. Brit J Dis Chest. 1976;70:206–8.
462. Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123:840–5.
463. Henneman P, Dempsey E, Carol E, Albright F. The cause of hypercalcemia in sarcoidosis and its treatment with hydrocorthison and natrium phytate. J Clin Invest. 1956;35:1229–42.
464. Herndon B, Quinn T, Wasson N, Nzabi M, Molteni A. Urease and Helicobacter spp. antigens in pulmonary granuloma. J Comp Path. 2013;148:266–77.
465. Hertel G, Stoltenburg G, Eiselt B. Muskelsarkoidose ais Erstmanifestation einer Sarkoidose in der Fruhphase. Prax Klin Pneumol. 1981;35:1003–5.
466. Heřman M, Kolek V. Možnosti výpočetní tomografie s vysokou rozlišovací schopností v diagnostice plicních onemocnění. II. Klinické aplikace. Čes Radiol. 1992;46:204–9.
467. Heřman M, Kolek V. Možnosti výpočetní tomografie s vysokou rozlišovací schopností v diagnostice plicních onemocnìní. I. technické aspekty. Čes Radiol. 1992;46:197–203.
468. Hetherington S. Sarcoidosis in young children. Am J Dis Child. 1982;136:3–15.

469. Heyll A, Meckenstock G, Aul C, et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14:161–4.
470. Hilbert DM, Cancro MP, Scherle PA, et al. T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells. J Immunol. 1989;143:4019–24.
471. Hilderson I, Van Laecke S, Wauters A, Donck J. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrol Dial Transplant. 2014;29:1841–7.
472. Hillerdal G, Frisk G, Diderholme H. High frequency of IgM antibodies to Coxsackie B virus in sarcoidosis patients and patients with asbestos-related lesions. Sarcoidosis. 1991;2:39–42.
473. Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32.
474. Hillerup S. Diagnosis of sarcoidosis from oral manifestation. Int J Oral Surg. 1976;5(2):95–9.
475. Hilzenrat N, Spanier A, Lamourex E, Bloom C, Sherker A. Colonic obstruction secondary to sarcoidosis: nonsurgical diagnosis and management. Gastroenterology. 1995;108:1556–9.
476. Hodder R. The role of collaborative self-management education in pulmonary rehabilitation. In: Donner CF, Ambrossino N, Goldstein RS. Pulmonary rehabilitation. London: Hodder Arnold; 2005. p. 205–18.
477. Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc Nephrol. 2016;11:137–54.
478. Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paedeatrica. 2007;93:30–6.
479. Hofmann S, Fischer A, Nothnagel M, Jacobs G, Schmid B, Wittig M, et al. Genome-wide association analysis reveals 12q13.3–q14.1 as new risk locus for sarcoidosis. Eur Resp J. 2013;41(4):888–900.
480. Hofmann S, Fischer A, Till A, Müller-Quernheim J, Häsler R, Franke A, et al. A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Resp J. 2011;38(5):1127–35.
481. Hofmann S, Franke A, Fischer A, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat genet. 2008;40:1103–6.
482. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nature genetics. 2008;40(9):1103.
483. Höglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol. 2010;10(10):724–34.
484. Hoitsma E, Drent M, Verstraete E, et al. Abnormal warm and cold sensation thresholds suggestive of small-fibre neuropathy in sarcoidosis. Clin Neurophysiol. 2003;114:2326–33.
485. Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis, Lancet. 2002;359:2085–6.
486. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18:673–83.
487. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872–97.
488. Holland AE, Dowman LM, Hill CJ. Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration. 2015;89:89–99.
489. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–46.
490. Holland AE, Wadell K, Spruit MA. How to adapt the pulmonary rehabilitation programme to patients with chronic respiratory disease other than COPD. Eur Respir Review. 2013;22:577–86.
491. Hollinger WM, Staton GW, Fajman WA., et al. Prediction of therapeutic responsex in steroid-treated pulmonary sarcoidosis. Evaluation of clinical parameters, bronchoalveolar lavage, gallium-67 lung scanning, and serum angiotensin-converting enzyme levels. Am Rev Resp Dis. 1985;132:65–9.

492. Homma H, Okano H, Mochizuki H. An attempt to isolate mycoplasma from patients with sarcoidosis. In: Levinsky L, Macholda F, editors. Proc. 5th Internat. Conf. Sarcoidosis Prague. Praha: Univerzita Karlova; 1977, p. 101.
493. Homma JY, et al. Bacteriological investigation on biopsy specimens from patients with sarcoidosis. Jap J Exp Med. 1978;48:251–5.
494. Homolka J, Altmann V, Votava V. Increasing prevalence of idiopatic pulmonary fibrosis in the Czech Republic. Chest. 1999;116(Suppl 2):155.
495. Homolka J, Lorenz J, Zuchold M, Müeller-Quernheim J. Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis. Clin Invest. 1992;70:909–16.
496. Homolka J, Müller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung. 1993;171:173–83.
497. Homolka J. Význam oxidových radikálů v patogeneze intersticiálních plicních procesů. Čas Lék Čes. 1989;128:555–8.
498. Honda O, Johkoh T, Ichikado K, et al. Comparison of high resolution CT findings of sarcoidosis, lymphoma, and lymphangitic carcinoma: is there any difference of involved interstitium? J Comput Assist Tomogr. 1999;23:374–9.
499. Honore LH. Asymptomatic Genital Sarcoidosis. NY J Obstet Gynecol. 1981;21:188–90.
500. Horii Y, Muraguchi A, Suematsu S, Matsuda T, Yoshizak, K, Hirano T, Kishimoto T. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol. 1988;141:1529–35.
501. Horsmanheimo M, Virolainen M. Acquesition of tuberculin sensitivity after injection of dialyzable transfer factor in sarcoidosis. Ann NY Acad Sci. 1976;278:129–34.
502. Horwitz O. Epidemiology of sarcoidosis in Denmark. In: Levinsky L, Macholda F, eds. Proceedings of the Fifth International Conference on Sarcoidosis. Prague: Universita Karlova, 1971:254–8.
503. Hosoda Y, Sasagawa S, Yasuda N. Epidemiology of sarcoidosis new frontiers to explore. Cur Op Pulm Med. 2002;8:424–8.
504. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemikology of sarcoidosis: What Story Do Prevalence and Incidence Tell Us? Clin Chest Med. 1997;18:681–94.
505. Hosoda Y. Epidemiology of sarcoidosis. State of art. In: Grassi C, Rizzato G, Pozzi E. Sarcoidosis. Amsterdam: Excerpta Medica; 1988. p. 279–90.
506. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-Term Treatment with Infliximab in Patients with Sarcoidosis. Respiration 2012;83:218–224.
507. Hoyle C, Dawson J, Mather G. Treatment of pulmonary sarcoidosis with streptomycin and cortisone. Lancet. 1955;268:638–43.
508. Hrycaj P, Wurm K, Mennet P, Mller W. Antibodies to heat shock proteins in patients with pulmonary sarcoidosis. Sarcoidosis. 1995;12:124–30.
509. https://www.frontiersin.org/articles/10.3389/fimmu.2019.02265/full
510. Hu Y, Yibrehu B, Zabini D, Kuebler WM. Animal models of sarcoidosis. Cell Tissue Res. 2017;367:651–61.
511. Huang H, Lu Z, Jiang C, Liu J, Wang Y, Xu Z. Imbalance between Th17 and Regulatory T-Cells in Sarcoidosis. Int J Mol Sci. 2013;14:21463–73.
512. Huang PL, Brooks R, Carpenter C, Garan H. Antiarrhythmic therapy guided by programmed electrical stimulation in cardiac sarcoidosis with ventricular tachycardia. Am Heart J. 1991;121:599–601.
513. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon? J Exp Med. 1984;160:310–6.
514. Huffstutter JG, Huffstutter JE. Hypercalcemia from sarcoidosis successfully treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:51–2.
515. Hugh A. Breakfast seminar: Myocardial sarcoidosis. Sarcoidosis. 1994;11:13.
516. Hughes JJ, Wilder WM. Computed tomography of renal sarcoidosis. J Comput Assist Tomogr. 1988;12:1057–8.

517. Huizar I, Malur A, Midgette YA, et al. Novel murine model of chronic granulomatous lung inflammation elicited by carbon nanotubes. Am J Respir Cell Mol Biol. 2011;45:858–66.
518. Hulten E, Agarwal V, Cahill M, et al. Presence of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Among Patients With Suspected Cardiac Sarcoidosis Is Associated With Adverse Cardiovascular Prognosis: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imaging. 2016;9:e005001.
519. Hunjan T, Chaudery M, Zaidy A, Beggs AD. Appendicular sarcoidosis mimicking acute appendicitis. BMJ Case Rep. 2012;2012:bcr2012006825.
520. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–73.
521. Hunninghake GW, Crystal DG. Pulmonary sarcoidosis. A disorder mediated by excess helper T-lymphocyte activity at sites of disease. N Engl J Med. 1981;305:429–34.
522. Hunninghake GW, Fulner JD, Young RC Jr, Gadek JE, Crystal RD. Localization of the immune response in sarcoidosis. Am Rev Resp Dis. 1979;120:49–57.
523. Hunninghake GW, Gadek JE, Fales HM, Crystal RG. Human alveolar marcophage-derived chemotactic growth factor for neutrophils. J Clin Invest. 1980;66:473–83.
524. Hunninghake GW, Garrett KC, Richerson HB, et al. State of art: pathogenesis of the granulomatous lung diseases. Am Rev Resp Dis. 1984;130:476–96.
525. Hunninghake GW, Glazier AJ, Monick MM, Dinarello CA. Interleukin-1 is a chemotactic factor for human T-lymphocytes. Am Rev Resp Dis. 1987;135:66–71.
526. Hunninghake GW, Kawanami O, Ferrans VJ, Young RC Jr, Roberts WC, Crystal RG. Characterization of the inflamatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Resp Dis. 1981;123:407–12.
527. Hunninghake GW. Release of interleukin 1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Resp Dis. 1984;129:569–72.
528. Hunninghake GW. Staging of pulmonary sarcoidosis. Chest. 1986;89:178–81.
529. Hunt BM, Vallires E, Buduhan G, Aye R, Louie B. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg. 2009;197:629–32.
530. Hunter FT. Hutchinson-Boeck's disease (generalised sarcoidosis). N Engl J Med. 1936;214:346–52.
531. Hušák V. Radiační zátěž pacientů v nukleární medicíně a hodnocení radiačního rizika. Čas Lék Čes. 1984;123:538–41.
532. Hutchinson J. Case of livid papillary psoriasis. Illustrations of Clinical Surgery. London: J and A Churchill Ltd; 1877.
533. Hutchinson J. Cases of Mortimer's malady. Arch Surg. 1888;9:307.
534. Hutchinson J. Mabey's malady and lupus pernio. Arch Surg. 1900;11:205.
535. Hutyrová B, Čtvrtlík F, Kolek V. Sarkoidóza a pleurální postižení. Stud Pneumol Phthiseol. 2014;74:25–30.
536. Hutyrová B, Kolek V, Benýšek Vl. Postižení pleury u sarkoidózy. Stud Pneumol Phthiseol. 2008;68:239–43.
537. Hutyrová B, Pentelidis P, Drábek J, et al. Interleiukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;165:148–51.
538. Hwang CJ, Gausas RE. Sarcoid-like Granulomatous Orbital Inflammation Induced by Interferon-? Treatment. Ophthalmic Plast Reconstr Surg. 2008;24:311–3.
539. Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014;108:793–9.
540. Chadelat K, Baculard A, Grimfeld A, et al. Pulmonary sarcoidosis in children: serial evaluation of bronchoalveolar lavage cells during corticosteroid treatment. Pediatric pulmonology 1993;16:41–7.
541. Chain JL, Martin AK, Mack DG, Maier LA, Palmer BE, Fontenot AP. Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation. J Immunol. 2013;191:1648–56.

542. Chaitow L. Osteopathic assessment and treatment of thoracic and respiratory dysfunction. In: Chaitow LD, Bradley Ch, Gilbert Ch, editors. Multidisciplinary approaches to breathing pattern disorders. Edinburgh: Churchill Livingstone; 2002. p. 131–72.
543. Challal S, Semerano L, Nunes H, Valeyre D, Boissier MC, Saidenberg-Kermanac'h N. Teriparatide for osteoporosis in patients with sarcoidosis: Report on risk-benefit ratio in four cases. Joint Bone Spine. 2016;83:344–5.
544. Chambellan A, Turbie P, Nunes H, Brauner M, Battesti JP, Valeyre D. Endoluminal Stenosis of Proximal Bronchi in Sarcoidosis: Bronchoscopy, Function, and Evolution. Chest. 2005;127:472–81.
545. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol. 1997;9:396–404.
546. Chang B, Steimel J, Moller DR, et al.: Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329–34.
547. Chaouat G, Cayol V, Mairovitz V, Dubanchet S. Localization of the Th2 Cytokines IL-3, IL-4, IL-10 at the Fetomaternal Interface During Human and Murine Pregnancy and Lack of Requirement for Fas/Fas Ligand Interaction for a Successful Allogeneic Pregnancy. Am J Reprod Immunol. 1999;42(1):1–13.
548. Chapelon C, Ziza JM, Piette JC, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine. 1990;69:261–76.
549. Chapman JS, Speight M. Further studies of mycobacterial antibodies in the sera of sarcoidosis patients. Acta Med Scand Suppl. 1964;425:61–7.
550. Chapman JT, Mehta A. Bronchoscopy in sarcoidosis: diagnostic and therapeutic interventions. Curr Opin Pulm Med. 2003;9:402–7.
551. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24:1741.
552. Charles J, Elpner DJ. Sarcoidosis: Hawaii rarity. Hawai Med J. 1991;50:204–10.
553. Chase MW, Siltzbach LE. Concentration of the active principle responsible for the Kveim reaction. In: Turiaf J, Chabot J, editors. Proceedings of the 4th International Conference on Sarcoidosis. Paris: Masson and Co; 1967. p. 150.
554. Chase MW. Preparation and standardisation of Kveim-testing antigen. Am Rev Respir Dis. 1961;84:86–8.
555. Cheidde L, Ajzen SA, Tamer Langen CH, Christophalo D, Heilberg IP. A critical appraisal of the radiological evaluation of nephrocalcinosis. Nephron Clinical Practice. 2007;106:119–24.
556. Chen ES, Moller DR. Etiology of Sarcoidosis. Clin Chest Med. 2008;29:365–77.
557. Chen ES, Moller DR. Etiologies of Sarcoidosis. Clin Rev Allergy Immunol. 2015;49:6–18.
558. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360–73.
559. Chevalet P, Clement R, Rodat O, Moreau A, Brisseau JM, Clarke JP. Sarcoidosis diagnosed in elderly subjects:retrospective study of 30 cases. Chest. 2004;126:1423–30.
560. Chiarchiaro J, Chen BB, Gibson JKF. New molecular targets for the treatment of sarcoidosis. Curr Opin Pulm Med. 2016;22:515–21.
561. Chida K, Shirai M, Sato M, Sato J, Nakamura H. Successful treatmen of hepatic sarcoidosis with hormone replacement in postmenopauzal woman. Respirology. 1999;4:259–61.
562. Chlumský J. Plicní funkce pro klinickou praxi. Praha: Maxdorf; 2014.
563. Cho SH, Seo JY, Choi DC, et al. Pathological changes according to the severity of asthma. Clin Exp Allergy. 1996;26:1210–9.
564. Choi JH, Shin JA, Park HK, et al. Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer. Case Rep Oncol Med. 2014;2014:203027.
565. Chopra A, Marc A. How are cancer and connective tissue diseases related to sarcoidosis? Curr Opin Pulm Med. 2015;21:517–24.
566. Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD. IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. Blood. 2011;118:3890–900.

567. Chrétien J, Venet A, Danel C, Israel-Biet D, Sandron D, Arnoux A. Bronchoalveolar lavage in sarcoidosis. Respiration. 1985;48:222–30.
568. Christ R, Eckert H, Sehrt I. Milzbeteiliging und Splenektomie bei Sarkoidose. Dt Gesundh Wesen. 1981;36:1354–6.
569. Chung JH, Cox CW, Forssen AV, Biederer J, Puderbach M, Lynch DA. The dark lymph node sign on magnetic resonance imaging: a novel finding in patients with sarcoidosis. J Thorac Imaging. 2014;29:125–9.
570. Chung JH, Little BP, Forssen AV, et al. Proton MRI in the evaluation of pulmonary sarcoidosis: comparison to chest CT. Eur J Radiol. 2013;82:2378–85.
571. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277– 301.
572. Ianuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. New Engl J Med. 2007;357:2153–65.
573. Ibitoye RT, Wilkins A, Scolding NJ. Neurosarcoidosis: a clinical approach to diagnosis and management. J Neurol. 2017;264:1023–8.
574. Ichikawa H, Kataoka M, Hiramatsu J, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:15–20.
575. Iida K, Kadota J, Kawakami K, Matsubara Y, Shirai R, Kohno S. Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis. Thorax. 1997;52:431–7.
576. Ijzerman RG, Voordouw JJ, Van Weissenbruch MM, et al. TNF-alpha levels are associated with skin capillary recruitment in humans: a potential explanation for the relationship between TNF-alpha and insulin resistance. Clin Sci (Lond). 2006;110:361–8.
577. Ikeda T, Hayashi S, Kamikawaji N, Sasazuki T, Shigematsu N. Adverse effect of chronic tonsillitis on clinical course of sarcoidosis in relation to HLA distibution. Chest. 1992;101:758–62.
578. Imamura F, Fukuda K, Tanaka F, Sugimoto M, Shima K. Polymorphism of the angiotensin converting enzyme (ACE) gene in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:6.
579. Imanishi T, Wakisaka A, Gojobori T. Genetic relationship among various human populations indicated by MHC polymorphisms. In: Aizawa M, Sasazuki T. editors. HLA 1991. Oxford: Oxford University Press; 1992. p. 627–32.
580. Ina Y, Takada K, Yamamoto M, Morishita M, Senda Y, Torii Y. HLA and sarcoidosis in the Japanese. Chest. 1989;95(6):1257–61.
581. Inui N, Murayama A, Sasaki S, et al. Correlation between 25-hydroxyvitamin D3 1-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001;110:687–93.
582. Ioannidis I, Ye F, McNally B, Willette M, Flano E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol. 2013;87:3261–70.
583. Israel HC, Patterson JD, Smukler N. Latex fixation tests in sarcoidosis. Acta Med Scand. 1964;176:40–6.
584. Israel HL, Atkinson GW. Sarcoidosis. Amer Thor Soc. 1978;7:1–48.
585. Israel HL, Fouts DW, Beggs RE. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973;7:609–14.
586. Israel HL, Goldstein RA. Relation of Kveim-antigen reaction to lymphadenopathy. Study of sarcoidosis and other diseases. N Eng J Med. 1971;284:3–7.
587. Israel HL, Ostrow A. Sarcoidosis and aspergilloma. In: Proceedings Vth Intern. Conf. Sarcoidosis. Praha: Universita Karlova; 1971. p. 495–6.
588. Israel HL, Sones AL. Sarcoidosis. Clinical observation on one hundred sixty cases. Arch Intern Med. 1958;102:766–76.
589. Israel HL, Washburn JD. Characteristics of sarcoidosis in black and white patients. In: Proceedings of the Ith International Conference on Sarcoidosis. Cardiff: Alpha Omega; 1980. p. 497–507.
590. Israel HL. Corticosteroid treatment of sarcoidosis – Who needs it? NY State J Med. 1987;87:490–1.

591. Israel HL. Influence of race and geographical origin on sarcoidosis. Arch Environ Health. 1970;20:608–9.
592. Israel HL. Some controversial aspects of sarcoidosis. Ann Allergy. 1977;38:112–5.
593. Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. Allergy. 2011;66:1107–13.
594. Itoh A, Yamaguchi E, Furuya K, et al. Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis. Thorax. 1993;48:1230–4.
595. Itoh A, Yamaguchi E, Furuya K, Kawakami Y. Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis. Respirology. 1998;3:247–51.
596. Iwai K, Sekiguti M, Hosoda Y, et al. Recital difference in cardic sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26–31.
597. Iwai K, Tachibana T, Hosoda Y, Matsui Y. Sarcoidosis autopsies in Japan. Frequency and trend in the last 28 years. Sarcoidosis. 1988;5:60–5.
598. Iwai K, Tachibana T, Hosoda Y, Matsui Y. Sarcoidosis autopsies in Japan. Frequency ane trend in the last 28 years. Sarcoidosis. 1988;5:60–5.
599. Iwai K, Tachibana T, Hosoda Y, Matsui Y. Statistics of sarcoidosis autopsies during these 25 years in Japan. In: Grassi C, Pozzi E, Rizzato G. Abstracts of the XI WCS. Milano: Congress Studio Publisher; 1987. p. 59.
600. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7-8):372–6.
601. Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis, 1994;11:26-31.
602. Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26–31.
603. Iwai K. Morbid anatomy of sarcoidosis in Japan. Sarcoidosis. 1992;9(Suppl 1):9–16.
604. Iwai K. Propionibacterum acnes in sarcoidosis. Sarcoidosis. 1989;6:73–5.
605. Iwainsky H, Winsel K, Grollmuss H, Unger U. Bronchoalveolare Lavage. Z Erkrank Atm Org. 1985;164:231–40.
606. Iyer S, Afshar K, Sharma OP. Peritoneal and pleural sarcoidosis: an unusual association - review and clinical report. Curr Opin Pulm Med. 2008;14:481–7.
607. Izumi T. Sarcoidosis in Kyoto (1963-1986). Sarcoidosis. 1988;5:142–6.
608. Jackson WP, Dancaster C. A consideration of the hypercalciuria in sarcoidosis, idiopathic hypercalciuria, and that produced by vitamin D; a new suggestion regarding calcium metabolism. J Clin Endocrinol Metab. 1959;19:658–80.
609. Jacobaeus HC. Uber die Moglichkeit, die Zystoskopie bei Untersuchung seroser Hohlungen anzuwenden. Munch Med Wschr. 1910;57:2090–2.
610. Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005;90:6316–22.
611. Jaffe HA, Buhl R, Mastragneli A, et al. Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of aerosol of recombinant intergeron-to the human lung. J Clin Invest. 1991;88:297–302.
612. James DG, Brett GZ. Prevalence of intrathoracic sarcoidosis in Britain. Acta Med Scan. 1964;425:115–7.
613. James DG, Carstairs LS, Trowell JS, Sharma OO. Treatment of sarcoidosis: Report of a controled therapeutic trial. Lancet. 1967;2:526.
614. James DG, Kendig EL Jr. Childhood sarcoidosis. Sarcoidosis. 1988;5:57–9.
615. James DG, Neville E, Carstairs LS. Bone and Joint Sarcoidosis. Semin Arthritis Rheum. 1976:6(1):53–81.
616. James DG, Neville E, Walker AN. Immunology of sarcoidosis. Am J Med. 1975;59:338–94.
617. James DG, Plyasens KHG, Neville E, et al. Possible genetic influences in familial sarcoidosis. Postgrad Med J. 1974;50:664–70.

618. James DG, Thompson AD. The course of sarcoidosis and its modification by treatment. Lancet. 1959;1:1057–61.
619. James DG, Timmis JB, Barnet TS, Carstairs BS. Radiology of sarcoidosis. Sarcoidosis. 1989;6:7–14.
620. James DG, Williams WJ. Immunology of sarcoidosis. 1982;72:5–8.
621. James DG, Williams WJ. Kveim-Siltzbach test revisited. Sarcoidosis. 1991;8:6–9.
622. James DG, Williams WJ. Sarcoidosis and other granulomatous disorders. Philadelphia: W. B. Saunders Co; 1985.
623. James DG. All that glitters is not sarcoidosis. Sarcoidosis. 1986;3:137–52.
624. James DG. Complications of Sarcoidosis. Chronic Fatigue Syndrome. Sarcoidosis. 1993;10:1–3.
625. James DG. Epidemiology of sarcoidosis. Sarcoidosis. 1992;9:79–87.
626. James DG. Historical aspects of sarcoidosis. Clio Medica. 1968;3:265–71.
627. James DG. Sarcoidosis olympiad in Tokyo. Separata de pneumologica. 1972;3:185–97.
628. James DG. Sarcoidosis. Postgrad Med J. 1984;60:234–41.
629. James G. Concensus conference: Treatment of sarcoidosis. Sarcoidosis. 1994;11:34–40.
630. Janda V, Vávrová M. Metodika senzomotorické stimulace. Rehabilitacia. 1992;25:14–34.
631. Jarman PR, Whyte MKB, Sabroe I, Hughes JMB. Sarcoidosis presenting with chylothorax. Thorax. 1995;50:1324–5.
632. Jaroszewicz W, Krychniad W, Rudzińska H, Zych D. Epidemiology of sarcoidosis in Poland (author's transl). Z Erkr Atmungsorgane. 1977;149(1):15–8.
633. Jeny F, Pacheco Y, Besnard V, Valeyre D, Bernaudin JF. Experimental models of sarcoidosis. Curr Opin Pulm Med. 2016:22:492–9.
634. Jiang D, Huang X, Geng J, Dong R, Li S, Liu Z, Wang C, Dai H. Pulmonary fibrosis in a mouse model of sarcoid granulomatosis induced by booster challenge with Propionibacterium acnes. Oncotarget. 2016;7:33703–14.
635. Jiang S, Dong C. A complex issue on CD4(+) T-cell subsets. Immunol Rev. 2013;252:5–11.
636. Johansson L, Mattson S, Nosslin B. Effective dose equivalent from radiopharmaceuticals. Eur J Nucl Med. 1984;9:485–8.
637. Johns CJ, Paz H, Kasper EK, Baughman K. Myocardial sarcoidosis: course and management. Sarcoidosis. 1992;9(Suppl 1):231–5.
638. Johns CJ, Schonfeld SA, Scott PP, Mac Gregor MI, Zachary JB. Longitudinal study of chronic sarcoidosis with low dose maintenance corticosteroid therapy: Ouctome and complications. In: Tenth International Conference on Sarcoidosis and Other Granulomatous Disorders. Ann NY Acad Sci. 1986;465:702–12.
639. Johns CJ, Schonfeld SA, Scott PP. Hemoptysis in sarcoidosis: Course of management. Sarcoidosis. 1986;3:192.
640. Johns CJ, Schonfeld SA, Scott PP. Sarcoidosis. Ann Rev Med. 1989;40:353–71.
641. Johns CJ. Breakfast Seminar: Management of sarcoidosis: Practical guidelines. Sarcoidosis. 1994;11:123–6.
642. Jones KP, Reynolds SP, Capper SJ, Kalinka S, Edwards JH, Davies BH. Measurement of interleukin-6 in bronchoalveolar lavage fluid by radioimmunoassay: Differences between patients with interstitial lung disease and control subjects. Clin Exp Immunol. 1991;83:30–4.
643. Jones-Williams W. The nature and original of Schaumann bodies. J Path Bact. 1960;79:193–201.
644. Jonsson S, Musher DM, Lawrence EC. Phagocytosis and killing of Haemophilus influenzae by alveolar macrophages: no difference between smokers and non-smokers. Eur J Respir Dis. 1987;70:309–15.
645. Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone E. Sarcoidosis Diagnosed After September 11, 2001, Among Adults Exposed to the World Trade Center Disaster. Occup Environment Med. 2011;53:966–74.
646. Jordana M, Sarnstrand B, Sime PJ, Ramis I. Immune-inflammatory functions of fibroblasts. Eur Respir J. 1994;7:2212–22.
647. Jörgensen G, Wurm K. Die Blutgruppen bei der Sarkoidose. Acta Med Scand. 1964;176(Suppl 425):213–5.

648. Jörgensen G. Die Genetik der Sarkoidose. Acta Med Scand. 1964;176(Suppl 425):209–12.
649. Jouzevicius JL, Rynes RI. Increased Helper (supressor T-lymphocytes ratio in the cerebrospinal fluid of a patient with neurosarcoidosis. Ann Intern Med. 1986;104:807–8.
650. Jozsef L, Khreiss T, Fournier A, Chan JSD, File JG. Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes. Br J Pharmacol. 2009;135:1167–74.
651. Judson M, Baughman RP, Thompson BW, et al; ACCESS Research Group. Sarcoidosis Vasc Diffuse Lung Dis, 2003;20:204–11.
652. Judson M, Costabel U, Drent M, et al; Organ assessment instrument investigators TW. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:19–27.
653. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial. Eur Respir J. 2008;31:1189–96.
654. Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44:1296–307.
655. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager HJr; the ACCESS Research group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86.
656. Judson MA, Baughman RP, Thompson BW, et al; ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Disease. 2003;20:204–11.
657. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large whote and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:119–27.
658. Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28:83–101.
659. Julian MW, Shao G, Schlesinger LS, et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest. 2013;143:461–70.
660. Jüngling O. Ostitis tuberculosa multiplex cystica. Fortschr R. 1920;27:375.
661. Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006;130:1496–502.
662. Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006;130:1496–502.
663. Kadakia JK, Collette PM, Sharma OP. Role of magnetic resonance imaging in neurosarcoidosis. Sarcoidosis. 1993;10:98–9.
664. Kage H, Borok Z. EMT and interstitial lung disease: a mysterious relationship. Curr Opin Pulm Med. 2012;18:517–23.
665. Kahi CJ, Saxena R, Temkit M, et al. Hepatobiliary disease in sarcoidosis. Sarcoidosis Vasc Diff Lung Dis. 2006;23:117–23.
666. Kalkanis A. Judson MA. Distinguishing Asthma from Sarcoidosis: An Approach to a Problem that is not Always Solvable. J Asthma. 2013;50:1–6.
667. Kalkoff KW. Zur Geschichte der Sarkoidose. Internist. 1969;10:289–93.
668. Kamada M, Irahara M, Maegawa M. Transient inrease in levels of T- helper cytokines in postmenopausal women and the effect of hormone replacement therapy. Gynecol Obstet Invest. 2001;52:82–8.
669. Kamikawaji N, Shigematsu N, Sasazuki T. Genetic control of immune Response to Streptococcal antigen. Sarcoidosis. 1991;8:155–9.
670. Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, van Daele PL. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res. 2014;29:2498–503.
671. Kamphuis LS, Lam-Tse WK, Dik WA, et al. Efficacy of Adalimumab in Chronically Active and Symptomatic Patients with Sarcoidosis. Am J Resp Crit Care Med. 2011;184:2014–6.

672. Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-?B activation: common genetic etiology with Blau syndrome. Blood. 2005;105:1195–7.
673. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131:624–32.
674. Kansas GS, Muirhead MJ, Dailey MO. Expression of the CD18/CD18, leukocyte adhesion molecule I, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood. 1996;76:2483–92.
675. Kaplan RM, Reis A, Atkins CJ. Behavioral issues in the management of chronic obstructive pulmonary disease. Ann Behav Med. 1985;7:5–10.
676. Kaplan H, Klatskin G. Sarcoidosis, psoriasis, and gout: syndrome or coincidence? Yale J Biol Med. 1960;32:335–52.
677. Karadall MN, Bosnak-Güçlü M, Camcioglu B, Kokturk N, Türktas H. Effects of inspiratory muscle training in subjects with sarcoidosis: a randomized controlled clinical trial. Respir Care. 2016;61:483–94.
678. Karagiannidis A, Karavalaki M, Koulaouzidis A. Hepatic sarcoidosis. Ann Hepatol. 2006;5:251–6.
679. Karakantza M, Matues E, MacLennan K, O'Connor NT, Srivastava PC, Catovsky D. Association between sarcoidosis and lymphoma revisited. J Clin Pathol. 1996;49:208–12.
680. Kataria YP, Whitcomb ME. Splenomegaly in sarcoidosis. Arch Intern Med. 1980;140:35–7.
681. Katchar K, Söderström K, Wahlstrom J, Eklund A, Grunewald J. Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur Respir J. 2005;26:77–85.
682. Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diff Lung Dis. 2003;20:133–7.
683. Kawanami O, Ferrans VJ, Crystal RG. Subplasmalemmal linear densities in cells of the mononuclear phagocyte system in lung. Am J Pathol. 1980;100(1):131–50.
684. Keane MP, Standiford TJ, Strieter RM. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. Eur Respir J. 1997;10:1199–202.
685. Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2013;41:743–51.
686. Keimowitz RI. Immunoglobulins in normal human tracheobronchial washings. A qualitative and quantitative study. Lab Clin Med. 1964;63:54–9.
687. Ken T, Kayo M,Toshiji- I. Sex hormon alter Th 1 Responses and Enhance Granuloma Formation in the Lung. Respiration. 2011;81:491–8.
688. Kendig EL, Niitu Y. Sarcoidosis in Japanese and American children. Chest. 1980;77:514–6.
689. Keohane GSG, Savin JA, Tidman MJ, The sarcoidosis- lymphoma syndrome: Acceleration of the cutaneous sarcoidosis during chemotherapy of lymphoma. Acta Derm Venereol. 1996;76:251–3.
690. Khan MM, Gill DS, McConkey B. Myopathy and external pulmonary artery compression caused by sarcoidosis. Thorax. 1981;36:703–4.
691. Kheogh BA, Crystal RG. Alveolitis: the key to the interstitial lung disorders. Thorax. 1982;37:1–10.
692. Kheogh BA, Hunninghake GW, Line BR, Crystal RG. The alveolitis of pulmonary sarcoidosis: evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Resp Dis. 1983;128:253–65.
693. Kiecolf-Glaser JK, Glaser R, Strain EC, et al. Modulation of cellular immunity in medical students. J Behav Med. 1986;9:311–20.
694. Kienböck R. Zur radigraphischen Anatomie ind Klinik der tuberculsen Erkrankung der Fingerknochen, spina ventosa. Z Heilk Abt Chirurch. 1902;23:186.
695. Kim DS. Sarcoidosis in Korea: report of the Second Nationwide Survey. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:176–80.
696. Kim JS, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, Prystowsky S. Cardiac sarcoidosis. Am Heart J. 2009;157:9–21.

697. Kini SROV. Color atlas of pulmonary cytopathology. New York: Springer; 2002.
698. Kiper N, Anadol D, Ouzçelik U, Göçmen A. Inhaled corticosteroids for maintenance treatment in childhood pulmonary sarcoidosis. Acta Paed. 2007;90:953–6.
699. Kirks DR, McCormick VD, Greenspan RH. Pulmonary sarcoidosis. Roentgenologic analysis of 150 patients. AJR Am J Roentgenol. 1973;117:777–86.
700. Kishi J, Nishioka Y, Kuwahara T, et al. Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice. Eur Respir J. 2011;38:415–24.
701. Kishore A, Borucka J, Petrkova J, Petrek M. Novel insights into miRNA in lung and heart inflammatory diseases. Mediators Inflamm. 2014;2014:259131.
702. Klech H, Haslam P, Turner-Warwick M. World wide clinical survey on bronchoalveolar lavage (BAL) in sarcoidosis. Experience in 62 centers in 19 countries. Preliminary analysis. Sarcoidosis. 1986;3:113–7.
703. Klech H, Hutter C. Clinical guidelines and indications for bronchoalveolar lavage (BAL): Report of the European Society of Pneumology Task Group on BAL. Europ Resp J. 1990;3:937–74.
704. Klemm P. Sarkoidose und Blutgruppen – eine Kausalanalyse. Z Erkrank Atm Org. 1981;157:355–8.
705. Klockars M, Petterson T, Weber T, et al. Angiotensin-converting enzyme (ACE), lysozyme (LZM), Beta-2-mikroglobulin (B2M) and adenosin deaminase (ADA) in sarcoidosis. In: Blasi A, Olivieri D, Pezzi A, editors. IV. Europ. Conf. on Sarcoidosis and Other Granulomatous Disorders. Sorrento; 1983. p. 293.
706. Klockars M, Petterson T, Weber T. Activity of serum adenosin deaminase in sarcoidosis. Clin Chem. 1985;31:155.
707. Klonoff A, Kleinhenz ME. Psychological factors in sarcoidosis: The relationship between life stress and pulmonary function. Sarcoidosis. 1993;10:118–24.
708. Knoontz CH, Joyner LR, Nelson RA. Transbronchial Lung Biopsy Via the Fiberoptic Bronchoscope in Sarcoidosis. Ann Intern Med. 1976;85:64–6.
709. Kodama K, Hasegawa T, Egawa M, Tomosugi N, Mukai A, Namiki M. Bilateral epididymal sarcoidosis presenting without radiographic evidence of intrathoracic lesion: review of sarcoidosis involving the male reproductive tract. Int J Urol. 2004;11:345–8.
710. Koike H, Misu K, Yasui K, Kameyama T, Ando T, Yanagi T, Sobue G. Differential response to corticosteroid therapy of MRI findings and clinical manifestations in spinal cord sarcoidosis. J Neurol. 2000;247:544–9.
711. Koinvunen E, Gronhagen-Riska C, Klockars M, Selroos O. Blood monocytes and serum bone marrow lysozyme in sarcoidosis. Acta Med Scand. 1981;210:107–10.
712. Kolar P, Kobesova A, Valouchova P, Bitnar P. Dynamic neuromuscular stabilization: developmental kinesiology: breathing stereotypes and postural-locomotion function. In: Chaitow L, Bradley D, Gilbert Ch. Recognizing and treating breathing disorders. Edinburg: Churchill Livingstone; 2014. p. 11–22.
713. Kolek V Jr, Váňa D, Kolek V, Říha V. Sarkoidóza v okrese Olomouc. Stud Pneumol Phtiseol Cechoslov. 1987;47:370–5.
714. Kolek V, Bačovský J, Krčová I, Čecháček M. Clinical experience with testing cellular immunity by immunoskintest. Sevac Acta Univ Palack Olomuc. 1987;115:299–306.
715. Kolek V, Budíková M, Mysliveček M, Lindušková M, Feitová S. Zkušenosti s antimalariky u sarkoidózy. Prakt Lék. 1990;70:905–6.
716. Kolek V, Dušek J, Dušková M, Václavík A, Vomáčka Z. Diagnostika poškození plic amiodaronem – přínos bronchoalveolární laváže. Vnitř Lék. 1990;36:75–80.
717. Kolek V, Dušek J, Jonah T, Šafránek M. Sarkoidóza v sekčním materiálu. Stud Pneumol Phtiseol Cechoslov. 1991;51:76–80.
718. Kolek V, et al. Doporučené postupy v pneumologii, 3rd ed. Praha: Maxdorf; 2019:273–95.
719. Kolek V, Fialová J, Petřek M, et al. Intersticiální plicní procesy. Význam nových vyšetřovacích metod při posuzování zevních a vnitřních faktorů. Stud Pneumol Phtiseol Cechoslov. 1993;53:104–10.
720. Kolek V, Hacarová M, Mysliveček M. Sarkoidóza s postižením horních cest dýchacích. Čs Otolaryngol. 1987;36:250–3.

721. Kolek V, Hutyrová B, Lošťáková V. MORSA - multicentrická moravská studie epidemiologických trendù sarkoidózy 1991-2000. Stud Pneumol Phtiseol. 2005;65:17–20.
722. Kolek V, Janíček M, Kroutilová J. Terminální hemoptoe. Prakt Lék. 1984;64:714–6.
723. Kolek V, Kleinová D, Koš V, Karásková J, Ošťádal O, Ehrmann J. Wegenerova granulomatóza a její souèasná klinická problematika. Stud Pneumol Phtiseol Cechoslov. 1988;48:623–9.
724. Kolek V, Konečný M, Fialová J. Occurence of interstitial lung diseases in central Moravia. 15 year survey. In: Proceedings of Eight International Conference on occupational lung diseases in Prague. Geneva: Intl Labour Organization; 1993, p. 787–9.
725. Kolek V, Laurincová B, Žurková M, Szotkowská J, Petřek M. Solubilní receptor pro IL-2, užitečný ukazatel aktivity a prognózy sarkoidózy. Stud Pneumol Phtiseol. 2001;1:13–6.
726. Kolek V, Lenhart K, Bártová A, Janků L. Rodinný výskyt kryptogenní fibrotizující alveolitidy. Stud Pneumol Phtiseol Cechoslov. 1989;49:81–5.
727. Kolek V, Lenhart K, Bártová A, Komenda S. Genetic aspects of sarcoidosis in northern Moravia. Sarcoidosis. 1986;3:172.
728. Kolek V, Lenhart K, Bártová A, Petřek M, Komeda S, Bártek M. Imunogenetické aspekty kryptogenní fibrotizující alveolitidy. Stud Pneumol Phtiseol. 1997;57:104–5.
729. Kolek V, Lenhart K, Bártová A. Imunogenetika sarkoidózy. Stud Pneumol Phtiseol Cechoslov. 1989;49:601–4.
730. Kolek V, Lenhart K, Komenda S, Bártová A, Ošťádal O. Genetické aspekty sarkoidózy. Čas Lék Čes. 1986;125:798–802.
731. Kolek V, Lenhart K, Kulifayová P, Vomáčka J, Navrátilová J, Bártová A. Kaplan-Klatskinův syndrom, ano či ne? (Ke koincidenci sarkoidózy, psoriázy a dny). Rheumatologia. 1989;3:41–8.
732. Kolek V, Mysliveček M, Budíková M, Hušák V, Merta Z. Galliová scintigrafie jako ukazatel aktivity sarkoidózy. Srovnání s rentgenovými nálezy, funkčním vyšetřením plic, cytologickým vyšetřením bronchoalveolární tekutiny a sérovou koncentrací enzymu konvertujícího angiotenzin. Čas Lék Čes. 1988;127:246–9.
733. Kolek V, Mysliveček M, Hušák V, Vykydal M. Gallium scintigraphy in active and inactive sarcoidosis. Europ Resp J. 1988;1(Suppl 2):298.
734. Kolek V, Ošťádal O, Říha V, Bártová A. Rodinný výskyt sarkoidózy. Vnitř Lék. 1984;30:247–56.
735. Kolek V, Pěničková V, Heřman M, Gronych M, Houdek M. Neurosarkoidóza. Přínos nových vyšetřovacích metod k včasné radiologii a terapii. Čas Lék Čes. 1996;135:141–4.
736. Kolek V, Pěničková V, Heřman M, Gronych M, Houdek M. Neurosarkoidóza. Přínos nových vyšetřovacích metod k včasné diagnostice a terapii. Čas Lék Čes. 1996;135:141–4.
737. Kolek V, Petřek M, Drábek J, Lenhart K, Bártová A. Immunogenetic study of cryptogenic fibrosing alveolitis.The Moravian experience. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:36.
738. Kolek V, Petřek M, Heřman M, Mysliveček M, Budíková M, Lošťáková V. Současné možnosti monitorování a léčby chronické plicní sarkoidózy. Stud Pneumol Phtiseol. 1993;53:277–84.
739. Kolek V, Rozhold O. Plicní fibróza u neuromyositidy. Stud Pneumol Phtiseol Cechoslov. 1980;40:49–52.
740. Kolek V, Salajka F, Skřičková J, Hořenková E, Janásková T. Dlouhodobé epidemiologické trendy sarkoidózy na Moravě a ve Slezsku. Stud Pneumol Phtiseol. 1994;54:165–72.
741. Kolek V, Vepřeková A, Krč I, Matoušková I. Vyšetřování stavu buněčné imunity u nemocných karcinomem plic pomocí Imunoskintestu Sevac. Stud Pneumol Phtiseol Cechoslov. 1986;46:215–20.
742. Kolek V, Vykydal M, Gaja A. Sarkoidóza a pohybové ústrojí. Fyziat Věst. 1986;64:241–7.
743. Kolek V, Wiedermann B, Oral I, Smečka Z. Plicní fibróza u syndromu Heřmanského – Pudláka. Stud Pneumol Phtiseol Cechoslov. 1985;45:233–8.
744. Kolek V, Žurková M, Lošťáková V, et al. Syndrom koincidence sarkoidózy a lymfomu. Stud Pneumol Phthiseol. 2011;71:122–30.
745. Kolek V, Žurková M, Lošťáková V. Sarkoidóza – současná léčebná strategie. Acta Medicinae. 2019;8:98–101.
746. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia in the period 1981-1990. L'Internista. 1995;3:105–8.

747. Kolek V. Epidemiology study on sarcoidosis in Moravia and Silesia. Sarcoidosis. 1994;12:110–2.
748. Kolek V. Granulomatózy – současný pohled na etiopatogenezi a klinický význam. Stud Pneumol Phthiseol. 2006;66:147–8.
749. Kolek V. Přínos galliové scintigrafie u sarkoidózy. Stud Pneumol Phtiseol Cechoslov. 1987;47:407–10.
750. Kolek V. Sarkoidóza jako stálá výzva. Stud Pneumol Phthiseol. 2018;78(5):151–2.
751. Kolek V. Sarkoidóza. Změny v péči o nemocné pod vlivem vývoje diagnostiky a mezinárodních úmluv v posledních letech. Stud Pneumol Phtiseol. 1996;56:163–7.
752. Kolls JK. CD4(+) T-cell subsets and host defense in the lung. Immunol Rev. 2013;252:156–63.
753. Kono M, Hasegawa J, Wakai S, et al. Living Kidney Donation From a Donor With Pulmonary Sarcoidosis: A Case Report and Review of the Literature. Transplant Proc. 2017;49:1183–6.
754. Kopřiva P, Griva M, Tüdös Z. Management of cardiac sarcoidosis – a practical guide. Cor et Vasa. 2018;60:e155–64.
755. Korenromp IH, Grutters JC, van den Bosch JM, Heijnen CJ. Post-inflammatory fatigue in sarcoidosis: personality profiles, psychological symptoms and stress hormones. J Psychosom Res. 2012;72:97–102.
756. Kormelink TG, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des. 2009;15:1868–78.
757. Korsten P, Mirsaeidi M, Sweiss NJ. Nonsteroidal therapy of sarcoidosis. Curr Opin Pulm Med. 2013;19:516–23.
758. Korsten P, Strohmayer K, Baughman, Sweiss NJ. Refractory pulmonary sarcoidosis: Proposal of a definition and recommendation for the diagnostic and therapeutic approach. Clin Pulm Med. 2016;23:67–75.
759. Kostura MJ, Tocci MJ, Limjuco G, et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl Acad Sci USA. 1989;86:5227–31.
760. Kourilsky O. Herpes and immunodepression states. Rev Prat. 1983;33(55):3067–70.
761. Kovach MA, Standiford TJ. The function of neutrophils in sepsis. Curr Opin Infect Dis. 2012;25:321–7.
762. Koyama T, Ueda H, Togashi K, Umeoka S, Kataoka M, Nagai S. Radiologic manifestations of sarcoidosis in various organs. RadioGraphics. 2004;24:87–104.
763. Kragsbjerg P, Jones I, Vikerfors T, Holmberg H. Diagnostic value of blood cytokine concentrations in acute pneumonia. Thorax. 1995;50:1253–7.
764. Kratochvíl S. Skupinová psychoterapie v praxi. Praha: Galén; 2009.
765. Kreibich K. Über lupus pernio. Arch Derm Syph (Wien). 1994;71:3.
766. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med. 1989;31:603–8.
767. Krombach F, Gerlach JT, Padovan C, et al. Characterization and quantification of alveolar monocyte-like cells in human chronic inflammatory lung disease. Eur Resp J. 1996;9:984–91.
768. Kueppers F, et al. HLA antigens of patients with sarcoidosis. Tissue Antigens. 1974;4:56–8.
769. Kuhlmann U, Riegner T, Lanser K. Fibronektin im plasma – ein aktivitatsparameter der aktiven sarkoidose? Germ. Prax Klin Pneumol. 1987;41:922–3.
770. Kühn M, Widder W, Gartmann J, Hartrmann G. Akutes Hypercalcaemia Syndrom bei der Sarkoidose. Schweiz Med Wocheschr. 1985;115:1365–7.
771. Kulich V, Šach L. Studie o krevních skupinách ve vztahu k sarkoidóze. Stud Pneumol Phtiseol Cechoslov. 1971;31:51–3.
772. Kulka WE. Sarcoidosis of heart: case of sudden and unexpected death. Circulation. 1950;1:772–6.
773. Kullberg S. in Svensk Lungmedicinsk Förening 2014 [online]. [cit. 3. 6. 2019] dostupné na: www.slmf.se/sites/default/files/VP_sarkoidos_web_140130.pdf
774. Kuznitzky E, Bittorf A. Boecksches Sarkoid mit Beteiligung innerer Organe. Mench Med Wochenschr. 1915;62:1349–53.
775. Kveim A. En ny og spesifikk kirtan reaksjon ved Boeck s sarcoid. Nord Med. 1941;9:169–72.
776. Kwon OJ, Au BT, Collins PD, et al. Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial. Am J Physiol. 1982;58:771–2.

777. Lacronique J, Auzeby A, Valeyre D, et al. Urinary Neopterin in Pulmonary Sarcoidosis: Relationship to Clinical and Biologic Assessment of the Disease. Am Rev Resp Med. 1989;139:1474–8.
778. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012;18:684–92.
779. Lane N, Robinson RA, Corne J. Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin Sci. 2010;119:75–86.
780. Larici AR, Glaudemans AW, Del Ciello A, Slart RH, Caladriello L, Gheysens O. Radiological and nuclear medicine imaging of sarcoidosis. Q J Nucl med Mol Imaging. 2018;62:14–33.
781. Laroche A, Chinchilla EA, Bourgeault E, Doré MA. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction. J Cut Med Surg. 2018;22:627–9.
782. Laviolette M, La Forge J, Tennina S, Boulet LP. Prognostic value of bronchoalveolar lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest. 1991;100:380–4.
783. Lebacq E, Verhaegen H. Renal involvement in sarcoidosis. In: Proc. Vth Intern. Conf. Sarcoidosis, Prague. Praha: Unverzita Karlova; 1971. p. 323–7.
784. Leclerc P, Baumann Ch, Orvoen-Frija E, Blais J, Rochemaure AJ. Place du dosage sérique de l' enzyme de conversion de 1 angiotensine, dans la sarcoidose. A propos de soixante-dix observations. Sem Hop. 1982;58:1291–4.
785. Legmann P. Imaging and lung disease: Uses and interpretation. Tubercle Lung Dis. 1993;74:147–58.
786. Lenhart K, Kolek V, Bártová A. HLA antigens associated with sarcoidosis. Dis Markers. 1990;8:23–9.
787. Lenique F, Brauner MW, Grenier P, Battesti JP, Loiseau A, Valeyre D. CT assessment of bronchi in sarcoidosis: endoscopic and pathologic correlations. Radiology. 1995;194:419–23.
788. Leon LR, White AA, Kluger MJ. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol. 1998;275:R269–77.
789. Leonard C, Tormey VJ, O'Keane C, Burke CM. Bronchoscopic diagnosis of sarcoidosis. Eur Respir J. 1997;10:2722–4.
790. Leunenberger PH, Vejdovsky R. Effects de le fumée de cigarettes sur la composition cellulaire des liquides de BAL eu pathologic pulmonaire. Schweis Med Wschr. 1984;114:924–9.
791. Leunenberger PH, Vonmoos S, Vejdovsky R. Morphological changes of alveolar macrophages in smoking sarcoidosis patients. Eur J Resp Dis. 1985;66(Suppl 139):72–5.
792. Leung AN, Brauner MW, Caillat-Vigneron N, Valeyre D, Grenier P. Sarcoidosis activity: correlation of HRCT findings with those of 67Ga scanning, bronchoalveolar lavage, and serum angiotensin converting enzyme assay. J Comput Assist Tomogr. 1998;22:229–34.
793. Leung WK, Lei KIK, Yim A, Sit YK, Lai CKW, Leung R. Sarcoidosis in a Hong Kong Chinese woman. Hong Kong Med J. 1998;4:333–6.
794. Levinský L, Altmann V. Pokus o zjištění prevalence plicní sarkoidózy na území ČSSR. Rozhl Tuberk. 1964;24:220–30.
795. Levinský L, Comminskey J, Romer FK, Wurm K, Buss J, Dorken H. Sarcoidosis in Europe: a cooperative study. Ann NY Acad Sci. 1976;278:335–46.
796. Levinský L, Švandová E, Hynčica V. The incidence of sarcoidosis in Czechoslovakia in the years 1971–1975. Z Erkrank Atm Org. 1977;143:19–24.
797. Lewit K. Manipulační léčba v myoskeletalní medicíně. 5th ed. Praha: Sdělovací technika; 2003.
798. Lexa FJ, Grossman RI. MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. AJNR Am J Neuroradiol. 1994;15:973–82.
799. Li J, Pritchard DK, Wang X, et al. cDNA microarray analysis reveals fundamental differences in the expression profiles of primary human monocytes, monocyte-derived macrophages, and alveolar macrophages. J Leukoc Biol. 2007;81:328–35.
800. Li L, Huang L, Vergis AL, et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120:331–42.

801. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25:455–71.
802. Lieberman J, Beutler E. Elevation of serum angiotensin-converting enzyme in Gaucher disease. N Engl J Med. 1976;294:1442–4.
803. Lieberman J, Zakria F. Effect of captopril and enalapril medication on the serum ACE test for sarcoidosis. Sarcoidosis. 1989;6:118–23.
804. Lieberman J. A next confirmatory test for sarcoidosis. Serum angiotensin – converting enzyme: effect of steroids and chronic lung diseases. Amer Rev Resp Dis. 1974;109:743–4.
805. Lieberman PH, Jones CR, Steinman RM, et al. Langerhans Cell (Eosinophilic) Granulomatosis: A Clinicopathologic Study Encompassing 50 years. Am J Surg Pathol. 1996;20:519–52.
806. Liebow AA. The J. Burns Amberson Lecture – Pulmonary angiitis and granulomatosis. Am Rev Respir Dis. 1973;108:1–18.
807. Lied GA, Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol. 2011;73:1–7.
808. Limaye AP, Paauw D, Raghu G, Schmidt RA, Liles WC. Sarcoidosis associated with recurrent pancreatitis. South Med J. 1997;90:431–3.
809. Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015;9:1697–702.
810. Lin PM, Wright JR. Surfactant protein A binds to IgG and enhances phagocytosis of IgG-opsonized erythrocytes. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1199–206.
811. Linke M, Pham HT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302.
812. Linnenberg JS, Medici TC, Rhyner K. The sarcoidosislymphoma syndrome: a lymphocyte dysregulation. Pneumologie. 1992;46:226–35.
813. Little BP. Sarcoidosis: Overview of pulmonary manifestations and imaging. Semin Roentgenol. 2015;50:52–64.
814. Liu DH, Cui W, Chen Q, Huang CM. Can circulating interleukin-18 differentiate between sarcoidosis and idiopathic pulmonary fibrosis? Scand J Clin Lab Ivest. 2011;71:593–7.
815. Liu H, Jakubzick C, Osterburg AR, et al. Dendritic Cell Trafficking and Function in Rare Lung Diseases. Am J Resp Cell Mol Biol. 2017;57:393–402.
816. lna Y, Takada K, Yamamoto M, Morishita M, Senda Y, Torii Y. HLA and sarcoidosis in Japanese. Chest. 1989;95:1257–61.
817. Loddenkemper R, Boutin C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respir J. 1993;6:1544–55.
818. Loddenkemper R, Bruns H, Costabel U, Schoenfeld N. Corticosteroid therapy in sarcoidosis: results from a prospective multicenter study of the W.A.T.L. Sarcoidosis Vasc Dif Lung Dis. 1997;14:10.
819. Löffler C, Löffler U, Tuleweit A, Uppenkamp M, Bergner R. Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients. Sarcoidosis Vasc Dif Lung Dis. 2015;31:306–15.
820. Löfgren S, Lundbäck H. The bilateral hilar lymphoma syndrome. The study of the relation to age and sex in 212 cases. Acta Med Scand. 1952;142:259–64.
821. Löfgren S, Lundbäck H. The bilateral hilar lymphoma syndrome; a study of the relation to age and sex in 212 cases. Acta Med Scand. 1952;142(4):259–64.
822. Lofgren S. Erythema nodosum studies on etiology and pathogenesis in 185 adult cases. Acta Med Scand. 1946;Suppl 174–91.
823. Lofgren S, Snellman B, Lindgren AG. Renal complications in sarcoidosis; functional and biopsy studies. Acta Med Scand. 1957;159:295–305.
824. Loke WS, Freeman A, Garthwaite L, et al. T-bet and interleukin-27: possible TH1 immunomodulators of sarcoidosis. Inflammopharmacology. 2015;23:283–90.
825. Loke WS, Herbert C, Thomas PS. Sarcoidosis: Immunopathogenesis and Immunological Markers. Int J Chron Dis. 2013;2013:928601.
826. Longcope WT, Freiman DG. A study of sarcoidosis. Medicine (Baltimore). 1952;31:128–32.

827. Longcope WT, Freiman DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from the Johns Hopkins Hospital and Massachusetts General Hospital. Medicine (Baltimore). 1952;31:1–132.
828. Loos T. Sarcoidosis in children. In: Proc. 3dr European Conference on Sarcoidosis. Novi Sad; 1982. p. 335.
829. Lorber M, Gibb H, Grant L, Pinto J, Pleil J,Cleverly D. Assessment of Inhalation Exposures and Potential Health Risks to the General Population that Resulted from the Collapse of the World Trade Center Towers. Risk Analysis. 2007;27(5):1203–21.
830. Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26:170070.
831. Lošťáková V, Lošťák J, Kriegová E, et al. Sarkoidóza pohybového ústrojí. Kazuistiky v alergologii, pneumologii a ORL. 2015;12:35–40.
832. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. RadioGraphics. 2005;25:1357–68.
833. Loverre A, Tataranni T, Castellano G, et al. IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibody-mediated rejection. Am J Transp. 2011;11:1248–59.
834. Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis. 1988;5:51–5.
835. Lower EE, Broderick JP, Brott TG. Diagnosis and Management of Neurological Sarcoidosis. Arch Intern Med. 1997;157:1864–8.
836. Luft C, Hausding M, Finotto S. Regulation of T cells in asthma: implications for genetic manipulation. Curr Opin Allergy Clin Immunol. 2004;4:69–74.
837. Luisetti M, Martinetti M, Cuccia M, et al. HLA class I and II in patients with sarcoidosis from Italy and Czechoslovakia. Chest. 1993;104(Suppl 1):13.
838. Luisetti M, Martinetti M, Cuccia M, et al. HLA class I, II and III polymorphism in sarcoidosis. Sarcoidosis. 1993;10:151–2.
839. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev. 2008;226:112–31.
840. Lympany PA, Petřek M, Southcott AM, et al. Glu 69 association with sarcoidosis. Eur J Immunogenetics. 1996;23:353–9.
841. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138–53.
842. Lynch J, Baughman RD, Scharrma O. Extrapulmonary sarcoidosis. Semin Respir Infect. 1998;13:229–54.
843. Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2014;35:372–90.
844. Lynch JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med. 1997;18:755–85.
845. Lynch JP, Voorhees JJ, Harrell ER. Sporotrichosis and Sarcoidosis. Arch Dermatol. 1971;103:298–303.
846. Lynch PJ, Voorhees JJ, Harrell ER. Sporotrichosis and sarcoidosis. Arch Dermatol. 1971;103(3):298–303.
847. Iyonaga K, Takeya M, Saita N, et al. Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseases. Hum Pathol. 1995;25:455–63.
848. Lyubsky S, Jacobson MJ. Lung cancer making the diagnosis. Chest. 1991;100:511–20.
849. Maasen W. Ergebnisse simultaner Biopsien bei Sarkoidose. Beitr Klin Tuberk. 1967;135:325–7.
850. Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lung using a gamma camera. J Nucl Med. 1981;23:731–5.
851. MacLennan I, Vinuesa C. Dendritic cells, BAFF, APRIL: innate players in adaptive antibody responses. Immunity. 2002;17:235–8.
852. MacRury SM, McQuaker G, Morton R, Hume R. Sarcoidosis: association with small bowel disease and folate deficiency. J Clin Pathol. 1992;45:823–5.
853. MacSearraigh ET, Doyle CT, Twomey M, O'Sullivan DJ. Sarcoidosis with renal involvement. Postgrad Med J. 1978;54:528–32.

854. Máček M, Radvanský J. Fyziologie a klinické aspekty pohybové aktivity. Praha: Galén; 2011.
855. Maertzdorf J, Weiner J, Mollenkopf HJ, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. PNAS. 2012;109:7853–8.
856. Mahévas M, Lescure FX, Boffa JJ, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine. 2009;88:98–106.
857. Maliarik M, Kost J, Harrington D, et al. Linkage analysis of major histocompatibility genes in familial sarcoidosis. Sarcoidosis. 1994;11:236–9.
858. Maná J, Marcova J, Graells J, Salazar A, Peyri J, Pujol R. Cutaneous Involvement in Sarcoidosis Relationship to Systemic Disease. Arch Dermatol. 1997;133:882–8.
859. Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis. 1995;12(1):20–37. Review.
860. Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis. 1995;12(1):20–37. Review.
861. Mankiewicz E, Van Walbeck M. Mycobacteriophages. Their role in tuberculosis and sarcoidosis. Arch Environ Hlth. 1962;5:122–8.
862. Manning P, Clancy L. HLA typing in a family with sarcoidosis and tuberculosis. Ir J Med Sci. 1987;156:16–17.
863. Manthuruthil S, Maroz N. Renal spectrum of sarcoidosis. Online SMGE books [online]. [cit. 3. 6. 2019] dostupné na: http://smgebooks.com/sarcoidosis-diagnosis/chapters/SARD-16-05.pdf
864. Manz JJ. Pathobiology of neurosarcoidosis and clinicopathologic correlation. Can J Neurol Sci. 1983;10:50–5.
865. Marac J. Interet du lavage broncho-alveolaires en pathologie pulmonaire. Rev Prat. 1980;30:2951–3.
866. Marcellis RG, Lenssen AF, de Vries GJ, et al. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung. 2013;191:43–52.
867. Marcellis RGJ, Lenssen AF, Kleynen S, De Vries J, Drent M. Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study. Lung. 2013;191:247–56.
868. Marcellis RGJ, van der Veeke M, Mesters I, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Dif Lung Dis. 2015;32:53–62.
869. Marcellis RGJ, Lenssen AF, Elfferich MDP, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Resp J. 2011;38:628–34.
870. Marcias S, Ledda MA, Perra R, Severino C, Rosetti L. Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis. 1994;11:118–22.
871. Marschke RF. Sarcoidosis and malignant neoplasm: the Mayo Clinic experience. Sarcoidosis. 1986;3:149–50.
872. Marsseven TV, Mullink R, Rensen R, Stam J. HLA-DR antigens in epithelioid cell granulomas of sarcoidosis, using semithin frozen sections. A concept about granuloma formation. Sarcoidosis. 1985;2:148–53.
873. Marsui Y. Clicopathological study on fatal myocardial sarcoidosis. Ann NY Acad Sci. 1976;278:455–70.
874. Martenstein H. Knochverandernungen bei Lupus pernio. Zentrablatt für Haut und Greschlechtskrankheiten sowie deren Grenzgebiete. 1923;7:308.
875. Martin RJ, Boguniewicz M, Henson JE, et al. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis. 1993;148:1677–82.
876. Martinetti M, Tinelli C, Kolek V, et al. The Sarcoidosis Map: A joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med. 1995;152:557–64.
877. Matsuo M, Ehara S, Tamakawa Y, Chida E, Nishida J, Sugai T. Muscular sarcoidosis. Skeletal Radiol. 1995;24:535–7.
878. Maturu VN, Rayamajhi SJ, Agarwal R, Aggarwal AN, Gupta D, Mittal BR. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:372–80.
879. Mayer KA, Spock G, Mayer KH, Waibel K, Leitner L. Das Angiotensin-converting Enzym bei Lungenkrankungen. Wien Med Wschr. 1985;135:109–13.

880. Mayer M, Mayerová S, Hollý P, et al. Funkcia plúc pri intratorakálnej sarkoidóze. Stud Pneumol Phtiseol Cechoslov. 1985;45:513–42.
881. Mayock RL, Bertrand P, Morrison CE, Scott JH. Manifestations of sarcoidosis: analysis of 145 patients, with a review of nine series selected from the literature. Am J Med. 1963;35:67–89.
882. McBrine CS, Fisher MS. Acrosclerosis in sarcoidosis. Radiology. 1975;115:279–81.
883. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2:CD003793.
884. McCormick PA, Malone D, Fitzgerald MX, Fitzgerald O. Pancreatitis in sarcoidosis. Br Med J. 1985;290:1472–3.
885. McGrath DS, Daniil Z, Foley P, et al. Epidemiology of familial sarcoidosis in the UK. Thorax. 2000;55:751–4.
886. McIntyre J, et al. Increased HLA B7 antigen frequency in South Carolina blacks in association with sarcoidosis. Transplant Proc. 1977;9:1973–6.
887. McKenna RJ, Haynie TP, Libshitz HI, Mountain CF, McMurtrey MJ. Critical evaluation of the gallium-67 scan for surgical patients with lung cancer. Chest. 1985;87:428–31.
888. McMaster KR, Hennigar GR. Drug-induced granulomatous hepatitis. Laboratory Investigation. J Tech Met Pathol. 1981;44:61–73.
889. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–35.
890. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43.
891. Melzack R. The short-form McGill pain questionnaire. Pain. 1987;30:191–7.
892. Mendelson DS, Gray CE, Teirstein AS. Magnetic resonance findings in sarcoidosis of the thorax. Magn Reson Imaging. 1992;10:523–9.
893. Menestrina F, Lestani M, Mombello A, et al. Transbronchial biopsy in sarcoidosis: the role of immunohistochemical analysis for granuloma detection. Sarcoidosis. 1992;9:95–100.
894. Meng XM, Chung AC, Lan HY. Role of the TGF-alpha/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond). 2013;124:243–54.
895. Mergo PJ, Ros PR, Buetow PC, Buck JL. Diffuse disease of the liver: radiologic-pathologic correlation. RadioGraphics. 1994;14:1291–307.
896. Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J. Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol. 2011;186:1809–15.
897. Metcalf JF. Pregnancy and sarcoidosis. In: Gleicher N, editor. Principles of Medical Therapy. New York: Plenum Press; 1985. p. 964–89.
898. Miedema JR, Kaiser Y, Broos CE, Wijsenbeek MS, Grunewald J, Kool M. Th17-lineage cells in pulmonary sarcoidosis and Löfgren's syndrome: Friend or foe? J Autoimmun. 2018;87:82–96.
899. Mihailovic-Vucinic V, Jovanovic D. Pulmonary sarcoidosis. Clin Chest Med. 2008;29:459–73.
900. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest. 2006;130:989–94.
901. Mijajlovic M, Mirkovic M, Mihailovic-Vucinic V, Aleksic V, Covickovic-Sternic N. Neurosarcoidosis: two case reports with multiple cranial nerve involvement and review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:662–7.
902. Mikami R. Sarcoidosis in Japan. Sarcoidosis. 1992;9(Suppl 1):5–8.
903. Miller BH, Rosado-de-Christenson ML, McAdams HP, Fishback NF. Thoracic sarcoidosis: radiologic-pathologic correlation. RadioGraphics. 1995;15:421–37.
904. Miller CT, Sweiss NJ, Lu Y. FDG PET/CT evidence of effective treatment of cardiac sarcoidosis with adalimumab. Clin Nuc Med. 2016;41:417–20.
905. Milman N, Andersen AB. Detection of antibodies in serum against M. tuberculosis using blot technique. Comparison between sarcoidosis patients and healthy subjects. Sarcoidosis. 1993;10:29–31.

906. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6:238–47.
907. Milman N, Hoffmann AL, Byg KE. Sarcoidosis in children. Epidemiology in Danes, clinical features, diagnosis, treatment and prognosis. Acta Paedeatrica. 2007;87:871–8.
908. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. Epidemiology and clinical picture. Sarcoidosis. 1990;7(1):50–7.
909. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. II. Course and prognosis. Sarcoidosis. 1990;7(2):113–8.
910. Minami J, Eishi Y, Ishige Y, et al. Pulmonary granulomas caused experimentally in mice by a recombinant trigger-factor protein of Propionibacterium acnes. J Med Dent Sci. 2003;50:265–74.
911. Minty BD, Jordan C, Jones JG. Rapid improvement in abnormal pulmonary epithelial permeability after stopping cigarettes. Br Med J. 1981;282:1183–6.
912. Mirmirani P, Maurer TA, Herndier B, Mark D. Weinstein: Sarcoidosis in a patient with AIDS: A manifestation of immune restoration syndrome. JAAD. 1999;41:285–6.
913. Mitchell D. Kveim antigen. In: Proceedings of WASOG and BSACI Joint Meeting. London; 1995. p. 5.
914. Mitchell DN, Scadding JG. Sarcoidosis. State of art. Am Rev Resp Dis. 1974;110:774–802.
915. Mitchell IC, Turk JL, Mitchell DN. Defection of mycobacterial mRNA in sarcoidosis with liquid-phase hybridisation. Lancet. 1992;339:1015–7.
916. Miyagawa Y, Asoh H, Nakanishi M, Shigematsu N. Epitheliolid cell granuloma formation in Lewis rats induced by Streptococcal cell wall (SCW). Sarcoidosis. 1991;8:154.
917. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203:359–70.
918. Moghaddam AS, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425–40.
919. Mohammedi I, Vedrinne JM, Floccard B, Reverdy ME, Duperret S, Motin J. Disseminated Rhodococcus equi and Nocardia farcinica infection in a patient with sarcoidosis. J Inf. 1998;36:134–5.
920. Moller DR, Koth LL, Maier LA, et al. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study. Sarcoidosis Protocol. Ann Am Thorac Soc. 2015;12:1561–71.
921. Moller E, Hedfors E, Wiman LG. HLA genotypes and MLR in familial sarcoidosis. Tissue Antigens. 1974;4:299–305.
922. Montagnani M, Gonnelli S, Zacchei F, et al. Calcium-phosphorus metabolism in sarcoidosis. Sarcoidosis. 1993;10:150–1.
923. Montemurro L, Fraioli P, Rizzato G. Bone Loss in Untreated Longstading Sarcoidosis. Sarcoidosis. 1991;8:29–34.
924. Montemurro L, Rizzato G. Is sarcoidosis a borreliosis? Sarcoidosis. 1991;8:134–5.
925. Mooney JJ, Elicker BM, Urbania TH, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013;144:586–92.
926. Moore SL, Teirstein AE. Musculoskeletal sarcoidosis: spectrum of appearances at MR imaging. RadioGraphics. 2003;23:1389–99.
927. Mordelet-Dambrine MS, Arnoux A, Stanislas-Legueren GM, Sandron D, Chrétien J, Huchon GJ. Processing of lung lavage fluid causes variability in bronchoalveolar cell count. Am Rev Resp Dis. 1984;130:305–7.
928. Mordelet-Dambrine MS, Stanislas-Legueren GM, Fuchon G, Bauman EC, Marsac JH, Chrétien J. Elevation of the bronchoalveolar concentration of angiotensin I converting enzyme in sarcoidosis. Am Rev Resp Dis. 1982;126:472–5.
929. Morgane V, Jean-Charles C, Nicolas M, et al. Renal sarcoid-like granulomatosis during anti--TNF therapy. Kidney Int. 2014;86:215.
930. Morgenroth K, et al. The Surfactant System of the Lungs. Berlin: Walter de Gruyter; 1988.
931. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31:372–9.

932. Mornex JF, Leroux C, Greenland T, Ecochard D. From granuloma to fibrosis in interstitial lung diseases: molecular and cellular interactions. Eur Respir J. 1998;7:779–85.
933. Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by adipose tissue--associated c-Kit+Sca-1+ lymphoid cells. Nature. 2010;463:540–4.
934. Morris DG, Jasmer R, Huang L, Gotway MB, Nishimura S, King TE Jr. Sarcoidosis Following HIV Infection: Evidence for CD4+ Lymphocyte Dependence. Chest. 2003;124:929–35.
935. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003;124:929–35.
936. Morrison JGL. Sarcoidosis in the Bantu. Brit J Dermatol. 1974;90:649–73.
937. Mortaz E, Adcock IM, Abedini A, et al. The role of pattern recognition receptors in lung sarcoidosis. Eur J Pharmacol. 2017;808:44–8.
938. Mortaz E, Eslaminejad A, Varahram M, et al. Are There Any Epigenetic Similarities Between Treatment Unresponsive Sarcoidosis, COPD and Severe Asthma? Iran J Allergy Asthma Immunol. 2015;14:472–5.
939. Mortaz E, Sereshki HA, Abedini A, et al. Association of serum TNF-alpha, IL-8 and free light chain with HLA-DR B alleles expression in pulmonary and extra-pulmonary sarcoidosis. J Inflamm. 2015;12:21.
940. Most J, Neumayer HP, Dierich MP. Cytokine-induced generation of multinucleated giant cells in vitro requires interferon gamma and expression of LFA-1. Eur J Immunol. 1994;20:1661–7.
941. Mostard RLM, Vöö S, van Kroonenburgh MJ, et al. Inflamatory activity assesment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105:1917–24.
942. Mourant AE, Kopec A, Domaniewska-Sobczak K. The distribution of human blood groups. London: Oxford University Press; 1976.
943. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named ChurgeStrauss syndrome). J Autoimun. 2014;48–49:99–103.
944. Mubarik A, Hassan SM, Felix M, Muddassir S, Haq F. A confusing manifestation: a case report of neurosarcoidosis presenting with confusion. Community Hosp Intern Med Perspect. 2018;8:363–7.
945. Müller NL, Kullnig P, Miller RR. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol. 1989;152:1179–82.
946. Müller-Quernheim J, Gaede K I, Prasse A, Zissel G. Chronische Berylliose Pneumologie. 2007;61:109–16.
947. Müller-Quernheim J, Prasse A, Zissel G. Pathogenesis of sarcoidosis. La Presse Médicale. 2012;41:e275–87.
948. Müller-Quernheim J, Saltini C, Crystal RG. Compartmentalized activation of the interleukin--2-gene by lung T-lymphocytes in active pulmonary sarcoidosis. J Immunol. 1986;137:3475–83.
949. Müller-Quernheim J, Zissel G, Schopf R, Vollmer E, Schlaak M. Differential diagnosis of berylliosis/sarcoidosis in a dental technician. Dtsch Med Wochenschr. 1996;121:1462–6.
950. Munck A, Mendel DB, Smith LI, et al. Glucocorticoid receptors and actions. Am Rev Respir Dis. 1990;141:2–10.
951. Munoz X, Sánchez-Ortiz M, Torres F, Villar A, Morell F, Cruz M-J. Diagnostic yield of specific inhalation challenge in hypersensitivity pneumonitis. Eur Respir J. 2014;44:1658–65.
952. Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum. 2009;60:1615–23.
953. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2016;9:e003738.
954. Musellim B, Kumbasar OO, Ongen G, Cetinkaya E, Turker H, Uzaslan E et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med. 2009;103(6):907–12.
955. Muthuswamy PP, Lopez-Majano V, Trainor D. Serum angiotensin-converting enzyme (SACE) activity as an indicator of total body granuloma load and prognosis in sarcoidosis. Sarcoidosis. 1987;4:142–8.

956. Muthuswanny P, Lopez-Majano V, Gupta BN. Gallium-67 scintigraphy and serum angiotensin converting-enzyme levels in reevaluation of previously treated sarcoidosis. Am Rev Resp Dis. 1982;125(Suppl):133.
957. Myers JL. Bronchocentric granulomatosis: disease or diagnosis? Chest. 1989;96:3.
958. Myrvik QN, Leake ES, Farris B. Studies on pulmonary alveolar macrophages from the normal rabbit: A technique to procure them in a high state of purity. J Immunol. 1961;86:128–32.
959. Mysliveček M, Hušák V, Kolek V, Budíková M, Koranda P. Absolute quantitation of gallium-67 citrate accumulation in the lungs and its importance for the evaluation of disease activity in pulmonary sarcoidosis. Eur J Nucl Med. 1992;19:1016–22.
960. Mysliveček M, Kolek V, Hušák V, et al. Metoda absolutní kvantifikace 67 Ga v plících a její význam při posuzování aktivity plicní sarkoidózy. Čes Radiol. 1988;42:210–20.
961. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging. 2015;16:634–41.
962. Nakajima T, Kazuhiro Y, Kurosu K, et al. The role of EBUS-TBNA for the diagnosis of sarcoidosis – comparisons with other bronchoscopic diagnostic modalities. Respir Med. 2009;103:1796–800.
963. Nakamura H, Genma R, Mikami T, et al. High Incidence of Positive Autoantibodies against Thyroid Peroxidase and Thyroglobulin in Patients with Sarcoidosis. Clin Endocrin. 1997;46(4):467–72.
964. Nakata K, Sugie T, Cohen H, Nakano H, Aoki M. Expansion of circulating ?/? T cells in active sarcoidosis closely correlates with defects in cellular immunity. Clin Immunol Immunopathol. 1995;3:217–22.
965. Nakládalová M, Štìpánek L, Kolek V, Žurková M, Tichý T. A case of accelerated silicosis. Occup Med. 2018;68:482–4.
966. Nakstad B, Lyberg T, Skjorten F, Boye NP. Subpopulations of human lung alveolar macrophages: ultrastructural features. Ultrastruct Pathol. 1989;13(1):1–13.
967. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. The J Exp Med. 1986;163:740–5.
968. Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464:1367–70.
969. Neumannová K, Zatloukal J, Koblížek V, Kopecký M. Plicní rehabilitace In: Kolek V, Kašák V, Vašáková M, et al. Pneumologie. 3rd ed. Praha: Maxdorf; 2017. p. 493–501.
970. Neumannová K, Zatloukal J, Koblížek V. Doporučený postup plicní rehabilitace [online]. [cit. 3. 6. 2019] dostupné na: http://www.pneumologie.cz/guidelines/
971. Neville E. Sarcoidosis: the clinical problem. Postgrad Med J. 1988;64(753):531–5. Review.
972. Newill CA, Johns CJ, Cohen BH, Diamond EL, Bias WB. Sarcoidosis, HLA and immunoglobulin markers in Baltimore blacks. In: Chrétien J, Marsac J, Saltiel JC, editors. Sarcoidosis and Other Granulomatous Disorders. Paris: Pergamon Press; 1981. p. 253–6.
973. Newman LS, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–30.
974. Newman LS, Rose CS, Maier LA. Sarcoidosis. New Engl J Med. 1992;336:1224–34.
975. Newman LS. To Be2+ or not to Be2+: immunogenetics and occupational exposure. Science. 1993;262(5131):197–8.
976. Ngprasert P, Crowson CS, Matteson EL. Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013. Neuroepidemiology. 2017;48:87–94.
977. Nguyen CTH, Kambe N, Kishimoto I, Ueda-Hayakawa I, Okamoto H. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. J Dermatol. 2007;44:789–97.
978. Nguyen CTH, Kambe N, Ueda-Hayakawa I, Okamoto H. Serological biomarkers of granuloma progression in sarcoidosis. Trends in Immunotherapy 2018;2(2):1–9.
979. Nici L, Donner C, Wouters E, et al. American thoracic society/European respiratory society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–413.

980. Nicod LP, Cochand L, Dreher D. Antigen presentation in the lung: dendritic cells and macrophages. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(3):246–55.
981. Nielsen JL, Romer FK, Ellegaard J. Serum angiotensin-converting enzyme and blood monocytes insplenectomized individuals. Acta Haematol. 1982;67:132–5.
982. Nishimura K, Itoh H, Kitaichi M, Nagai S, Izumi T. CT and pathological correlation of pulmonary sarcoidosis. Semin Ultrasound CT MR. 1995;16:361–70.
983. Nishimura K, Itoh H, Kitaichi M, Nagai S, Izumi T.Pulmonary sarcoidosis: correlation of CT and histopathologic findings. Radiology. 1993;189:105–9.
984. Nishioka Y, Manabe K, Kishi J, et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol. 2007;149:317–26.
985. Nishiwaki T, Yoneyama H, Eishi Y, et al. Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice. Am J Pathol. 2004;165:631–9.
986. Nitter L. Changes in the chest roentgenogram in Boeck s sarcoid of the lungs. Acta Radiol. 1953;(Suppl):7–29.
987. Noon-Song EN, Ahmed CM, Dabelic R, Canton J, Johnson HM. Controlling nuclear JAKs and STATs for specific gene activation by IFNgamma. Biochem Biophys Res Comm. 2011;410:648–53.
988. Nowiński A, Puścińska E, Goljan A, et al. The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study. Clin Resp J. 2015;11:648–56.
989. Nozaki K, Judson MA. Neurosarcoidosis. Curr Treat Options Neurol. 2013;15:492–504.
990. Nunes H, Brillet PY, Valeyre D, Brauner MW, Wells AU. Imaging in sarcoidosis. Semin Respir Crit Care Med. 2007;28:102–20.
991. Nunes H, Uzunhan Y, Freynet O, et al. Pulmonary hypertension complicating sarcoidosis. La Presse Médicale. 2012;41:e303–16.
992. Nureki S, Miyazaki E, Ando M, et al. Circulating levels of both Th1 and Th2 chemokines are elevated in patients with sarcoidosis. Respir Med. 2008;102:239–47.
993. O'Brien GM, Baughman RP, Broderick JP, Arnolds L, Lower EE. Paraniod Psychosis due to neurosarcoidosis. Sarcoidosis. 1994;11:34–6.
994. O'Keefe GM, Nguyen VT, Benveniste EN. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. Eur J Immunol. 1999;29:1275–85.
995. O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med. 1986;315:727–30.
996. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006;55:978–81.
997. Oakley JR, Lawrence S, Fiddian V. Sarcoidosis associated with Crohn's disease of ileum, mouth and oesophagus. J Royal Soc Med.1983;76:1069–71.
998. Obara K, Maejima H, Mii S, Katayama C, Takasu H, Amoh Y. A case of cutaneous sarcoid vasculitis with livedo and review of the literature Rheum Inter. 2015;35:195–6.
999. Odum N, Milman N, Jacobsen BK, Georgsen J, Svejgaard A. HLA class II (DR, DQ, DP) in patients with sarcoidosis: evidence of an increased frequency of DR W6. Exp Clin Immunogenet. 1991;8:227–32.
1000. Oeki K, Sato S, Uchiyama T, et al. Philadelphia chromosome in a sarcoidosis patient. Br J Haematol. 1991;78:457.
1001. Ogbogu PU, Rosing DR, Horne MK. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:457–75.
1002. Ogunye O, Young R. Possible afferent limb immune defect in sarcoid lymphocytes. East Afr Med J. 1982;59:199–205.
1003. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.

1004. Ohno S. HLA and sarcoidosis. Acta Ophmatol. 1984;62(Suppl 165):36–7.
1005. Ohshimo S, Guzman J, Costabel U, Bonella F. Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series Pathology for the clinician Edited by Peter Dorfmüller and Alberto Cavazza. Eur Respir Rev. 2017;26:170012.
1006. Okabe T, Yamagata K, Fujisawa M, et al. Increased angiotensin-converting enzyme in perpheral blood monocytes from patients with sarcoidosis. J Clin Invest. 1985;75:911–4.
1007. Okamoto H, Mizuno K, Horio T. Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients. J Dermatol. 2003;30:503–9.
1008. Oksanen V, Fyhrquist F, Gronhagen-Riska C, Somer H. CSF angiotensin – converting enzyme in neurosarcoidosis. Lancet. 1985;1:1050–1.
1009. Oksanen V, Grönhagen-Riska C, Tikanoja S, Somer H, Fyhrquist F. Cerebrospinal fluid lysozyme and microglobulin in neurosarcoidosis. J Neurol. 1986;73:79–87.
1010. Oksanen V. Neurosarcoidosis. Sarcoidosis. 1994;11:76–9.
1011. Oksanen V. New cerebrospinal fluid, neurophysiological and neuroradiological examinations in the diagnosis and follow-up of neurosarcoidosis. Sarcoidosis. 1987;4:105–10.
1012. Olafsson M, Simonsson MG, Hansson SB. Bronchial reactivity in patients with recent pulmonary sarcoidosis.Thorax. 1985;40:51–3.
1013. Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol. 2010;185:7067–76.
1014. Olenchock SA, Heise ER, Marx J. HLA-B8 in sarcoidosis. Ann Allergy. 1981;47:151–3.
1015. Olenchock SA, Marx JJ Jr, Mum J, et al. Immunology of clinically inactive sarcoidosis. Serum factors. Ann Alerg. 1981;47:28–31.
1016. Oliwiecki S, Kotecha B, Kingston T, Rothera P. Sarcoidosis- lymphoma syndrome. J R Soc Med 1992;85:176–7.
1017. Olmeda B, Martinez-Calle M, Perez-Gil J. Pulmonary surfactant metabolism in the alveolar airspace: Biogenesis, extracellular conversions, recycling. Ann Anat. 2017;209:78–92.
1018. Olsson T, Björnstad-Pettersen H, Sternberg NL. Bronchostenosis due to Sarcoidosis: A Cause of Atelectasis and Airway Obstruction Simulating Pulmonary Neoplasm and Chronic Obstructive Pulmonary Disease. Chest. 1979;75:663–6.
1019. Omoto Y, Yamanaka K, Tokime K, et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci. 2010;59:129–35.
1020. Orii M, Imanishi T, Teraguchi I, et al. Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis. Circ J. 2015;79:1585–92.
1021. Ornvold K, Carstensen H, Christensen L, Larsen JK, Christensen IJ. DNA aneuploidy in arcoid granuloma (letter). J Clin Pathol. 1989;42:1225–6.
1022. Ost D, Yeldandi A, Cugell D. Acute Sarcoid Myositis With Respiratory Muscle Involvement: Case Report and Review of the Literature. Chest. 1995;107:879–82.
1023. Ostadkarampour M, Eklund A, Moller D, et al. Higher levels of interleukin IL-17 and antigen--specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren's syndrome. Clin Exp Immunol. 2014;178:342–52.
1024. Ostadkarampour M, Eklund A, Moller D, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren's syndrome. Clin Exp Immunol. 2014;178:342–52.
1025. Oswald-Richter KA, Richmond BW, Braun NA, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol. 2013;190:5446–53.
1026. Ota M, Amakawa R, Uehira K, et al. Involvement of dendritic cells in sarcoidosis. Thorax. 2004;59:408–13.
1027. Otake S, Banno T, Ohba S, Noda M, Yamamoto M. Muscular sarcoidosis: findings at MR imaging. Radiology. 1990;176:145–8.
1028. Otake S, Ishigaki T. Muscular sarcoidosis. Semin Musculoskelet Radiol. 2001;5:167–70.

1029. Owen CI, Jabeen F, Bhattacharjee A. Application of the modified Zajicek criteria to diagnose probable spinal cord neurosarcoidosis. Clin Case Rep. 2018;6:1718–22.
1030. Oyoshi MK, He R, Kanaoka Y, et al. Eosinophil-derived leukotriene C4 signals via type 2 cysteinyl leukotriene receptor to promote skin fibrosis in a mouse model of atopic dermatitis. Proc Natl Acad Sci USA. 2012;109:4992–7.
1031. Padilla ML, Schileto GJ, Teirstein AS. Sarcoidosis and Transplantation. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:16–22.
1032. Pacheco Y, Charrin C, Villa L, et al. Etude caryotypique des lymphocytes sanguins dans la sarcoidose. Rev Pneumol Clin. 1989;45:199–202.
1033. Palchevskiy V, Hashemi N, Weigt SS, et al. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenesis Tissue Repair. 2011;4:10.
1034. Pannier R, Puspowidjono I, Burz D. Užití hrudní scintigrafie galliem 67 u nemocí dýchacího ústrojí. Stud Pneumol Phtiseol Cechoslov. 1985;45:15–25.
1035. Panselinas E, Judson MA. Acute Pulmonary Exacerbations of Sarcoidosis. Chest. 2012;142:827–36.
1036. Pantelidis P, Southcott AM, Black CM, du Bois RM. Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. Clin Exp Immunol. 1997;108:95–104.
1037. Paone G, Leone A, Batzella S, et al. Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers. Inflamm Res. 2013;62:325–32.
1038. Papadimitriou JM, Spector WG. The origin, properties and fate of epithelioid cells. J Pathol. 1971;105(3):187–203.
1039. Papapoulos SE, et al. 1,25-Dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis. Lancet. 1979;1:627–30.
1040. Paparel P, Devonec M, Perrin P, et al. Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24:95–101.
1041. Parajuli B, Sonobe Y, Kawanokuchi J, et al. GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J Neuroinflammation. 2012;9:268.
1042. Paramothayan S, Jones PW. Corticosteroid Therapy in Pulmonary SarcoidosisA Systematic Review. JAMA. 2002;287:1301–7.
1043. Park H, Park SG, Kim J, Ko YG, Kim S. Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. Cytokine. 2012;20:148–53.
1044. Parkers SA, Baker SBC, Bourdillon RE Murray CRH, Rakshit M. Epidemiology of sarcoidosis inthe Isle of Man-1: A case controlled study. Thorax. 1987;42:420–6.
1045. Pasha SF, Sharma VK, Crowell MD. Current concepts and treatment options in eosinophilic esophagitis. Curr Opin Investig Drugs. 2006;7:992–6.
1046. Pastorová B, Kolek V, Žurková M, Voláková E, Tichý T, Kriegová E. Věkové aspekty sarkoidózy. Stud Pneumol Phthiseol. 2018;78:102–6.
1047. Patel JN, Jager A, Schalkwijk C, et al. Effects of tumour necrosis factor-? in the human forearm: blood flow and endothelin-1 release. Clin Sci. 2002;103:409–15.
1048. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–77.
1049. Patterson KC, Franek BS, Muller-Quernheim J, et al. Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine. 2013;61:906–11.
1050. Patterson KC, Hogarth K, Husain AN, Sperling AI, Niewold TB. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Translat Res. 2012;160:321–31.
1051. Patterson KC, Chen ES. The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment. Chest. 2018;153:1432–42.
1052. Patzold U, Brewitt H, Krumsiek J, Sybrecht GM. Boeck mit einseitigen Optikusbefall. Klin Monatsbl Augenheilkd. 1984;184:222–4.

1053. Paurtier LM. Syndrome de Heerfordt et Maladie de Besnier-Boeck-Schaumann. Bull Soc Méd Hp Paris. 1937;53:1608.
1054. Pavlovic-Popovic Z, Duric B, Belic M, Skodric V. Tumor-like sarcoidosis of trachea. Proceedings WASOG and BSACI Joint Meeting. London; 1995, p. 48.
1055. Pechkovsky DV, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G. Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis. FEMS Immunol Med Microbiol. 2006;46:30–8.
1056. Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes and Infection. 2012;14:247–61.
1057. Perez RL, Duncan A, Hunter RL, Staton GW Jr. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest. 1993;103:1100–6.
1058. Perrin-Fayolee M, Pacheco Y, Harf R, Montagnon B, Biot N. Angiotensin-converting enzyme in bronchoalveolar lavage fluid in pulmonary sarcoidosis. Thorax. 1981;34:790–2.
1059. Perry A, Viutch F. Causes of death in patients eith sarcoidosis: A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167–72.
1060. Pešek M, Bittenglová R, Fremundová L, Turková-Sedláčková T, Dettmar PW. Průkaz pepsinu v sekretech dýchacích cest u intersticiálních plicních procesů. Stud Pneumol Phtiseol. 2014;74:168–73.
1061. Petřek M, Drábek J, Kolek V, et al. HLA-DRB1 Glu 69+ Alleles in Czech patients with Sarcoidosis. Eur J Imunogenetics. 1998;25(Suppl 1).
1062. Petřek M, Kolek V, Szotkowská J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J. 2002;20:1206–12.
1063. Petřek M, Kolek V. Subpopulace T-lymfocytů v bronchoalveolární laváži u plicní sarkoidózy a u jiných onemocnění plicního intersticia. Čas Lék Čes. 1993;132:365–8.
1064. Petřek M, Pantelidis P, Southcott AM, et al. The source and role of RANTES in interstitial lung disease. Eur Respir J. 1997;10:1207–16.
1065. Petřek M. Personalized medicine in sarcoidosis: predict responders and nonresponders. Current opinion in pulmonary medicine. 2015;21:532–7.
1066. Pettersson T. Rheumatic features of sarcoidosis. Curr Opin Rheumatol. 1998;10:73–8.
1067. Pforte A, Gerth C, Voss A, et al. Proliferating alveolar macrophages in BAL and lung function changes in interstitial lung disease. Eur Respir J. 1993;6:951–5.
1068. Pforte A, Schiessler A, Kressenstein S, et al. ICAM-1 expression on alveolar macrophages and in serum of sarcoidosis patients. J Clin Lab Immunol. 1995;46:125–35.
1069. Pickuth D, Heywang-Köbrunner SH. Neurosarcoidosis: evaluation with MRI. J Neuroradiol. 2000;27:185–8.
1070. Pietinalho A, Hiraga Y, Hosoda Y, Löfroos AB, Yamaguchi M, Selroos O. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12:61–7.
1071. Pietinalho A, Selroos O. Double-blind placebo controlled study of Budesonide in patients with newry diagnosed sarcoidosis. In: Proceedings of WASOG and BSACI Joint Meeting. London; 1995, p. 23.
1072. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. The Finnish Pulmonary Sarcoidosis. Early Treatment of Stage II Sarcoidosis Improves 5-Year Pulmonary Function. Chest. 2002;121:24–31.
1073. Pietra R, Edel J, Sabbioni E, Rizzato G. Sarcoidosis and trace metals as investigated by neutron activation analysis. In: Grassi C, Rizzato G, Pozzi E, editors. Sarcoidosis. Proceedings of the XI World Congress. Amsterdam: Excepta Medica; 1988. p. 411–5.
1074. Pintera J. Analysis of variance of blood groups of the AB0 system in the regions of Brno and of Olomouc. Scr Med Fac Med Brun. 1960;33:41–52.
1075. Piper SC, Ferguson J, Kay L, et al. The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells. PLoS ONE. 2013;8:e63365.

1076. Planck A, Eklund A, Grunewald J. Inflammatory BAL-fluid and serum parameters in HLA DR17 positive vs. DR17 negative patients with pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:64–9.
1077. Planck A, Katchar K, Eklund A, Gripenback S, Grunewald J. T-lymphocyte activity in HLA--DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:110–7.
1078. Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab. 2008;93:543–9.
1079. Polák J. Radiodiagnostika nemocí dýchacího ústrojí. Praha: Avicenum; 1989.
1080. Poletti V, Pagelli M, Ferracini R, Simonetti M, Spiga L. Transbronchial lung biopsy in infiltrative lung disease. The importance of the pathologic approach. Sarcoidosis. 1988;5:43–50.
1081. Pollak B. Epidemiology of sarcoidosis in Canada. J Int Med. 1964;174:145.
1082. Polychronopoulos VS, Prakash UBS. Airway Involvement in Sarcoidosis. Chest. 2009;136:1371–80.
1083. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines on diagnosis and treatment of acute and chronic heart failure. EHJ. 2016;37(27):2129–200.
1084. Popović OS, Brkić S, Bojić P, Kenić V, Jojić N, Djurić V, Djordjević N. Sarcoidosis and protein losing enteropathy. Gastroenterology. 1980;78:119–25.
1085. Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. QJM: Int J Med. 2003;96:553–61.
1086. Poyanli A, Poyanli O, Sencer S, Akan K, Sayrak H, Acunas B. Vertebral sarcoidosis: imaging findings. Eur Radiol. 2000;10:92–4.
1087. Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping Sarcoidosis from a Pulmonary Perspective. Am J Respir Crit Care Med. 2008;177:330–6.
1088. Price AE, Liang HE, Sullivan BM, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA. 2010;107:11489–94.
1089. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17:45–56.
1090. Prior C, Frank A, Fuchs D, et al. Urinary neopterin excretion in pulmonary sarcoidosis: Correlation to clinical course of the disease. Clin Chim Acta. 1988;177:211–20.
1091. Prizant H, Hammes SR. Minireview: Lymphangioleiomyomatosis (LAM): The Other Steroid--Sensitive Cancer. Endocrinology. 2016;157:3374–83.
1092. Procino G, Mastrofrancesco L, Tamma G, Lasorsa DR, Ranieri M, Stringini G, Emma F, Svetlo M, Valenti G. Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study. PLoS One. 2012;7:e33145.
1093. Pryor JA, Prasad SA. Physiotherapy techniques. In: Pryor JA, Prasad SA. Physiotherapy for respiratory and cardiac problems. Edinburgh: Churchill Livingstone; 2008. p. 134–217.
1094. Puar HS, Young RC Jr, Armstrong FM. Bronchial and transbronchial lung biopsy without fluoroscopy in sarcoidosis. Chest. 1985;87:303–6.
1095. Purriel P, Navarrete E. Epidemiology of sarcoidosis in Uruguay and other countries of Latin America. Am Rev Respir Dis. 1961;84:155–61.
1096. Putkonen T, Hannuksela M, Halme H. Calcium and phosphorus metabolism in sarcoidosis. Acta Medica Scandinavica. 1965;177:327–35.
1097. Quaden C, Leblond IT, Delobbe A, et al. Necrotising sarcoid granulomatosis: clinical, functional, endoscopical and radiographical evaluations. Eur Resp J. 2005;26:778–85.
1098. Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL. Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor-alpha/beta secretion. J Immunol. 1993;150:4844–55.
1099. Rabinowitz JG, Ulrich S. The usual and unusual manifeslation of sarcoidosis. Amer J Roentgenol. 1974;120:821–31.
1100. Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016;48:179–86.

1101. Ramos-Casals M, Mañá J, Nardi N, et al. Sarcoidosis in Patients With Chronic Hepatitis C Virus Infection: Analysis of 68 Cases. Med (Baltimore). 2005;84:69–80.
1102. Ramstein J, Broos CE, Simpson LJ, et al. IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells. Am J Respir Crit Care Med. 2016;193:1281–91.
1103. Reid JD, et al. Inflammatory predictors for the development of the adult respiratory distress syndrome. Thorax. 1995;50:1023–6.
1104. Reid JD, Chiodini RJ. Serologic reactivity against Mycobacterium paratuberculosis antigens in patients with sarcoidosis. Sarcoidosis. 1993;10:32–5.
1105. Reich JM. Mortality of Intrathoracic Sarcoidosis in Referral vs Population-Based Settings: Influence of Stage, Ethnicity, and Corticosteroid Therapy. Chest. 2002;121:32–9.
1106. Reichel H, et al. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989;320:980–91.
1107. Remy-Jardin M, Giraud F, Remy J, Wattinne L, Wallaert B, Duhamel A. Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology. 1994;191:675–80.
1108. Rennard SI, Crystal RG. Fibronectin in human bronchoalveolar lavage fluid: elevation in patients with interstitial lung disease. J Clin Invest. 1982;69:113–22.
1109. Reschner A, Hubert P, Delvenne P, Boniver J, Jacobs N. Innate lymphocyte and dendritic cell crosstalk: a key factor in the regulation of the immune response. Clin Exp Immunol. 2008;152:219–26.
1110. Reuhl J, Schneider M, Sievert H, et al. Myocardial sarcoidosis as a rare cause of sudden cardiac death. Forensic Sci Int. 1997;89:145–53.
1111. Reutgen H, Eckert H, Christ R. Der Kveimtest in der Sarkoidosediagnostik. Z Erkrank Atm Org. 1988;170:306–11.
1112. Reynolds HY, Newbald HH. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med. 1974;84:559.
1113. Reynolds HY. Classification, definition and correlation between clinical and histologic staging of interstitial lung disease. Semin Respir Med. 1984;6:1–19.
1114. Ricker W, Clark M. Sarcoidosis: a clinicopathologic review of 300 cases, including 22 autopsies. Am J Clin Pathol. 1949;19:725–49.
1115. Riedemann NC, Guo RF, Hollmann TJ, et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 2004;18:370–2.
1116. Richardson MD, Brownlie CE, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol. 1992;30:433–41.
1117. Richeldi L, Sorrentino R, Saltini C. HLA-DRB1 Glutamine 69: Agenetic marker of beryllium disease. Science. 1993;262:242–4.
1118. Richerson HB, Bernstein IL, Fink JN, et al. Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the Subcommittee on Hypersensitivity Pneumonitis. J Allergy Clin Immunol. 1989;84:839–44.
1119. Rivera NV, Hagemann-Jensen M, Ferreira MAR, et al. Common variants of T-cells contribute differently to phenotypic variation in sarcoidosis. Sci Rep. 2017;7:5623.
1120. Rivera NV, Ronninger M, Shchetynsky K, et al. High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences. Am J Respir Crit Care Med. 2016;193:1008–22.
1121. Rivera NV, Ronninger M, Shchetynsky K, Franke A, Nöthen MM, Müller-Quernheim J, et al. High-density genetic mapping identifies new susceptibility variants in sarcoidosis phenotypes and shows genomic-driven phenotypic differences. Am J Resp Crit Care Med. 2016;193(9):1008–22.
1122. Rizzato G, Blasi A. An European survey on Ga67 lung scan in sarcoidosis. Experience in 12 centres in 7 different countries. In: Abstracts IVth European Conf. Sarcoidosis. Sorrento; 1983. p. 111–26.

1123. Rizzato G, Montemurro L, Fraioli P. Sarcoid extrapulmonary features. Shift of the bioptic approach from the mediastinoscopy to the pleuroscopy. Sarcoidosis. 1993;10:157–8.
1124. Rizzato G, Tosi G, Mella C, et al. Prednisone induced bone loss in sarcoidosis: a risk especially in post menopausal women. Sarcoidosis. 1988;5:93–8.
1125. Rizzato G. Markers of sarcoidosis. Sarcoidosis. 1985;2:12–5.
1126. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.
1127. Rockoff SD, Rohatgi PK. Unusual manifestations of thoracic sarcoidosis. AJR Am J Roentgenol. 1985;144:513–28.
1128. Rodman JS, Mahler RJ. Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am. 2000;27:275–85.
1129. Rodrigo MJ, Benavent MI, Cruz MJ, et al. Detection of specific antibodies to pigeon serum and bloom antigens by enzyme linked immunosorbent assay in pigeon breeder's disease. Occup Environ Med. 2000;57:159–64
1130. Rodriguez GE, Shin BC, Bernathy RS, Kending EL Jr. Serum angiotensin-converting enzyme activity in normal children and in those with sarcoidosis. J Pediatr. 1981;99:68–72.
1131. Rogers RM, Tantum KR. Bronchopulmonary lavage. A new approach to old problems. Med Clin North Am. 1970;54:755–71.
1132. Rohatgi PK, Baier H. Quantitative gallium scanning in pulmonary sarcoidosis. Respiration. 1983;44:304–13.
1133. Rohatgi PK, Ryan JW. Simple radioassay for measuring serum activity of angiotensin-converting enzyme in sarcoidosis. Chest. 1980;78:69–75.
1134. Rohrhach MS, Vuk-Pavlovič Z, Martin WJ, De Laval P, Genetet N. Induction of angiotensin converting enzyme in cultured human monocytes by a factor present in the bronchoalveolar lavage fluid of sarcoidosis patients. Sarcoidosis. 1988;5:17–23.
1135. Roman JR, McDonald JA. Cellular Processes in Lung Repair. Chest. 1991;100:245–8.
1136. Romer FK, Ahebom G, Jensen JU. Relationship between angitensin-converting enzyme and lysozyme in sarcoidosis. Eur J Respir Dis. 1982;63:330–6.
1137. Romer FK, Solling K. Repeated measurments of serum immunoglobulin-free light chain in early sarcoidosis. Eur J Respir Dis. 1984;65:292–5.
1138. Romer FK. Angiotensin-converting enzyme activity in sarcoidosis and other disorders. Sarcoidosis. 1985;2:25–34.
1139. Romer FK. Angiotensin-converting enzyme in hypercalcaemic disorders. Acta Med Scan. 1982;211:31–3.
1140. Romero J, Ramon y Cajal S, Vargas JA, et al. Association of sarcoidosis, low-grade B-lymphoma and epidermoid carcinoma. Postgrad Med J. 1998;872:382–5.
1141. Rose RM, Lee RG, Costello P. Solitary nodular sarcoidosis. Clin Radiol. 1985;36:589–92.
1142. Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Path Lab Med. 1977;101:170–4.
1143. Rosen Y. Pathology of sarcoidosis. Semin Respir Crit Care Med. 2007;28:36–52.
1144. Rosseel B, Vierendeells T, Noppen M, et al. Posterior mediastinal sarcoidosis. Chest. 1986;90:462–4.
1145. Rossman MD, Dauber JH, Cardillo ME, Daniele RP. Pulmonary sarcoidosis: correlation of serum angiotensin-converting enzyme with blood and bronchoalveolar lymphocytes. Am Rev Resp Dis. 1982;125:366–9.
1146. Rossman MD, Newman LS, Baughman RP, et al. A double-blind, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffusef Lung Dis. 2006;23:201–8.
1147. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PGH, Drent M. Potential Usefulness of Inflammatory Markers to Monitor Respiratory Functional Impairment in Sarcoidosis. Clin Chem. 2003;49:1510–7.
1148. Rothova A. Ocular involvement in sarcoidosis. Br J Ophtalmol. 2000;84:110–6.

1149. Rottoli P, Bianchi Bandinelli ML, Rottoli L, Zazzi M, Panzardi G, Valensin PE. Sarcoidosis and infections by human lymphotropic viruses. Sarcoidosis. 1990;7:31–3.
1150. Rubini G, Cappabinaca S, Altini C, et al. Current clinical use of 18FDG-PET/CT in patients with thoracic and systemic sarcoidosis. Radiol Med. 2014;119:64–74.
1151. Rubinstein I, Baum GL, Hiss Y. Sarcoidosis of the penis: Report of case. J Urol. 1986;135:1016–7.
1152. Rubinstein I, Solomon A, Baum GL, Hiss Y. Pulmonary sarcoidosis presenting with unusual roentgenographic manifestations. Eur J Respir Dis. 1985;67:335–40.
1153. Ruettner JR, Spycher MA, Vogt P. Lung fibrosis associated with rare earth exposure. In: Proc. 7th Internat. Pneumoconiosis Conf. Pittsburg; 1988. p. 127.
1154. Ruocco MG, Chaouat G, Florez L, Bensussan A, Klatzmann D. Regulatory T-cells in pregnancy: historical perspective, state of the art, and burning questions. Front Immunol. 2014;5:389.
1155. Rybicki BA, Levin AM, McKeigue P, et al. A genome-wide admixture scan for ancestry-linked genes predisposing to sarcoidosis in African-Americans. Genes Immun. 2011;12:67–77.
1156. Řehák F. Chirurgická plicní biopsie u sarkoidózy. Stud Pneumol Phtiseol Cechoslov. 1982;42:112–4.
1157. Říha V, Palyza J. Sarcoidosis in North Moravia – an epidemiological study. Acta Univ Palacki Olomouc. 1970;55:35–44.
1158. Saboor SA, Johnson NM, McFadden J. Detection of mycobacterila DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet. 1992;339:1012–5.
1159. Saenz SA, Siracusa MC, Perrigoue JG, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature. 2010;464:1362–6.
1160. Saetta M, Baraldo S, Turato G, et al. Increased proportion of CD8+ T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:28–32.
1161. Sahashi K, Ina Y, Takada K, Sato T, Yamamoto M, Morishita M. Significance of interleukin 6 in patients with sarcoidosis. Chest. 1994;106:156–60.
1162. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Resp J. 2011;38:1145–50.
1163. Saidenberg-Kermanac'h N, Semerano L, Nunes H, et al. Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a crosssectional study on 142 patients. Arthritis Res Ther. 2014;24:R78.
1164. Saidenberg-Kermanac'h N, Valeyre D, Boissier MC. Vitamin D supplementation in patients treated for sarcoidosis: Controversy or consensus? Joint Bone Spine. 2017;84:521–3.
1165. Saint-Remy JR, Mitchell DN, Cole PJ. Variation in immunoglobulin levels and circulating immune complexes in sarcoidosis. Am Rev Resp Dis. 1983;127:23–7.
1166. Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol, 2016;12:817–25.
1167. Salazar A, Mañá J, Sala J, Landoni BR, Manresa F. Combined Portal and Pulmonary Hypertension in Sarcoidosis. Respiration. 1994;61:117–9.
1168. Salez F, Gosset P, Copin MC, Lamblin Degros C, Tonnel AB, Wallaert B. Transforming growth factor-beta1 in sarcoidosis. Eur Respir J.1998;12:913–9.
1169. Salsbury AJ. Splenomegaly and splenectomy in sarcoidosis. J Clin Pathol. 1979;32:1050–3.
1170. Saltini C, Brugni N, Magnani C, et al. Chemiluminiscence measurment of phagocytic activity of pulmonary macrophages. Respiration. 1984;45:291–5.
1171. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maitenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T-cells. N Engl J Med. 1989;320:1103–9.
1172. Samokhin AO, Bühling F, Theissig F, Brömme D. ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis. Am J Pathol. 2010;176:1148–56.
1173. Samokhin AO, Gauthier JY, Percival MD, Brömme D. Lack of cathepsin activities alter or prevent the development of lung granulomas in a mouse model of sarcoidosis. Respir Res. 2011;12:13.

1174. Sansonetti M, et al. Fibrose pulmonaire interstitielle diffuse familiale. Etude ï une famille. Rev Respir. 1985;2:75–81.
1175. Sartin JS, Walker RC. Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic. Mayo Clin Proc. 1991;66:914–8.
1176. Sato A. Renal dysfunction in patients with sarcoidosis. Intern Med. 1996;35:523–4.
1177. Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PloS ONE. 2012;7:e43588.
1178. Savan R, Ravichandran S, Collins JR, Sakai M, Young HA. Structural conservation of interferon gamma among vertebrates. Cytokine Growth Factor Rev. 2009;20:115–24.
1179. Savarino E, Marabotto E, Bodini G, et al. Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2017;63:175–83.
1180. Scadding JG, Chappell AG, Sutherland I. Familia association in sarcoidosis. Tubercle. 1973;54:87–98.
1181. Scadding JG, Mitchell DN, The Immunology of Sarcoidosis. In: Sarcoidosis. Boston, MA: Springer; MA, 1985. p. 414–443.
1182. Scadding JG. Further observations on sarcoidosis associated with M. tuberculosis infection. In: Proc. 5th'International Conference on Sarcoidosis. Praha: Univerzita Karlova; 1977. p. 89–92.
1183. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961;2:1165–72.
1184. Scott J. Transplantation of the lungs and heart and lungs for patients with severe pulmonary compliations. Sarcoidosis. 1990;7:9–11.
1185. Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol. 2007;64:691–6.
1186. Seaworth JF, Davis SJ, Donovan WN. Aggressive diagnostic approach indicated in testicular sarcoidosis. Urology. 1983;21:396–8.
1187. Sehrt I, Christ R. Serum Angiotensinkonverting Enzyme Aktivitt und klinischer Verlauf der Sarkoidose. Verlaufsuntersuchungen beim Löfgren-Syndrom. Z Erkrank Atm Org. 1985;164:39–42.
1188. Sehrt I. Biochemische Aktivitatsmarker. Z Erkrank Atm Org. 1988;170:284–90.
1189. Seidemann W. Hydronephrose durch vergrosserte reproperitoneale Lymphkoten bei Sarcoidose. Dtsch Med Wochenschr. 1987;112:1583–5.
1190. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: Diagnostic, prognostic, and therapeutic considerations. Cardiovascular Drugs and Therapy. 1996;10:495–510.
1191. Selroos O, Koivunen E. Usefulness of fine-needle aspiration biopsy of spleen in diagnosis of sarcoidosis. Chest. 1983;83:193–5.
1192. Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis: a prospespective evaluation of alternate day a 15nd daily dosage in stage II disease. Scand J Respir Dis. 1979;60:215–21.
1193. Selroos O. Budesonide in the treatment of pulmonary sarcoidosis. Ann NY Acad Sci. 1986;465:713–21.
1194. Selroos O. Sarcoidosis and pregnancy: a review with results of a retrospective survey. J Int Med. 1990;227:221–4.
1195. Selroos OB. Biochemical markers in sarcoidosis. Crit Rev Clin Lab Sci. 1986;24:185–216.
1196. Selroos OB. Breakfast seminar: Inhalational corticosteroids. Sarcoidosis. 1994;11:137–8.
1197. Semenzato G, Agostini C, Pezzutto A, et al. Distribution of natural killer cells in sarcoidosis. J Clin Lab Immunol. 1984;13:25–8.
1198. Semenzato G, Agostini C, Trentin L, et al. Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients. Clin Exp Immunol. 1984;57:331–7.
1199. Semenzato G, Bortolin M, Facco M, Perin A, Basso U, Agostini C. Immunological response of sarcoidosis Thl versus Th2. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:7.

1200. Semenzato G, Trentin L, Zambello R, et al. Cytotoxic lymphocytes in the lung of patients with hypersensitivity pneumonitis: functional and molecular analysis. Ann NY Acad Sci. 1988;137(53):447–50.
1201. Semenzato G. Assessment of disease activity in sarcoidosis: Deeds and misdeeds. Sarcoidosis. 1993;10:100–3.
1202. Semenzato G. Bias toward use of T-cell receptor variable regions in the lung: research tool or clinically useful technigue? Eur J Respir. 1997;10:767–9.
1203. Sempowski GD, Derdak S, Phipps RP. Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol. 1996;167:290–6.
1204. Shabo Y, Lotem J, Rubinstein M, et al. The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood. 1988;72:2070–3.
1205. Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol. 2009;30:953–61.
1206. Shah RNH, Mills PR, George PJ, Wedzicha JA. Upper airways sarcoidosis presenting as obstructive sleep apnoea. Thorax. 1998;53:228–9.
1207. Shaik-Dasthagirisaheb YB, Varvara G, et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol. 2013;26:327–35.
1208. Shamaei M, Mortaz E, Pourabdollah M, et al. Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. Hum Immunol. 2018;79:63–9.
1209. Sharma AM, Kadakia J, Sharma OP. Gastrointestinal Sarcoidosis. Semin Respir Med. 1992;13:442–9.
1210. Sharma O. Hypercacinemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6:442–7.
1211. Sharma OM. Sarcoidosis and other autoimmune disorders. Curr Opin Pulm Med. 2002;8:452–6.
1212. Sharma OP, et al. Course of pulmonary sarcoidosis with and without corticosteroid therapy as determined by pulmonary function test. Am J Med. 1966;41:541–5.
1213. Sharma OP, Jaces DG. Did Olser's patient, Hannah W. have sarcoidosis? An historical footnote. Chest. 1984;86:263–4.
1214. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253–8.
1215. Sharma OP, Vatti R. Liver involvement in sarcoidosis. In: Proceedings of WASOG and BSACI Joint Meeting. London; 1995. p. 19.
1216. Sharma OP. Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art. Chest. 2003;123:18–9.
1217. Sharma OP. Epidemiology of sarcoidosis: a report of the papers and posters presented at the tenth international conference on sarcoidosis, Baltimore, USA, 1984. Sarcoidosis. 1985;2:9–11.
1218. Sharma OP. Francesco Sassetti and Sarcoidosis. Sarcoidosis. 1989;6:163–4.
1219. Sharma OP. Functional impairment in sarcoidosis. Sarcoidosis. 1988;5:11–2.
1220. Sharma OP. Chloroquine and hydroxychloroquine are effective in treating patients of sarcoidosis with neurological involvement. Am J Respir Critic Care Med. 1997;155:944.
1221. Sharma OP. Neurosarcoidosis. Chest. 1991;100:301–2.
1222. Sharma OP. Pulmonary sarcoidosis and corticosteroid. Am Rev Respir Dis. 1993;147:1598–600.
1223. Sharma OP. Thallium-201 imaging in the management of myocardial sarcoidosis. In: Proceedings 9th International Conference on Sarcoidosis. London: Pergamon Press; 1983. p. 619.
1224. Sharma OP. Unusual manifestations of pulmonary sarcoidosis. A radiographic panorama. In: Proceedings VIIIth Intern. Conf. Sarcoidosis. Cardiff: Alpha Omega Press; 1980. p. 386–7.
1225. Shefield EA. The vascular structure of granulomas. Sarcoidosis 1994; 11(Suppl 1):155–156.
1226. Sherlock S, Dooley JC. Diseases of the Liver and Biliary System. 9th ed. Oxford: Blackwell; 1993.
1227. Sherlock S. The liver in sarcoidosis. Semin Liver Dis. 1992;13:450–4.

1228. Shijubo N, Imai K, Shigehara K, et al. Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Clin Exp Immunol. 1994;95:156–61.
1229. Shijubo N, Imai K, Shigehara K, Hinoda Y, Abe S. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in patients with sarcoidosis. Clin Exp Immunol. 1996;106:549–54.
1230. Shin K, Nigrovic PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 2009;182:647–56.
1231. Shorr AF, Hnatiuk OW. Circulating D dimer in patients with sarcoidosis. Chest. 2000;117:1012–6.
1232. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001;120:109–14.
1233. Shorr AF, Torrington KG, Hnatiuk W. Endobronchial Involvement and Airway Hyperreactivity in Patients With Sarcoidosis. Chest. 2001;120:881–6.
1234. Schachter EN, Smith GJW, Cohen GS, Lee SH, Lasser A. Pulmonary Granulomas in a Patient with Pulmonary Veno-occlusive Disease. Chest. 1975;67:487–9.
1235. Scharkoff T. Epidemiologie der Sarkoidose. Z Erkr Atmungsorgane. 1988;170:238–41.
1236. Scharkoff T. Sarkoidose und Beruf. Z Erkrank Atm Org. 1977;143:50–9.
1237. Schaumann J, Seeberg G. On cutaneous reactions in cases of lymphogranulomatosis benigna. Acta Derm Venereol. 1948;28(2):158–68.
1238. Schaumann J. Lupus pernio: Zambaco Prize Essay. Stockholm: P. A. Norstedt and Soner; 1934.
1239. Schermuly W, Sonnentag W. Die Beurteilung der Sarkoidoseaktivitat anhand rontgendiagnostischer und szintigraphischer Methoden. Fortschr Rontgenstr. 1982;136:49–55.
1240. Schermuly W. Röntgenologische und Szintigraphische Befunde bei Sarkoidosepatiente. Internist. 1982;23:325–34.
1241. Schieppati E. Mediastinal lymph node puncture through the tracheal carina. Surg Gynecol Obstet. 1958;110:243–6.
1242. Schiodt M, Thorn J. Criteria for the salivary component of Sjogren's syndrome. Clin Exp Rheumatol. 1989;7:119–22.
1243. Schmuth M, Prior C, Illersperger B, Topar G, Fritsch P, Sepp N. Systemic sarcoidosis and cutaneous lymphoma: is the association fortuitous? Br J Dermatol. 1999;140:952–5.
1244. Schnerch J, Prasse A, Vlachakis D, et al. Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. Am J Respir Cell Mol Biol. 2016;55:749–57.
1245. Schoenberger CL, Line BR, Kheogh BA, Hunninghake GW, Crystal RG. Lung inflamation in sarcoidosis. Comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assesment of the T-lymphocyte alveolitis. Thorax. 1982;37:19–25.
1246. Schröder AK, Von der Ohe M, Kolling U, et al. Polymorphonuclear leucocytes selectively produce anti-inflammatory interleukin-1 receptor antagonist and chemokines, but fail to produce pro-inflammatory mediators. Immunology. 2006;119:317–27.
1247. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925–9.
1248. Schupp JC, Vukmirovic M, Kaminski N, Prasse A. Transcriptome profiles in sarcoidosis and their potential role in disease prediction. Curr Opin Pulm Med. 2017;23:487–92.
1249. Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J. 2018; 51:1700991.
1250. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus study. Resp Med. 2010;194:717–23.
1251. Sietsma K. Sarcoidosis and the diffusing capacity for carbon monoxide. Sarcoidosis. 1990;7:12–4.
1252. Sikorski K, Chmielewski S, Olejnik A, et al. STAT1 as a central mediator of IFN? and TLR4 signal integration in vascular dysfunction. JAK-STAT. 2012;1:241–9.

1253. Siltzbach LE, Cahn LR. Randon biopsy of bronchial and palatal mucosa in the diagnosis of sarcoidosis. In: Proceedings IIIrd Intern. Conf. Sarcoidosis. Stockholm: Svenska Beleforlaget; 1963. p. 230–4.
1254. Siltzbach LE, Ehrlich JC. The Nickerson-Kveim reaction in sarcoidosis. Am J Med. 1954;16:790–803.
1255. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med. 1974;57:847–52.
1256. Siltzbach LE, Posner A, Medine MM. Cortisone therapy in sarcoidosis. J Am Med Assoc. 1951;147:927–9.
1257. Siltzbach LE. An international Kveim test study. Acta Med Scand. 1964;(Suppl 425):178–86.
1258. Siltzbach LE. Geographic aspects of sarcoidosis. Trans NY Acad Sci. 1967;29:364–74.
1259. Siltzbach LE. The Kveim test in sarcoidosis. A study of 750 patients. JAMA. 1961;178:476–82.
1260. Silva M, Nunes H, Valeyre D, Sverzellati N. Imaging of sarcoidosis. Clin Rev Allerg Immunol. 2015;49:45–53.
1261. Silva PH, Parra ER, Zocolaro WS, et al. Immunophenotyping and extracellular matrix remodeling in pulmonary and extrapulmonary sarcoidosis. J Bras Pneumol. 2012;38:321–30.
1262. Silver MR, Messner LV. Sarcoidosis and its ocular manifestations. J Am Optom Assoc.1994;65:321–7.
1263. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.
1264. Simecek C. Cytological investigation of intrathoracic lymph nodes in carcinoma of the lung. Thorax. 1996;21:369–71.
1265. Sipahi S, Tuzun S, Ozaras R, et al. Bone mineral density in women with sarcoidosis. J Bone and Miner Metab. 2004;22:48–52.
1266. Skeggs LT, Kahn JR, Shumway NP. The preparation and function of the hypertension-converting enzyme. J Exp Med. 1956;103:296–9.
1267. Sköld CM, Larsen FF, Rasmussen E, Pehrsson SK, Eklund AG. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med. 2002;252:465–71.
1268. Smedema JP, Snoep G, van Kroonenburgh MPG, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–90.
1269. Smith LJ, Lawrence JB, Katzenstein ALA. Case Report: Vascular Sarcoidosis: A Rare Cause of Pulmonary Hypertension. Am J Med Sci. 1983;285:38–44.
1270. Smolíková L, Máček M. Respirační fyzioterapie a plicní rehabilitace. Brno: Národní centrum ošetřovatelství a nelékařských zdravotnických oborů; 2013.
1271. Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG. Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol. 2011;48(2):91–7.
1272. Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG. Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol. 2011;48(2):91–7.
1273. Sobic-Saranovic DP, Grozdic IT, Videnovic-Ivanov J, et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin Nucl Med. 2013;38:516–21.
1274. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med. 2009;103:268–73.
1275. Sofi MH, Li W, Kaplan MH, Chang CH. Elevated IL-6 expression in CD4 T cells via PKCtheta and NF-kappaB induces Th2 cytokine production. Mol Immunol. 2009;46:1443–50.
1276. Solaymani-Dodaran M, West J, Smith C, Hubbard R. Extrinsic allergic alveolitis: incidence and mortality in the general population. QJM. Int J Med. 2007;100:233–7.
1277. Soler P, Basset F. Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann NY Acad Sci. 1976;278:147–61.

1278. Sommer N, Weller M, Petersen D, Wiethölter H, Dichgans J. Neurosarcoidosis without systemic sarcoidosis. Eur Arch Psychiatry Clin Neurosci. 1991;240:334–8.
1279. Sones M, Israel HL. Course and prognosis of sarcoidosis. Am J Med. 1960;28:84–93.
1280. Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest. 2004;126:2000–7.
1281. Sopacua M, Hoeijmakers JGJ, Merkies ISJ, Lauria G, Waxman SG, Faber CG. Small-fiber neuropathy: Expanding the clinical pain universe. J Peripher Nerv Syst. 2019;24:19–33.
1282. Soria LM, Valverde Garda J, Sole JM, Badrinas Vancells F. Familial sarcoidosis, a case report. Sarcoidosis. 1990;7:133–5.
1283. Soskel NT, Sharma OP. Pleural involvement in sarcoidosis: case presentation and detailed review of the literature. Semin Respir Med. 1992;13:492–514.
1284. Southcott AM, Gelder CM, et al. Granulocyte chemoattractant gene expression: key roles in pulmonary fibrosis. Am J Respir Crit Care Med. 1994;149:862.
1285. Southcott AM, Jones KP, Majumdar DLS, et al. IL-8, differential expresion in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med. 1995;151:1604–12.
1286. Soylu A, Türkmen MA, Kavukçu S. Childhood sarcoidosis. Arch Rheumatol. 2005;20:65–74.
1287. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med. 2014;2:416–28.
1288. Spagnolo P, Oldham JM, Jones MG, Lee JS. Personalized medicine in interstitial lung diseases. Curr Opin Pulm Med. 2017;23:231–6.
1289. Spagnolo P, Richeldi L, Raghu G. The role of bronchoalveolar lavage cellular analysis in the diagnosis of interstitial lung diseases. Eur Respir Mon. 2009;46:36–46.
1290. Spagnolo P, Sverzellati N, Wells AU, Hansell DM. Imaging aspects of the diagnosis of sarcoidosis. Eur Radiol. 2014;24:807–16.
1291. Spector WG. Epitheloid cells, giant cells and sarcoidosis. Ann NY Acad Sci. 1976;278:3–7.
1292. Spencer M, Yao-Borengasser A, Unal R, et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab. 2010;299:e1016–27.
1293. Spencer N, Ross G, Helm G, Madisen J, Ur H. Aqueductal obstuction in sarcoidosis. Clin Neuropathol. 1989;8:158–61.
1294. Spiteri MA, Clarke SW, Poulter LW. Alveolar macrophages that suppress T-cell responses may be crucial to the pathogenetic outcome of pulmonary sarcoidosis. Eur Respir J. 1992;5(4):394–403.
1295. Spiteri MA, Matthey F, Gordon T, Carstairs LS, James DG. Lupus pernio-a clinico-radiological study of thirty-five cases. Brit J Dermatol. 1985;112:315–22.
1296. Spiteri MA, Newman SP, Clarke SW, Poulter LW. Inhaled cortisteroids can modulate the immunopatogenesis of pulmonary sarcoidosis. Eur Respir J. 1989;2:218–24.
1297. Spiteri MA, Poulter LW, Geraint-James D. The macrophage in sarcoid granuloma formation. Sarcoidosis. 1989;6(Suppl 1):12–4.
1298. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol. 2011;12:21–7.
1299. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester CF. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13–64.
1300. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60:32–8.
1301. Spruit MA, Wouters EFM, Gosselink R. Rehabilitation programmes in sarcoidosis: a multidisciplinary approach. Eur Respir Mon. 2005;32:316–26.
1302. Spurzem JR, Saltini C, Kirby M, Konishi K, Crystal RG. Expression of HLA class II genes in alveolar macrophages of patients with sarcoidosis. Am Rev Respir Dis. 1989;140(1):89–94.
1303. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11:615–28.

1304. Stadnyk AN, Rubinstein I, Grossman RF, et al. Clinical features of sarcoidosis in elderly patients. Sarcoidosis. 1988;5:121–3.
1305. Standiford TJ, Rolfe MW, Kunkel SL, et al. Macrophage inflammatory protein-1 ï expression in interstitial lung disease. J Immunol. 1995;151:2852–63.
1306. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann NY Acad Sci. 2012;1247:56–68.
1307. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), The European Respiratory Society (ERS) and The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.
1308. Steenland K, Ward E. Lung cancer incidence among patients with Beryllium disease: A cohort mortality study. J Nat Cancer Inst. 1991;83:1380–5.
1309. Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91:939–49.
1310. Steiger J, Nickerson PW, Steurer W, Moskovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol. 1995;155:489–98.
1311. Stern BJ, Schonfeld SA, Sewell C. The Treatment of Neurosarcoidosis With Cyclosporine. Arch Neurol. 1992;49:1065–72.
1312. Stern PH, De Olazabal J, Bell NH. Evidence for abnormal regulation of circulating 1 alpha, 25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J Clin Invest. 1980;66:852–5.
1313. Stewart TA, Weare JA, Erdos G. Human peptidyl dipeptidase (convertingenzy me, kininase II). Meth Enzymol. 1981;80:450–60.
1314. Straub JP, van Kamp GJ, van Marsseven TC, Stam J. Biochemical parameters in BAL of sarcoidosis. Sarcoidosis. 1995;12:51–7.
1315. Strausz J, Muller-Quernheim J, Steppling J, Ferlinz R. Sauerstoffradikalproduktin alveolarer Entzundungszellen bei Sarkoidose und idiopathischer Lungenfibrose. Pneumologie. 1989;43:440–5.
1316. Strejček J, Lokaj J. Imunologie v klinické praxi. Praha: Avicenum; 1985.
1317. Strom KE, Eklund AG. Smoking does not prevent the onset of respiratory failure in sarcoidosis. Sarcoidosis. 1993;10:26–8.
1318. Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M. Predictors of fatigue in sarcoidosis: The value of exercise testing. Respir Med. 2016;116:49–54.
1319. Strookappe B, Elfferich M, Swigris J, et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:43–52.
1320. Strookappe B, Saketkoo LA, Elfferich M, et al. Physical activity and training in sarcoidosis: review and experience-based recommendations. Expert Rev Respir Med. 2016;10:1057–68.
1321. Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M. Benefits of physical training in sarcoidosis. Lung. 2015;193:701–8.
1322. Stříž I, Mio T, Adachi Y, Carnevali S, Romberger DJ, Rennard SI. Effects of interferons alpha and gamma on cytokine production and phenotypic pattern of human bronchial epithelial cells. Int J Immunopharm. 2000;22:573–85.
1323. Stříž I, Mio T, Adachi Y, Romberger DJ, Rennard SI. Effects of interferons alpha and gamma on cytokine production and phenotypic pattern of human bronchial epithelial cells. Immunol letters. 1999;70:83–8.
1324. Stříž I, Slavčev A, Kalanin J, Jarešová M, Rennard SI. Cell-cell contacts with epithelial cells modulate the phenotype of human macrophages. Inflammation. 2001;25:241–6.
1325. Stříž I, Wang YM, Kalacioglu O, Costabel U. Expression of alveolar macrophage adhesion molecules in pulmonary sarcoidosis. Chest. 1992;102:882–6.

1326. Stříž I, Wang YM, Švarcová I, Trnka L, Sorg C, Costabel U. The phenotype of alveolar macrophages and its correlation with immune cells in bronchoalveolar lavage. Eur Respir J. 1993;6:1287–9.
1327. Stříž I, Wang YM, Teschler H, Sorg C, Costabel U. Phenotypic markers of alveolar macrophage maturation in pulmonary sarcoidosis. Lung. 1993;171:293–303.
1328. Studdy P, Bird R, James DG, Sherlock S. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet. 1978;2:1331–4.
1329. Studdy PR, James DG. The specificity and sensitivity of serum angiotensin converting enzyme in sarcoidosis and other diseases. Experiences in twelve centers in six different countries. In: Chrétien J, Marsac J, Saltiel JC, editors. Sarcoidosis. Paris: Pergamon Press; 1983. p. 332–44.
1330. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Fron Immunol. 2016;7:160.
1331. Sugiyama Y, Kasahara T, Mukaida N, Matsushima K, Kitamura S. Chemokines in bronchoalveolar lavage fluid in summer-type hypersensitivity pneumonitis. Eur Respir J. 1995;8:1084–90.
1332. Suchankova M, Bucova M, Tibenska E, et al. Triggering receptor expressed on myeloid cells and in bronchoalveolar lavage fluid in pulmonary sarcoidosis. Respirology. 2013;18:455–62.
1333. Sulavik SB, Spencer RP, Weed DA, Shapiro HR, Shiue ST, Castriotta RJ. Recognition of Distinctive Patterns of Gallium-67 Distribution in Sarcoidosis. J Nucl Med. 1990;31:1909–14.
1334. Sulavik SE, Palestro CJ, Spencer RP, Swyer AJ, Goldsmith SJ, Tiertein AS. Extrapulmonary sites of radiogallium accumulation in sarcoidosis. Clin Nucl Med. 1990;15:876–8.
1335. Sulavik SE, Weed D, Spencer R, Shapiro H, Castriotta R. A combinational analysis of 67Ga scanning of the head and thorax in the diagnosis of sarcoidosis. The Panda Sign. In: Sarcoidosis Proceedings of the XI World Congress. Amsterdam: Excepta Medica International Congress Series; 1988. p. 517–8.
1336. Sulica R, Teirstein A, Kakarla S, Neman N, Behnegar A, Padilla M. Distinctive Clinical, Radiographic, and Functional Characteristics of Patients With Sarcoidosis-Related Pulmonary Hypertension. Chest. 2005;128:1483–9.
1337. Sun J, Zheng X, Mao X, et al. Endobronchial Ultrasound Elastography for Evaluation of Intrathoracic Lymph Nodes. Respiration. 2017;93:327–38.
1338. Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. NK cells and immune memory. J Immunol. 2011;186:1891–7.
1339. Suresh S, Tirabosco R, Saifuddin A, O'Donnell P. An unusual presentation of muscular sarcoidosis. Skeletal Radiol. 2007;36:995–8.
1340. Suzuki K, Akama T, Kawashima A, Yoshihara A, Yotsu RR, Ishii N. Current status of leprosy: Epidemiology, basic science and clinical perspectives. J Dermatol. 2012;39:121–9.
1341. Svachova V, Sekerkova A, Hruba P, et al. Dynamic changes of B-cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection. Transplant Internat. 2016;29:540–8.
1342. Svarcova I, Striz I. Detection of antibodies against Mycobacterium tuberculosis. Chest. 1990;97:506.
1343. Swaisgood CM, Oswald-Richter K, Moeller SD, et al. Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol. 2011;44:166–74.
1344. Sweiss NJ, Curran J, Baughman RP. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clin Dermatol. 2007;25:341–6.
1345. Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic Manifestations of Sarcoidosis. Semin Respir Crit Care. 2010;31:463–73.
1346. Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43:1525–8.
1347. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988–2007. Am J Respir Crit Care Med. 2011;183:1524–30.
1348. Szabady RL, McCormick BA. Control of neutrophil inflammation at mucosal surfaces by secreted epithelial products. Front Immunol. 2013;4:220.

1349. Szklarz E. Expression of HLA-DR antigens, Fc IgG and C3 receptors on lung macrophages in sarcoidosis and idiopathic lung fibrosis. Arch Immunol Ther Exp. 1990;38:185–95.
1350. Šefčíková A, Turková M, Žurková M. Sarkoidóza ženského pohlavního ústrojí. Čes Gynek. 2016;81:458–62.
1351. Šimeček C, Ošťádal O, Kubašta M, Dušek J, Jezdinská V. Die diagnostische Bedeutung der Nadelbiopsie der Leber bei Sarkoidose der intrathorakalen Lymphknoten. Resp. 1969;26:356–8.
1352. Šimeček C. Nemoci mediastina a nitrohrudních uzlin. Praha: Avicenum; 1981.
1353. Šimeček C. Perbronchiální a pertracheální diagnostické punkce. Acta Univ Palack Olom. 1965;1:199–204.
1354. Šťastný B, Tříska J. Transbronchiální plicní biopsie. Stud Pneumol Phtiseol Cechoslov. 1982;42:107–9.
1355. Taflin C, Miyara M, Nochy D, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol. 2009;174:497–508.
1356. Tachibana T, Hiraga Y, Oritu M, Yamamoto M. Clinical study of familial occurrence of sarcoidosis in Japan. Sarcoidosis. 1994;11:244–7.
1357. Tachibana T, Shirakura R, Yamazaki Y. HLA-DR antigens in sarcoidosis. Sarcoidosis. 1985;2:83.
1358. Takada Y, Hiwada K, Akutsu H, Hashimoto A, Kokubu T. The immunocytochemical detection of angiotensin-converting enzyme in alveolar macrophages from patients with sarcoidosis. Lung. 1984;162:317–23.
1359. Takahashi A, Konno S, Hatanaka K, Matsuno Y, Yamaguchi E, Nishimura M. A case of sarcoidosis with eosinophilia in peripheral blood and bronchoalveolar lavage fluid. Respir Med Case Rep. 2013;8:43–6.
1360. Takahashi Y. Studies on the immunological and local hyperglobulinosis. In: Proceedings of the 6th Intern. Conf. Sarcoidosis. Tokyo: Tokyo University Press; 1974. p. 210–8.
1361. Takemotoa Y, Sakatania M, Takamib S, et al. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax. 1998;53:459–62.
1362. Takemura T, Hiraga Y, Oomichi M, Oritsu M, Akiyama O, Matsui Y, Eishi Y, Mikami R. Ultrastructural features of alveolitis in sarcoidosis. Am J Respir Crit Care Med. 1995;152(1):360–6.
1363. Takemura T, Matsui Y, Saiki S. et al. Pulmonary vascular involvement in sarcoidosis: A report of 40 autopsy cases. Hum Pathol. 1992;23:1216.
1364. Takemura T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y. Pathology of hypersensitivity pneumonitis. Curr Opin Pulm Med. 2008;14:440–54.
1365. Takizawa H, Satoh M, Okazaki H, et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol. 1997;107:175–81.
1366. Talbert JL, Schwartz DA, Steele MP. Familial Interstitial Pneumonia (FIP). Clin Pulm Med. 2014;21:120–7.
1367. Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, Emmett L. Impact of Patient Preparation on the Diagnostic Performance of 18F-FDG PET in Cardiac Sarcoidosis: A Systematic Review and Meta-analysis. Clin Nucl Med. 2016;41:e327–39.
1368. Tartaglino B, Albera C, Ramus VG, Cesano L. Immunoreactivita liufocitaria in vitro in pazienti affetti da sarcoidosis. Stimulacione con antigene di Kveim. Arch Sci Med. 1982;139:183–6.
1369. Tatnall EM, Barnes HM, Sarkany I. Sarcoidosis of the vulva. Clin Exp Dermatol. 1985;10:384–5.
1370. Taylor RL, Rodriquez GE. Angiotensin-converting enzyme and lysozyme levels in twins. Sarcoidosis. 1985;2:53.
1371. Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016;37:521–47.
1372. Teilum G. Morphogenesis and development of sarcoidosis lesions. Similarities to the group of collagenosis. Acta Med Scand. 1964;176(Suppl 425):14–8.
1373. Teirstein AS, Siltzbach LE, Berger H. Patterns of sarcoidosis in three population groups in New York City. Ann NY Acad Sci. 1976;278:371–6.

1374. Ten Berge B, Paats MS, Bergen IM, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology. 2012;51:37–46.
1375. Tenneson M. Lupus pernio. Ann Dermatol. Syphiligr Paris. 1892;3:1142–4.
1376. Tercelj M, Rott T, Rylander R. Antifungal treatment in sarcoidosis-a pilot intervention trial. Respir Med. 2007;101:774–8.
1377. Tessier V, Chadelat K, Baculard A, Housset B, Clement A. BAL in children: a controlled study of differential cytology and cytokine expression profiles by alveolar cells in pediatric sarcoidosis. Chest. 1996;109:1430–8.
1378. Thakker B, Black M, Foulis AK. Mycobacterial nucleic acids in sarcoid lesions. Lancet. 1992;339:1537–8.
1379. The BAL Co-operative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. Am Rev Respir Dis. 1990;141:169–202.
1380. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis. 1987;135:747–60.
1381. Thompson C, Checkly S. Short term memory deficit in a patient with cerebral sarcoidosis. Br J Psychiatry. 1981;139:160–1.
1382. Thorburn E, Kolesar L, Brabcova E, et al. CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines. APMIS. 2009;117:477–87.
1383. Tchernev G, Tana C, Schiavone C, Cardos JC, Ananiev J, Wollina U. Sarcoidosis vs. Sarcoid--like reactions: The Two Sides of the same Coin? Wien Med Wochenschr. 2014;164:247–59.
1384. Tiwari JL, Terasaki PI. Pulmonary diseases. In: Tiwari JL, Terasaki PI, editors. HLA and Disease Associations. New York: Spinger; 1985. p. 379–82.
1385. Tománek A, Fišer F, Helbich P. Zkušenosti a výsledky endoskopických a cytologických vyšetření u sarkoidózy. Stud Pneumol Phtiseol Cechosl. 1978;38:459–67.
1386. Tomankova T, Kriegova E, Liu M. Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking. Am J Physiol Lung Cell Mol Physiol. 2015;308:L603–18.
1387. Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016;193:745–52.
1388. Tomita H, Sato S, Matsuda R, et al. Serum Lysozyme Levels and Clinical Features of Sarcoidosis. Lung. 1999;177:161–7.
1389. Tondell A, Ro AD, Borset M, Moen T, Sue-Chu M. Activated CD8+ T cells and natural killer T cells in bronchoalveolar lavage fluid in hypersensitivity pneumonitis and sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2015;31:316–24.
1390. Toner GC, Bosl GJ. Sarcoidosis, sarcoid-like lymphadenopathy, and testicular germ cell tumors. Am J Med. 1990;5:651–6.
1391. Topilsky M, Siltzbach LE, Williams M, Glade PR. Lymphocyte response in sarcoidosis. Lancet. 1972;1:117–20.
1392. Tormo AJ, Letellier MC, Sharma M, Elson G, Crabé S, Gauchat JF. IL-6 activates STAT5 in T cells. Cytokine. 2012;60:575–82.
1393. Torralba KD, Quismorio FP Jr. Sarcoid arthritis: a review of clinical features, pathology and therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:95–103.
1394. Torre O, Elia D, Caminati A, Harari S. New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26:170042.
1395. Torringron G, Shorr AF, Parker JW. Endobronchial disease and Recital. Diferences in pulmonary sarcoidosis. Chest. 1997;111:619–22.
1396. Tracey KJ, Lowry SF, Cerami A. Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis. 1988;157:413–20.
1397. Trisolini R, Lazzari AL, Cancellieri A, et al. Transbronchial needle aspiration improves the diagnostic yield of bronchoscopy in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:147–51.

1398. Trowsdale J, Hansou I, Mockridge I. Sequences encoded in the class II region of the MHC related to the ABC superfamily of transporters. Nature. 1990;348:741–4.
1399. Trum DL, Ettinger DS, Feldman MJ, Dragon LH. Sarcoidosis and sarcoid-like lesions: Their occurrence after cytotoxic and radiation therapy of testis cancer. Arch Intern Med. 1981;141:37–8.
1400. Tsiligianni I, Antoniou KM, Kyriakou D, et al. Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med. 2005;5:8.
1401. Tsutsumi T, Nagai S, Imai K, Setoyama Y, Uchiyama T, Izumi T. Soluble Interleukin-2 receptor in blood from patients with sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis. 1994;11:102–9.
1402. Tuder RM. A pathologist's approach to interstitial lung disease. Curr Opin Pulm Med. 1996;2:357–60.
1403. Tukiainen P, Taskinen E, Riska H. The prognostic value of bronchoalveolar lavage in sarcoidosis. Sarcoidosis. 1994;11:69–72.
1404. Tunkel AR, Sebastianelli KJ, Paudit N, Brody JI. Development of 5q-myelodysplasia in a patient with sarcoidosis. Am J Hematol. 1990;34:225–7.
1405. Turner-Warwick M, McAllister W, Lawrence R, Britten A, Haslam PL. Corticosteroid treatment in sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin-converting enzyme measurements and gallium-67 scans help management? Thorax. 1986;41:903–13.
1406. Tutor-Ureta P, Citores MJ, Castejon R, et al. Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis. Cytometry B Clin Cytom. 2006;70B:416–22.
1407. Udwadia ZF, Pilling JR, Jenkins PF, Harrison BD. Bronchoscopic and bronchographic findings in 12 patients with sarcoidosis and severe or progressive airways obstruction. Thorax. 1990;45:272–5.
1408. Ueda E, Kokubu T, Tachibana T. Prognosis significance of the serum angiotensin- converting enzyme levels in sarcoidosis patients. Jpn J Med. 1981;20:39–42.
1409. Ueda-Hayakawa I, Tanimura H, Osawa M, et al. Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology. 2013;52:1658–66.
1410. Uehlinger EA. Epidemiology of sarcoidosis in Switzerland. Am Rev Respir Dis. 1961;84:153–4.
1411. Uehlinger EA. Morbid anatomy of sarcoidosis. Am Rev Respir Dis. 1961;84:6–13.
1412. Ueki K, Sato S, Uchiyama T, Tamura J, Kawada E, Sawamura M, Murakami H, Kubota K, Naruse T, Tsuchiya J. Philadelphia chromosome in a sarcoidosis patient? Br J Haematol. 1991;78(3):457.
1413. Uesake E, Izumi T, Tsuki S. Nocardia-like organisms isolated from lesions of sarcoidosis. In: Iway K, Hosoda Y, editors. Proc. VI Internat. Conf. On Sarcoidosis. Tokyo: University of Tokyo Press; 1974.
1414. Ulbright TM, Amin MB, Young RH. Miscellaneous primary tumors of the testis, adnexa, and spermatic cord. In: Rosai JS, editor. Atlas of tumor pathology: tumor of the testis, adnexa, spermatic cord, and scrotum, fasc 25, ser 3. Washington: Armed Forces Institute of Pathology; 1999. p. 235–366.
1415. Ungprasert P, Crowson CS, Matteson EL. Sarcoidosis increases risk of hospitalized infection. A population- based study, 1976–2013. Ann Am Thorac Soc. 2017;14:676–81.
1416. Vaddi K, Keller M, Newton RC. Chemokine Facts Book. San Diego: Academic Press; 1997.
1417. Vahid B, Spodik M, Braun KN, Ghazi LJ, Esmaili A. Sarcoidosis of gastrointestinal tract a rare disease. Dig Dis Sci. 2007;52:3316–20.
1418. Valentine HA, Tagelaar HD, Macoviak J, et al. Cardiac sarcoidosis: Response to steroids and transplantation. J Heart Transplant. 1987;6:245–50.
1419. Valesky A, Wolfart W, Seith U. Die Bedeutung der histologischen Sicherung der Diagnose Sarkoidose (Morbus Boeck). Dtsch Med Wschr. 1971;96:1833–6.
1420. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155–67.

1421. Valeyre D, Soler P, Clerici C, Pré J, Battesti JP, Georges R, Hance AJ. Smoking and pulmonary sarcoidosis: effect of Ccigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988;43:516–24.
1422. Van der Vieren M, Le Trong H, et al. A novel leukointegrin adb2 binds preferentially to ICAM-3. Immunity. 1995;3:683.
1423. Van Dorp WT, Jie K, Lobatto S. Renal failure due to granulomatous interstitial nephritis after pulmonary sarcoidosis. Nephrol Dial Transplant. 1987;2:573–5.
1424. van Helmondt S. Literature review on depressive symptoms in patiens with sarcoidosis 2009 – 2010 [online]. [cit. 3. 6. 2019] dostupné na: http://arno.uvt.nl/show.cgi?fid=114192.
1425. Van Marsseven TC, de Groot J, Stam J, van Diest PJ. Peripolesis in alveolar sarcoidosis. Am Rev Respir Dis. 1993;147:1259–63.
1426. Vaněk J, Schwarz J. Demonstration of acid-fast rods in sarcoidosis. Am Rev Respir Dis. 1970;101:395–400.
1427. Vaněk J. Nález acidorezistentních tyčinek charakteru mykobakterií u sarkoidózy. Rozhl Tuberk. 1967;27:461–2.
1428. Vardhanabhuti V, Venkatanarasimha N, Bhatnagar G, et al. Extra-pulmonary manifestations of sarcoidosis. Clin Radiol. 2012;67:263–76.
1429. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. Am J Respir Crit Care Med. 2017;196:680–9.
1430. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Skibova J, Striz I. Cytokine gene polymorphisms in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:70–5.
1431. Vasakova M, Sterclova M, Kolesar L, et al. Bronchoalveolar Lavage Fluid Cellular Characteristics, Functional Parameters and Cytokine and Chemokine Levels in Interstitial Lung Diseases. Scand J Immunol. 2009;69:268–74.
1432. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens. 2006;67:229–32.
1433. Vašáková M, Šterclová M. Sekce intersticiálních plicních procesů České Pneumologické a Ftiseologické společnosti. Idiopatická plicní fibróza- doporučený postup pro diagnózu, léčbu a sledování (3. aktualizace) [online]. [cit. 3. 6. 2019] dostupné na: www.pneumologie.cz
1434. Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:73–6.
1435. Veien NK, Wulf HC. Chromosome analysis in patients with sarcoidosis. Arch Dermatol Res. 1980;268:9–13.
1436. Vejrosta Z, Hornová J. Sarkoidóza v orofaciální oblasti. Stomatol. 1971;71:284–9.
1437. Verstraeten A, Demedts M, Verwilghen J, et al. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest. 1990;98:560–7.
1438. Vis R, Malviya G, Signore A, Grutters JC, Meek B, van de Garde EM, Keijsers RG. mTc--anti-TNF-alpha antibody for the imaging of disease activity in pulmonary sarcoidosis. Eur Respir J. 2016;47:1198–207.
1439. Visser H, Vos K, Zanelli E, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis. 2002;61:499–504.
1440. Vojta V, Peters A. Vojtův princip: svalové souhry v reflexní lokomoci a motorická ontogeneze. Praha: Grada; 1995.
1441. Voortman M, Hendriks GHR, Elfferich MDP, Bonella F. The burden of sarcoidosis symptomes from a patients perspective. Lung. 2019;197:155–61.
1442. Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs Azathioprine in Second--line Therapy of Sarcoidosis. Chest. 2013;144:805–81.
1443. Voskens CJ, Goldinger SM, Loquai C, et al. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS ONE. 2013;8:e53745.
1444. Votava V, Altman V. Kožní citlivost na tuberkulin u nemocných s hilovou adenopatií. Stud Pneumol Phtiseol Cechoslov. 1970;30:151–5.

1445. Votava V, et al. Bilaterální hilová adenopatie při Sjögrenově syndromu. Stud Pneumol Phtiseol Cechoslov. 1976;36:109–13.
1446. Votava V, Wisingerová E. Význam angiotensin-konvertujícího enzymu u sarkoidózy. Čas Lék Čes. 1985;124:974–6.
1447. Votava V. Acidoresistentní tyèinky a mykobakteria tuberkulózy u sarkoidózy. Stud Pneumol Phtiseol Cechoslov. 1987;47:596–9.
1448. Votava V. Indikace a postup pøi léèbì sarkoidózy kortikoidy. Stud Pneumol Phtiseol Cechoslov. 1985;45:193–7.
1449. Votava V. Klinický a rentgenový obraz intratorakální sarkoidózy. Stud Pneumol Phtiseol Cechoslov. 1982;42:84–9.
1450. Votava V. Lysozym u sarkoidózy. Stud Pneumol Phtiseol Cechoslov. 1989;49:47–51.
1451. Votava V. Sarkoidóza očnice. Stud Pneumol Phtiseol Cechoslov. 1984;44:121–4.
1452. Votava V. Sarkoidóza. Praha: Avicenum; 1985.
1453. Vucinic V, Djuric O, Sekulic S, et al. The influence of corticosteroids therapy (high and morbostatic doses) on airway obstruction. An clinical findings in pulmonary sarcoidosis-one year follow up study. Sarcoidosis. 1992;9:463–4.
1454. Wahlström J, Dengjel J, Persson B, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007;117:3576–82.
1455. Wahlström J, Dengjel J, Winqvist O, et al. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol. 2009;133:353–63.
1456. Wait JL, Movahed A. Anginal chest pain in sarcoidosis. Thorax. 1989;44:391–5.
1457. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852–63.
1458. Wallaer B, Ramon P, Fournier E, Tonne PAB, Voisin C. Bronchoalveolar lavage, serum angiotensin-converting enzyme, and gallium-67 scanning in extrathoracic sarcoidosis. Chest. 1982;82:553–5.
1459. Wang HD. Association of HLA with sarcoidosis. Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih. 1989;12:200–3.
1460. Wang KP, Britt EJ, Haponik EF, Fishman EK, Siegelman SS, Erozan YS. Rigid transbronchial needle aspiration biopsy for histological specimens. Ann Otol Rhinol Laryngol. 1985;94:382–5.
1461. Wang KP, Terry PB. Transbronchial needle aspiration in the diagnosis and staging of bronchogenic carcinoma. Am Rev Respir Dis. 1983;127:344–7.
1462. Wang KP. Flexible transbronchial needle aspiration biopsy for histology specimens. Chest. 1985;88:860–3.
1463. Wanstrup J, Christensen HE. Sarcoidosis. 1. Ultrastructural investigations on epithelioid cell granulomas. Acta Pathol Microbiol Scand. 1966;66(2):169–85.
1464. Ward K, Fitzgerald MX. Smoking does not affect prevalence of short term functional outcome of sarcoidosis in Ireland. In: Grassi C, Rizzato G, Pozzi E, editors. Sarcoidosis. Amsterdam: Excerpta Medica; 1988. p. 315–6.
1465. Ward K, O'Connor C, Odlum C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: The critical influence of disease presentation. Thorax. 1989;44:6–12.
1466. Warshauer DM, Lee JKT. Imaging manifestations of abdominal sarcoidosis. AJR Am J Roentgenol. 2004;182:15–28.
1467. Warshauer DM, Molina PL, Hamman SM, et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology. 1995;195:757–62.
1468. Webb AK, Mitchell DN, Bradstreet CMP, Salsbury AJ. Splenomegaly and splenectomy in sarcoidosis. J Clin Pathol. 1979;32:1050–3.
1469. Webb W. Efficacy of CT-MR imaging in lung cancer staging. Lung Cancer. 1994;25.
1470. Webling DD. Sarcoidosis in an Australia Aboriginal. Med J Aust. 1978;1(3):169–70.
1471. Wegener F. Über generalisierte, septische gefasserkrankungen. Verhandlungers der Deutschen Gesselschaft für Pathologie.1936;29:202–9.

1472. Weinstock JV. Function and regulation of granulomatous response (experimental granulomatosis). In: James DG, editor. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel Dekker; 1994. p. 99–118.
1473. Weinstock JV. The possible role of angiotensin I-converting enzyme (ACE) in granulomatous inflammation. Sarcoidosis. 1985;2:58.
1474. Weissler JC. Southwestern Internal Medicine Conference: Sarcoidosis: Immunology and Clinical Management. Am J Med Sci. 1994;307:233–44.
1475. Wells AU, Denton CP. Interstitial lung disease in connective tissue disease—mechanisms and management. Nat Rev Rheumatol. 2014;10:728–39.
1476. Werner F, Jain MK, Feinberg MW, et al. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem. 2000;275:36653–8.
1477. Werner JL, Escolero SG, Hewlett JT, et al. Induction of pulmonary granuloma formation by propionibacterium acnes is regulated by MyD88 and Nox2. Am J Respir Cell Mol Biol. 2017;56:121–30.
1478. Werner JL, Escolero SG, Hewlett JT, Mak TN, Williams BP, Eishi Y, et al. Induction of Pulmonary Granuloma Formation by Propionibacterium acnes Is Regulated by MyD88 and Nox2. Am J Respir Cell Mol Biol. 2017;56(1):121–30.
1479. Wewers MD, Saltini C, Sellers S, Tocci MJ, Bayne EK, Schmidt JA, Crystal RG. Evaluation of alveolar macrophages in normals and individuals with active pulmonary sarcoidosis for the spontaneous expression of the interleukin-1 beta gene. Cell Immunol. 1987;107:479–88.
1480. White DA, Smith GJW, Cooper JAD, Glicktein M, Rankin JA. Hermansky-Pudlak syndrome and interstitial lung disease: report of a case with lavage findings. Am Rev Resp Dis. 1984;130:138–41.
1481. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage. 2009;37:107–28.
1482. WHO. The World Health Organization Quality of Life [online]. [cit. 3. 6. 2019] dostupné na: https://www.who.int/mental_health/publications/whoqol/en/
1483. Wilcox A, Bharadwaj P, Sharma OP. Bone sarcoidosis. Opin Rheumatol. 2000;12:321–30.
1484. Wilkinson R, Wang X, Roper KE, Healy H. Activated human renal tubular cells inhibit autologous immune responses. Nephrol Dial Transplant. 2011;26:1483–92.
1485. Willan R. On Cutaneos Diseases. London: J. Johnson; 1808.
1486. Williams J, Alrawaf S, Alsaggaf M. Sarcoidosis Progression. Am J Respir Crit Care Med. 2017;195:A5377.
1487. Williams JD, Smith MD, Davies BH. Interaction of immune complexes and T – suppressor cells in sarcoidosis. Thorax. 1982;37:602–6.
1488. Williams PF, Thomson D, Anderton JL. Reversible renal failure due to isolated renal sarcoidosis. Nephrol. 1984;37:246–9.
1489. Williams R, Nickerson D. Skin reactions in sarcoid. Proc Soc Exp Biol Med. 1935;33:402–405.
1490. Williams RH, Nickerson DA. Skin reactions in sarcoid. Proc Soc Exp Biol Med. 1935;33:402–5.
1491. Williams WJ, Wallach ER. Laser Microprobe Mass Spectometry (LAMMS) Analysis of beryllium, sarcoidosis and other granulomatous diseases. Sarcoidosis. 1989;6:111–7.
1492. Wilsher M, Hopkins R, Zeng I, Cornere M, Douglas R. Prevalence of asthma and atopy in sarcoidosis. Respirology. 2011;17:285–90.
1493. Wilsher ML. Seasonal clustering of sarcoidosis presenting with erythema nodosum. Eur Respir J. 1998;12:1197–9.
1494. Wilson RK, Fechner RE, Greenberg SD, Estrade R, Stevens PM. Clinical implications of a Non specific transbronchial biopsy. Am J Med. 1978;65:252–6.
1495. Winnacker JL, Becker KL, Katz S. Endocrine aspects of sarcoidosis. N Eng J Med. 1968;278:483–92.
1496. Winsel K. Oxidativer Metabolismus. Z Erkrank Atm Org. 1988;170:301–2.
1497. Winterbauer RH, Hutchinson JF. Clinical significance of pulmonary function tests. Use of pulmonary function tests in the management of sarcoidosis. Chest. 1980;78:640–7.

1498. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18:937–43.
1499. Winters SL, Cohen M, Greenberg S, Stein B, Curwin J, Pe E, Gomes JA. Sustained ventricular tachycardia associated with sarcoidosis: Assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18:937–43.
1500. Wirnsberger RM, De Vries J, Breteler MH, Van Heck GL, Wouters EF, Drent M. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92:750–6.
1501. Witte E, Witte K, Warszawska K, Sabat R, Wolk K. Interleukin-22: A cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010;21:365–79.
1502. Wojno ED, Hunter CA. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 2012;33:91–7.
1503. Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CH, et al. snP Variants in Major histocompatibility complex are associated with sarcoidosis. 2017;19;8:422.
1504. Wollschlager C, Khan F. Aspergillomas complicating sarcoidosis: a prospective study in 100 patients. Chest. 1984;86:585–8.
1505. Woodward PJ, Sohaey R, O'Donoghue MJ, Green DE. From the archives of the AFIP: tumors and tumorlike lesions of the testis—radiologic-pathologic correlation. RadioGraphics. 2002;22:189–216.
1506. Wurm K, Reindell H, Doll E. Klinik und Aetiologie der Sarcoidose. In: Hoppe R. Sarkoidose. Stuttgart: Schattauer; 1965. p. 23–65.
1507. Wurm K, Reindell H, Heilmeyer L. Der Lungenboeck im Rontgenbild. Stuttgart: Georg Thieme Verlag; 1958.
1508. Wurm K, Reindell H. Die Stadienlehre der Sarkoidose. Dtsch Med Wchsr. 1983;108:1028–32.
1509. Wurm K. Charakteristika und Besonderheiten der Lungensarkoidose im Röentgenbild. Radiologe. 1968;8:103–7.
1510. Wurm K. Prognosis of sarcoidosis. In: Proceedings VIth Intern. Conf. Sarcoidosis. Tokyo: Tokyo University Press; 1974. p. 485–8.
1511. Wurm K. Therapie der Sarkoidose. Internist. 1982;23:348–55.
1512. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, Veazey RS. IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol. 2012;5:658–69.
1513. Yamada H, Ishii W, Ito S, et al. Sarcoid myositis with muscle weakness as a presenting symptom. Mod Rheumatol. 2007;17:224–43.
1514. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine- 18-Fluorodeoxyglucose and Carbon-11 Methionine Evaluation of Lymphadenopathy in Sarcoidosis. J Nucl Med. 1998;39:1160–8.
1515. Yamaguchi E, Kawakami Y. Analysis of HLA antigen in Japanese patients with sarcoidosis. Nihon Rinsho. 1994;52(6):1443–8.
1516. Yamaguchi E, Okazaki N, Itoh A, Abe S, Kawakami Y, Okuyama H. Interleukin-1 production by alveolar macrophages is decresed in smokers. Am Rev Respir Dis. 1989;140:379–402.
1517. Yamaguchi E, Okazaki N, Itoh A, Furuya K, Abe S, Kawakami Y. Enhanced expression of CD2 antigen on lung T cells. Am Rev Respir Dis. 1991;143:829–33.
1518. Yamaguchi E, Okazaki N, Tsuneta Y, Abe S, Terai T, Kawakami Y. Inlerleukins in pulmonary sarcoidosis. Am Rev Resp Dis. 1988;138:645–51.
1519. Yamaguchi M, Odaka M, Hosoda Y, Iwai K, Tachibana T. Excess death of lung cancer among sarcoidosis patients. Sarcoidosis. 1991;8:51–5.
1520. Yamamoto M, Sharma OP, Hosoda Y. The 1991 descriptive definition of sarcoidosis. Sarcoidosis. 1992;9:33–4.
1521. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–10.

1522. Yeager H, Rabin DL, Stein SR, Richardson MSA, Scott CL. Sarcoidosis: Possible role of socioeconomic (SES) factors. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:11.
1523. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med. 2001;135:27–31.
1524. Yoon HY, Kim HM, Kim YJ, Song JW. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based Study. Respir Res. 2018;19:158.
1525. Young RC. Alpha-l-antitrypsin levels in sarcoidosis. Relationship to disease activity. In: Proceedings VIth Intern. Conf. Sarcoidosis. Tokyo: Tokyo University Press; 1974. p. 436–47.
1526. Young RL, Harkleroad LE, Lordon RE, Weg JG. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med. 1970;73:207–12.
1527. Youssef G, Leung E, Mylonas I, et al. The use 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and meta analysis including the Ontario experience. J Nucl Med. 2012;53:241–8.
1528. Yung RC, Liu MC, Groshong SD, Zhang Y, Tuder RM, Moller DR. Serum Amyloid A Regulates Granulomatous Inflammation in Sarcoidosis through Toll-like Receptor-2. AJRCCM. 2010;181:360–73.
1529. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. AJRCCM. 1997;155:9154873.
1530. Zagai U, Lundahl J, Klominek J, Venge P, Skold CM. Eosinophil cationic protein stimulates migration of human lung fibroblasts in vitro. Scand J Immunol. 2009;69:381–6.
1531. Zajaczkowska J. Transbronchial lung biopsy in diffuse pulmonary disease. VEB J. A. Barth, Leipzig. Z Erkrank Atm Org. 1988;170:132–9.
1532. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis: diagnosis and management. Q J Med. 1999;93:103–17.
1533. Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five year, controlled follow-up study. NY State J Med. 1987;87:496–9.
1534. Zatloukal J, Mayer M, Neumannová K, Dvořák R, Lošťáková V. Mechanika dýchání a její terapeutické ovlivnění u pacientů s plicní formou sarkoidózy. Rehabilitace a Fyzikální Lékařství. 2011;18:167–72.
1535. Zatloukal J, Neumannová K, Olšáková H, et al. An effect of the outpatient rehabilitation programme in patients with chronic respiratory diseases. Acta Universitatis Palackianae Olomucensis Gymnica. 2013;43:33–8.
1536. Zatloukal J, Neumannova K. Efekt rehabilitační léčby na změnu zdravotního stavu a kvality života u pacientů s plicní formou sarkoidózy. Stud Pneumol Phthiseol. 2013;73:192–7.
1537. Zatloukal P, et al. Bronchoalveolární laváž u některých difuzních onemocnìní plic, sarkoidózy a bronchitidy. Stud Pneumol Phtiseol Cechoslov. 1988;48:60–6.
1538. Zavala DC. Transbronchial biopsy in diffuse lung disease. Chest. 1978;73(Suppl 5):727–33.
1539. Zeimer HJ, Greenaway TM, Slavin J, et al. Parathyroid-hormone-related protein in sarcoidosis. Am J Pathol. 1998;152:17–21.
1540. Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732.
1541. Zhang JM. 18 cases of sarcoidosis and a review of relevant literature. Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih. 1989;12:214–6.
1542. Zheng L, Teschler H, Guzman J, Hübner K, Striz I, Costabel U. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med. 1995;152:1061–6.
1543. Zhou Y, Lower EE, Feng Y, Du S, Huiping L, Baughman RP. Clinical characteristics of sarcoidosis patients in the United States versus China. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34;209–16.
1544. Zhou Y, Lower EE, Li H, Farhey Y, Baughman RP. Clinical characteristics of patients with bone sarcoidosis. Semin Arthritis Rheumat. 2017;47:143–8.

1545. Zhou Y, Lower EE, Li HP, et al. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. Chest. 2017;151:139–48.
1546. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci. 2012;122:487–511.
1547. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Ouernheim J. Sarcoidosis: TNF-alpha release of alveolar macrophages and serum level of sIL2R are prognostic markers. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:11.
1548. Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21:407–13.
1549. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF-alpha Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. AJRCCM. 1997;156:1586–92.
1550. Ziegler-Heitbrock HWL, Ströbel M, Fingerle G, et al. Small (CD14+/CD16+) monocytes and regular monocytes in human blood. Pathobiology. 1991;59:127–30.
1551. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:e74–80.
1552. Zimmermann A, Knecht H, Häsler R, et al. Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota. Eur Respir J. 2017;50:1600746.
1553. Zindanci I, Okur HK, Kavala M, et al. A Case of Sarkoidosis that Developed Lupus Pernio Lesions in the Chronic Stage. Respir Case Rep. 2014;3:145–8.
1554. Zipse MM, Sauer WH. Electrophysiologic manifestations of cardiac sarcoidosis. Curr Opin Pulm Med. 2013;19:485–92.
1555. Zisman D, Biermann JS, Martinez F, Devaney KO, Lynch JP. Sarcoidosis presenting as a tumor-like muscular lesion: case report and review of the literature. Medicine. 1999;78:112–22.
1556. Zissel G, Ernst M, Schlaak M, Müller-Quernheim J. Accessory function of alveolar macrophages from patients with sarcoidosis and other granulomatous and nongranulomatous lung diseases. J Investig Med. 1997;45:75–86.
1557. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med. 1996;154:713–9.
1558. Zurkova M, Turkova M, Tichy T, Pilka R, Kolek V, Kriegova E. Sarcoidosis of female reproductive organs in a postmenopausal woman: a case report and review of the literature: is there a potential for hormone therapy? Menopause. 2015;22:549–53.
1559. Zych D, Pawlicka L, Zielinski J. Inhaled Budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis. 1993;10:56–61.
1560. Žarnayová L, Žurková M, Kolek V. Biologicky cílená léèba sarkoidíozy. Acta medicinae. 2018;6:48–50.
1561. Žurková M, Kolek V, Lošťáková V, Kriegová E. Nové léky u sarkoidózy. Interní medicína pro praxi. 18;2016:180–3.
1562. Žurková M, Kolek V, Tomankova T, Kriegova E. Extrapulmonary involvement in patients with sarcoidosis and comparison of routine laboratory and clinical data to pulmonary involvement. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:613–20.
1563. Žurková M, Kriegová E, Zapletalová J, Vykoupil K, Kolek V. Srovnání klinických parametrů u pacientů s nitrohrudní a generalizovanou formou sarkoidózy. Stud Pneumol Phthiseol. 2013;73:237–42.
1564. Žurková M, Loštáková V, Kolek V, et al. Postižení srdce jako primární projev sarkoidózy. Stud Pneumol Phthiseol. 2017;77:227–33.
1565. Žurková M, Otruba P, Lošťáková V, Tüdös Z, Kolek V, Kriegová E. Neurosarkoidóza u muže středního věku – kazuistika a přehled diagnostiky a léčby. Česká a Slovenská Neurolologie a Neurochirurgie. 2016;79:225–30.